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Introduction and outline of the thesis
Kidneys play an important role in maintaining salt and water balance, and 
removing toxic waste products. The functional unit of a kidney is called the 
nephron. It is composed of different sections; the glomerulus, proximal tubule, 
loop of Henle, distal tubule and collecting duct, all contributing to the renal 
clearance. The glomerulus consists of a cluster of capillaries that branches 
from the afferent arteriole and is surrounded by the Bowman’s capsule. 
Driven by a local high blood pressure, water and small molecules are filtered 
from the glomerulus and are collected in the Bowman’s capsule to form 
primary urine. Then, passing the tubular sections, several secretion and 
(re)absorption processes determine the final composition of the urine.
This thesis focuses on the structure and function of the glomerular filter, and 
more in detail the epithelial cells called podocytes, and their role in 
developing the histological finding focal segmental glomerulosclerosis 
(FSGS).
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The Glomerular Filtration Barrier
The glomerulus consists of a cluster of capillaries appearing in a looped formation supported 
by mesangial cells. While blood plasma passes the glomerular capillary loops, the local 
intracapillary pressure drives plasma through the glomerular filtration barrier which consists 
of at least three layers (figure 1). A recent review by Salmon et al describes new insights in 
the structure of the glomerular filtration barrier and distinguishes two additional layers which 
play an important role in permeability [1].
The glomerular endothelial cells, which separate the blood and tissue compartments, 
represent the traditional first layer. The endothelial cells are highly flattened cells and 
regulate vasomotor tone and haemostasis [2]. The role of the endothelial cells in selective 
filtration seems not to be substantial since they are highly fenestrated and highly permeable 
to water and small solutes. However, a recent study has shown that morphological 
alterations in the endothelial cell glycocalyx, making the cell surface extremely negatively 
charged, have functional consequences for glomerular permeability [3]. Using the GAG- 
degrading enzyme chondroitinase decreasing the thickness of the endothelial cell glycocalyx 
resulted in an increase of albumin clearance [3]. This endothelium surface layer, composed 
of the endothelial-cell glycocalyx, secreted proteoglycans, and trapped plasma constituents, 
now emerges as an additional glomerular filtration barrier [1 ]. The arrangement and density 
of these constituents influences the degree of molecular sieving [1].
The endothelium is completely surrounded by the glomerular basement membrane 
(GBM). This dense structure of extracellular matrix components provides structural support 
for the capillary wall necessary to maintain local high blood pressure. The main components 
of the GBM (collagen type IV, laminins, nidogen, and proteoglycans) contribute to the 
selective permeability of the GBM based on size and charge [4]. In the past years, many 
studies were focussing on the structure of the GBM because it was considered to be the 
leading part of the glomerular filtration barrier. Although structural abnormalities in the GBM 
may lead to proteinuria and hematuria, as it occurs in Alport’s syndrome (mainly due to 
collagen IV a5 chain mutations, but also collagen IV a3 and a4 chains) or Pierson’s 
syndrome (due to laminin ß2 mutations) [5,6], the discovery of several novel proteins 
important for glomerular permeability made the podocytes the favourite candidate for 
constituting the main part of the glomerular filtration barrier.
The podocytes, or visceral epithelial cells, represent the next layer. They are highly 
specialized, terminally differentiated cells with cytoplasmic extensions, the so-called foot 
processes. Podocytes have an important role in size and charge selective permeability, but 
also in synthesising and maintaining the GBM [7]. Furthermore the fenestration of endothelial 
cells depends most notably on vascular endothelial growth factor A (VEGF-A) secreted from 
differentiated podocytes [2].
The foot processes of the podocytes attach to the outer surface of the GBM through 
cell membrane receptors (a3ß1 integrins linked to talin, vinculin and paxillin, and a-, and ß- 
dystroglycans linked to utrophin, see figure 2) [8]. Adjacent foot processes interdigitate, 
forming a pore of about 25-40 nm in width. This pore, or slit, is covered by a membrane with
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a “zipper-like” structure [9]. When primary urine passes the podocyte slit membrane it enters 
the urinary space and it is generally assumed that no further significant resistance to fluid 
movement occurs until the exit into the proximal tubule. However, serial section transmission 
electron microscopy revealed three ultrastructurally distinct urinary spaces of which the 
subpodocyte space covers approximately 60% [1,10]. The subpodocyte space is defined by 
the space between the podocyte cell body and foot processes. Primary urine exits this space 
to the next urinary division through a narrow pore-like structure at the periphery of the 
podocyte by extravascular pressure regulated by this exit pore [1,10]. Further studies are 
required to determine the exact role of the subpodocyte space in the glomerular filtration 
barrier.
Recently, the structure of the slit membrane became the focus of many studies, and 
although the complete structure is not elucidated yet, several new proteins were found to be 
important for its function. Many components of the slit membrane are involved in the 
pathogenesis of (nephrotic range) proteinuria.
Figure 1 A cross section (electron microscopy, original magnification 30,000x) of the glomerular 
filtration barrier with the capillary space (Cs), urinary space (Us), endothelial cells (E), glomerular 
basement membrane (BM), and podocytes (P).
Nephrotic Syndrome - Focal Segmental Glomerulosclerosis
A nephrotic syndrome (NS) is defined by the occurrence of heavy proteinuria, oedema, and 
hypoalbuminaemia, and is classified as steroid-sensitive or steroid-resistant. In children NS 
occurs most commonly at a young age, with a peak incidence at two years. In most cases 
(~80%, according to the International Study of Kidney Disease in Children (1967-1974),
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ISKDC ) patients have minimal change NS (MCNS), which is characterized by 
responsiveness to steroid treatment accompanied with more or less frequent relapses. In 5­
10% of NS patients (ISKDC) focal segmental glomerulosclerosis (FSGS) is found [11,12]. 
Less frequent histologic lesions are mesangial proliferative glomerulonephritis, 
membranoproliferative glomerulonephritis, and membranous glomerulopathy [11].
FSGS is a histological finding commonly seen in a large variety of conditions with 
different underlying causes. These conditions share the focal (only some of the glomeruli are 
involved) segmental (only part of an entire glomerulus is involved) sclerosis of the glomerular 
capillary tuft and manifests with proteinuria. As the disease progresses, the sclerosis has a 
more diffuse and global pattern. The biopsy may show mesangial deposits of 
immunoglobulin M or complement C3 and hyaline deposits all over the capillary loops [13]. 
Podocyte alterations (like foot process effacement) are most notably in FSGS.
Recently, FSGS has been classified in five sub-categories: collapsing variant, tip 
lesion variant, cellular variant, perihilar variant, and FSGS not otherwise specified (NOS) 
[14,15 for further reading]. Whether subdividing FSGS in different subcategories gives insight 
in clinical features and renal outcome is a subject of several reports recently reviewed by 
D’Agati [16]. Collected data from adult patients with biopsy proven FSGS showed a 
predisposition of younger and more often African-American patients for the collapsing variant 
of FSGS [17]. The collapsing and tip variants usually manifest with more severe proteinuria 
compared to the perihilar and NOS variants. Patients with the last two morphologic variants 
tend to have higher blood pressure and pathologically more arteriosclerosis [17]. As far as 
renal outcome concerns, the patients with tip lesion variant of FSGS seem more often to 
achieve complete remission, whereas the collapsing variant of FSGS has worse renal 
survival rates [17]. It is not excluded that different morphologic variants represent different 
stages of disease progression in FSGS.
FSGS commonly progresses to end stage renal disease (ESRD) requiring dialysis or 
renal transplantation. Post-transplant recurrence occurs in 35-40% of patients with idiopathic 
FSGS [18,19], mainly a few days after transplantation, and is often sensitive to 
plasmapheresis and cyclophosphamide treatment [20-22]. The recurrence may be due to a 
circulating plasma factor [20]. This factor may be responsible for an increase in podocyte 
integrin-linked kinase activity leading to podocyte detachment from the GBM as found in 
some patients [23]. Recently, cardiotrophin like cytokine-1has been identified as being a 
candidate for the FSGS permeability factor [24].
Lately, the role of Notch signaling, which is involved in the regulation of many cellular 
processes like proliferation, differentiation, and cell death [25], in the development of renal 
diseases is debated. Although NotchI protein plays a crucial role during kidney development, 
very little active NotchI can be detected in mature kidneys [26]. In glomerular epithelial cells 
of patients with diabetic nephropathy or FSGS, however, an increased presence of the active 
protein domain of NotchI was found, which, based on the homology with mouse podocyte 
biology [27], may be involved in apoptosis induction.
Another classification of FSGS is based on the underlying cause and subdivides it 
into three categories: idiopathic, genetic, and secondary due to injury, medication, or drug
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abuse [13,16]. The last years genetic linkage studies have identified several genes involved 
in the development of FSGS and have contributed to the understanding of its 
pathophysiology (table 1). A subset of genes enlisted in table 1 are discussed below in more 
detail and figured in figure 2.
NPHS1
One of the major components of the slit membrane is the transmembrane protein nephrin 
(NPHS1). Nephrin has an important role in maintaining the structure of the podocyte slit 
membrane, as shown by nephrin deficient mice which develop proteinuria and foot process 
effacement [28]. Injection of anti-nephrin antibody in animals also results in foot process 
effacement [29]. Intracellularly, nephrin functions as a signalling molecule [30,31]. Nephrin 
(and also CD2AP, another component of the slit membrane) associates with the p85 
regulatory subunit of phosphoinositide 3-OH kinase (PI3K) thereby stimulating the AKT 
signalling pathway controlling cell growth, migration, and survival [30].
Nephrin oligomers associate with lipid rafts in the slit membrane [32]. A rat model of 
antibody (recognizing a podocyte-specific 9-O-acetylated GD3 ganglioside) induced foot 
process effacement showed morphological changes of the filtration slits with apical 
dislocation and tyrosine phosphorylation of nephrin [32]. As such, tyrosine phosphorylation 
may regulate the subcellular redistribution of slit membrane proteins [32,33]. Furthermore, a 
study in Fyn deficient mice, showed an important role for tyrosine phosphorylation in nephrin- 
dependent intracellular signalling [34]. Fyn, a member of the Src protein kinase family, 
tyrosine phosphorylates the cytoplasmic domain of nephrin and Fyn deficient mice develop 
proteinuria and foot process effacement [34].
NPHS1 was found mutated in patients with the congenital nephrotic syndrome of the 
Finnish type (CNF). CNF has an incidence of 1:10,000 births in Finland, but less frequently in 
other countries. Although several missense mutations were found in CNF patients, two 
mutations, the Finmajor (deletion nucleotides 121 and 122) and Fin,™- (premature stop at 
amino acid 1109), account for over 90% of the cases in Finland [35]. Recurrence of CNF 
may occur in 20-25% of the patients after receiving a renal allograft and may be caused by 
anti-nephrin antibodies [36,37]. In addition to the renal disease, patients with NPHS1 
mutations may also show neurological symptoms including muscular hypotonia, dyskinesia, 
mild cerebral atrophy and hearing impairment of still obscure origin [38].
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NPHS2
Podocin (NPHS2), a member of the stomatin protein family, is exclusively expressed in the 
podocytes and localizes at the insertion of the slit membrane. Due to its similarity to stomatin, 
it is believed that podocin forms a hairpin like structure with intracellular NH2- and COOH- 
termini [39,40].
Podocin, like nephrin, associates with lipid rafts [39], and recruits nephrin and CD2AP 
in these rafts ensuring a stable and proper functioning filtration barrier. The COOH- terminal 
cytoplasmic tail of podocin interacts with nephrin and Cd2ap (the mouse homolog) [41]. This 
protein interaction greatly enhances nephrin-induced signalling in vitro [31]. The COOH- 
terminal domain of podocin also binds NEPH-1, a podocyte slit membrane protein structurally 
related to nephrin [42]. NEPH-1 is involved in maintaining the structure of the filtration barrier 
and also interacts with nephrin [43].
Podocin dysfunction leads to alterations of the slit membrane assembly and to 
proteinuria in experimental models. NPHS2-/" mice develop proteinuria and massive 
mesangial sclerosis (different from FSGS seen in humans), the podocytes are enlarged and 
focally vacuolized. The sclerosis rapidly progresses with age. Beside the absence of 
podocin, no nephrin is found in the foot processes as well. The podocin deficient mice die a 
few days after birth [44].
In human, NPHS2 mutations, are mainly associated with autosomal recessive steroid- 
resistant nephrotic syndrome (SRN1) [38], but were also found in sporadic cases of steroid 
resistant nephrotic syndrome patients [45-48]. A recent study has demonstrated that also 
milder NPHS1 mutations can cause a childhood-onset steroid-resistant nephrotic syndrome 
with underlying histological lesions ranging from minimal change nephropathy to FSGS [49].
The podocin variant R229Q is often found and has an allele frequency of 3.6% in a 
control population. The mutant protein has a decreased binding efficiency to nephrin and 
enhances FSGS susceptibility in association with a second NPHS2 mutation [47]. The 
R229Q variant is also associated with microalbuminuria in the general population [50].
Mutated podocin may cause a disturbance in recruiting nephrin to the plasma 
membrane [51,52], which is comparable with the lack of nephrin in the slit membrane found 
in podocin deficient mice [44]. The R138Q NPHS2 mutant (one of the most common found 
mutation) results in retainment of the mutant podocin in the endoplasmatic reticulum. The 
R138X NPHS2 mutant yields a mutant podocin protein that is not able to associate with lipid 
rafts in the plasma membrane. Both mutant proteins were unable to recruit nephrin to the 
lipid rafts and lost their ability to enhance nephrin signaling [51,52]. NH2-terminal mutant 
proteins were still able to associate with lipid rafts and had no effect on nephrin localization 
[53]. Collected clinical data from patients with NPHS2 mutations showed that podocin 
mutants retained in the endoplasmatic reticulum are associated with earlier onset of the 
disease than those correctly targeted to the cell membrane [52].
Early reports showed that patients with NPHS2 mutations had no recurrence of FSGS 
after renal transplantation. Now it is believed that patients with NPHS2 mutations have a 
lower risk for recurrent FSGS after renal transplantation compared to patients with idiopathic
16
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FSGS [54-56]. Patients carrying a heterozygous NPHS2 mutation show a higher risk for 
recurrent FSGS (5 out of 8 published) in contrast to patients with homozygous or compound 
heterozygous mutations (5 out of 68 published) [57]. The authors state that grafts from 
carriers of NPHS2 mutations, such as from parents, should be avoided because of the higher 
risk of recurrent FSGS. Furthermore, carriers of heterozygous NPHS2 mutations should be 
strictly monitored in the post-graft phase [57].
CD2AP
Although first found in a yeast two-hybrid screen as a protein binding to the T-cell membrane 
protein CD2 during cell-cell interaction [58], an important role for Cd2ap (CD2 associated 
protein) in the kidney became evident when Cd2ap knockout mice died because of renal 
failure involving the glomerulus [59]. The Cd2ap-/" mice died at an age of 6 to 7 weeks, but 
already at one week glomeruli were increased in size and cellularity (mesangial cell 
proliferation and glomerulosclerosis) and electron microscopy showed extensive foot 
processes effacement [59]. Cd2ap+/" mice showed no proteinuria, but have an increased 
susceptibility to glomerular injury by immune complexes and nephrotoxic antibodies [60]. At 9 
months of age, glomerular lesions were present with an increase in mesangial cellularity. 
Some lesions were similar to human FSGS and for this reason primary FSGS patients were 
tested for mutations in the CD2AP gene (the human homolog of Cd2ap, originally named 
CMS) [60] One heterozygous splice-site mutation was detected in two patients. The 
predicted mutated protein would lack more than 80% of the protein. Immunoblotting CD2AP 
isolated from immortalized B-lymphocytes showed a reduction in CD2AP expression in these 
patients [60].
CD2AP/Cd2ap is a multifunctional adaptor molecule localized to the cytoplasm, 
membrane ruffles, and leading edges of cells [61]. The protein plays a role in cytoskeletal 
remodeling [56,59], cell survival [30,62], and endocytosis [63-65]. The COOH-terminus of 
CD2AP directly interacts with the cytoskeletal protein filamentous actin (F-actin) [61,66] and 
synaptopodin, an actin bundling protein [67]. At the slit membrane, CD2AP interacts with 
nephrin and podocin [41,68] and serves as a linker anchoring slit membrane proteins to the 
actin cytoskeleton of podocytes.
CD2AP and nephrin bind to the p85 regulatory subunit of phosphoinositide 3-OH 
kinase (PI3K) stimulating the serine-threonine kinase AKT [30]. One of the target proteins of 
AKT is Bad, a proapoptotic Bcl2 family member that interacts with prosurvival Bcl2 family 
members to promote apoptosis. Phosphorylated Bad is inactive and protects podocytes 
against detachment-induced cell death [30].
Combined mutations in two podocyte genes may be a common etiology for 
glomerular disease [67]. Crossbreeding heterozygous Cd2ap knockout mice with mice 
heterozygous (knockout) for synaptopodin or Fyn, which alone did not result in clinical kidney 
pathology, resulted in spontaneous proteinuria and FSGS-like glomerular damage supporting 
a role for CD2AP haploinsufficiency [60].
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ACTN4
Alpha-actinin-4 (ACTN4) is an actin-bundling protein important for the integrity of the 
podocyte cytoskeleton associated with cell motility. Transgenic ACTN4 mice develop a 
severe glomerular disease and FSGS [69,70]. Lymphocytes of homozygous ACTN4 deficient 
mice displayed an increase in lymphocyte chemotaxis, supporting the role of ACTN4 in cell 
motility [70]. Podocyte cell lines derived from these ACTN4 deficient mice show less 
adherence to the GBM components collagen IV and laminins-10 and -11, also indicating its 
role in maintaining glomerular architecture and preventing disease [71].
ACTN4 is highly expressed in several human tissues. Despite the overall expression 
of ACTN4, the human phenotype associated with ACTN4 mutations only manifests in the 
kidney. Mutations in ACTN4 are associated with an autosomal dominant form of familial 
FSGS. By now, only 3 ACTN4 missense mutations have been described in literature [72,73]. 
The mutated ACTN4 proteins showed a higher binding affinity to F-actin, and may change 
the mechanical characteristics of the podocyte [72]. In vitro studies in podocytes of mice 
homozygous for the human disease-causing K225E substitution, shows aggregation of the 
mutant a-actinin-4 with F-actin. Furthermore, the conformational change also leads to an 
increase of the actin-binding stoichiometry and a resistance to regulation by Ca2+ [74]. In 
sporadic cases of FSGS, without an apparent familial disease pattern, ACTN4 amino acid 
substitutions were also found [73]. However, cellular localization of the mutated proteins and 
actin-binding assays show that these mutations are probably not disease causing or 
contributing to the disease [73].
WT1
Another well described genetic defect in patients with primary nephrotic syndrome is the 
spectrum of clinical pictures caused by mutations in WT 1 (for review 75-77), a transcription 
factor regulating several programs of cellular proliferation and differentiation. The WT1 gene 
is positionally cloned based on its role in the development of Wilms tumors, the most 
common form of cancer in children [78,79]. Heterozygous de novo mutations in WT1 cause 
Denys-Drash syndrome (DDS) and Frasier syndrome (FS), two overlapping syndromes [80], 
characterized by nephrotic syndrome with either diffuse mesangial sclerosis (DMS in DDS) 
or FSGS (in FS), genitourinary defects, and a higher risk of developing Wilms tumor (in DDS) 
or gonadal dysgerminoma (in both DDS and FS).
WT1 has a transcription regulating domain (encoded by exons 1 to 6) and a DNA 
binding zinc finger domain (encoded by exons 7 to 10). There are four major isoforms due to 
the insertion of the amino acids KTS between zinc fingers 3 and 4 (alternative splice site 
directly situated after exon 9), and due to the insertion of 17 amino acids completely encoded 
by exon 5. The insertion/deletion of KTS influences the space between zinc fingers 3 and 4 
and thereby the binding properties of the protein [81].
18
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The mutations found in DDS patients, but also in cases of isolated DMS, are mostly 
missense mutations (80%) in zinc fingers 2 and 3 (exon 8 and 9). The R394W (1180 C>T, 
exon 9) substitution is most frequently found in almost 50% of the DDS patients [75,82,83]. 
These mutations affect the DNA binding stability of WT1 to the target gene [84]. FS patients 
usually present with intron 9 splice site mutations affecting the +KTS/-KTS ratio [85,86]. The 
fact that DDS and FS are overlapping syndromes is strengthened by the finding of intron 9 
splice site mutations in patients with a phenotype of DDS [80,81,87,88], and an exon 9 
mutation in a patient with FS [89].
TRPC6
TRPC (transient receptor potential cation channel subfamily C, 1 -7) is a subgroup of the TRP 
family of cation channels involved in the regulation of Ca2+ influx. These ion channels can be 
activated subsequent to either depletion of Ca2+ from internal stores or through receptor- 
mediated processes [90]. TRPC channels are expressed in many tissues. In the podocytes 
TRPC-1, -2, -5, and -6 are expressed [91]. TRPC6 is localized to the podocyte cell body, 
primary processes and in close vicinity to the slit membrane were it interacts with nephrin 
and podocin (not CD2AP) [91]. TRPC6 is also abundantly expressed in mesangial cells [92]. 
In diabetic nephropathy, the mesangial contractile function is impaired, most probably due to 
a reduced Ca2+ influx. A recent study showed that high glucose downregulates the TRPC6 
protein which might contribute to the impaired Ca2+ signaling of mesangial cells seen in 
diabetes [93].
TRPC6 was found mutated in families with an autosomal dominant form of FSGS 
[91,94]. These mutations may cause a gain of function. The P112Q mutated TRPC6 protein 
showed an enhanced influx of Ca2+, especially after activation of the G-protein-coupled 
receptor AT1 by angiotensin II, and the cellular localization of the mutant protein is more 
situated at the plasma membrane [94]. An increase in Ca2+ influx is also seen in two other 
missense mutations (R895C and E897K), but absent in three different ones (N143S, S270T, 
and K874X) [91]. In these cases an altered channel regulation or an altered interaction with 
other slit membrane proteins (like nephrin and podocin) may cause the disease [91 ]. In 
addition to the effects of gain-of-function mutations in the TRPC6 gene, also elevated levels 
of wild-type TRPC6 protein in some acquired glomerular diseases (like membranous 
nephropathy and puromycin aminonucleoside (PAN)-induced albuminuria) may lead to 
podocyte dysfunction [95]. The pathways that TRPC6 may modulate are discussed in a 
recent seminar [96].
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o List of diseases Mode of inheritance Protein
Protein
function Gene Chrom.
Protein expression 
kidney
Congenital Nephrotic 
syndrome of the Finnish 
type (CNF)
autosomal
recessive nephrin
key component 
of the podocyte 
slit diaphragm
NPHS1 19q13.1 podocyte slit membrane
Steroid-Resistant 
Nephrotic Syndrome 
(SRN1)
autosomal
recessive podocin
establishment of 
the podocyte slit 
diaphragm
NPHS2 1q25-q31 podocyte slit membrane
familial FSGS autosomalrecessive
CD2 associated 
protein
cytoskeletal 
remodelling, cell 
motility, 
endocytosis
CD2AP 6 podocyte slit membrane
familial tocal segmental
glomerulosclerosis
(FSGS1)
autosomal
dominant alpha-actinin-4 anchoring protein ACTN4 19q13
predominantly podocyte 
cell body
Denys-Drash Syndrome 
(DDS) / Frasier Syndrome 
(FS)
de novo 
(dominant) Wilms tumor 1
transcription
factor WT1 11 p13
nucleus and cytoplasm of 
podocyte cell body
familial focal segmental
glomerulosclerosis
(FSGS2)
autosomal
dominant
transient receptor 
potential cation 
channel 6
Ca2+ entry during 
cell proliferation TRPC6 11 q21 -q22
tubules, podocytes, 
mesangial and endothelial 
cells
early onset familial 
nephrotic syndrome
autosomal
recessive
phospholipase C 
epsilon
involved in cell 
growth and 
differentiation, 
gene expression
PLCE1 10q23 cytoplasm podocyte cell body
Pierson’s syndrome autosomalrecessive laminin ß2 chain
establishment of 
the glomerular 
basement 
membrane
LAMB2 3p21 glomerular basement membrane
mitochondrial disorder maternal non-protein tRNA amino acid supply NA mtDNA mitochondrion renal cells
CoQ10 deficiency autosomalrecessive
parahydroxybenz
o-ate-polyprenyl-
transferase
electron carrier in 
mitochondrial 
respiratory chain
COQ2 4q21.23 mitochondrion renal cells
Table 
1 
C
haracteristics 
of 
hereditary 
diseases 
involved 
in 
nephrotic 
syndrom
e
List of diseases Mode of inheritance Protein Protein function Gene Chrom.
Protein expression 
kidney
nail-patella syndrome de novo (dominant)
LIM homeobox 
transcription factor 1 
beta
transcription factor LMX1B 17q11 nucleus and cytoplasm of podocyte cell body
Schimke immuno- 
osseous dysplasia
autosomal
recessive
SWI/SNF2-related, 
matrix-associated, 
actin-dependent 
regulator of 
chromatin, subfamily 
a-like 1
gene regulation, 
replication, 
recombination, 
and DNA repair
SMARCAL1 2q34-q36 nucleus of podocyte cells and proximal tubule
mandibuloacral
dysplasia
autosomal
recessive
zinc metallo- 
proteinase STE24
potentially involved 
in processing of 
farnesylated proteins
ZMPSTE24 1 p34 unknown
Galloway-Mowat
syndrome
autosomal
recessive GMS1 unknown GMS1 unknown podocytes
Fechtner syndrome autosomal
dominant
nonmuscle 
myosinllA heavy 
chain
actin-based motility MYH9 22q12.3 tubular epithelia, 
mesangial cells and 
podocyte
action myoclonus- 
renal failure 
syndrome
autosomal
recessive
lysosomal integral 
membrane protein 
type 2
lysosomal 
degradation of 
macromolecules, 
RNA and DNA
SCARB2 4q13-21
lysosomal membrane of 
glomerular cells (study in 
mice)
0)çx
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O
O
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Chapter 1
PLCE1
PLCE1 (phospholipase C epsilon) belongs to the phospholipase C (PLC) family involved in 
intracellular signaling, necessary for cell growth and differentiation. PLC plays an important 
role in regulating the Ca2+ release from internal stores as well as the influx of Ca2+ through 
cation channels (like TRPC). PLC is activated by binding of a hormone or growth factor to its 
receptor and PLC in turn converts phosphatidylinositol-4,5-bisphosphate (PIP2) into inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). Plasma membrane channels are 
activated and cations flow into the cell [97].
In the kidney, PLCE1 expression is found in the podocyte cell body and foot 
processes [98]. PLCE1 expression appears at the S-shaped stage of glomerular 
development and is highly expressed during the early capillary loop stage [98]. Recently, 
positional cloning identified the PLCE1 gene being involved in families with early-onset NS 
and ESRD [98]. Renal histopathology generally shows DMS and histochemistry reveals 
reduced nephrin expression. In two patients (carrying the nontruncating missense mutation 
S1484L) biopsies revealed FSGS. In these patients the age of onset was relatively late as 
was the age of reaching ESRD [98]. A recent study in patients with isolated (non-syndromic) 
DMS, showed that PLCE1 truncating mutations are more frequently found than mutations in 
WT1 or LAMB2, two genes known to cause isolated DMS as well [99]. The authors speculate 
that missense mutations in PLCE1 may be associated with a milder disease course in 
isolated DMS or other histologic variants such as FSGS [98,99].
A zebrafish knockdown model was used to investigate the role of PLCE1 in the 
maintenance of the podocyte filtration barrier during development. The zebrafish PLCE1 
ortholog was knocked-down in embryo’s using antisense morpholino oligonucleotides and 
barrier function was assayed at 4-day-old embryo’s by vascular retention of a large FITC- 
labeled tracer molecule. In control embryo’s, the tracer molecule retained in the vasculature. 
Morpholino injected embryo’s showed abundant FITC-positive endocytic vesicles in the 
pronephric tubule, distal to the glomerulus. This indicated a breakdown of the barrier function 
in the pronephric glomerulus [98].
Laminin ß-2
The heterotrimeric laminin is assembled by three polypeptide chains: a, ß, and y. Different 
isoforms have been identified. Laminin-11 (a5ß2Y1) is predominantly found in the adult GBM 
and replaces the laminin-1 (a1 ß1 y1 ) isoform, initially expressed during kidney development 
[100].
Mutations in the LAMB2 gene, encoding the laminin ß2 chain, are associated with the 
Pierson’s syndrome. This syndrome is characterized by early onset nephrotic syndrome with 
DMS rapidly progressing to ESRD and distinct ocular abnormalities (in particular microcoria) 
[6]. The LAMB2 mutations result in loss of laminin-ß2 expression in the kidney and other 
tissues studied [6]. Mutations were also found in patients with congenital nephrotic syndrome
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(and FSGS) with or without minor ocular changes [101]. These results indicate genotype- 
phenotype correlations among patients with LAMB2 mutations. The authors speculated that 
complete loss-of-function (e.g. truncating) mutations appear to be associated with the 
complete Pierson syndrome, whereas missense mutations may display variable phenotypes 
ranging from a milder variant of Pierson’s syndrome to isolated congenital nephrotic 
syndrome with or without minor ocular abnormalities [101 ]. The frequency of hematuria in 
these patients is not clear from the clinical data.
Endothelium
Figure 2 Molecular anatomy of the podocyte slit membrane, schematic representation.
P = paxillin, V = vinculin, T = talin, Ca = calcium,© = negatively charged glycogalyx. Modified from [7], 
with permission.
Mitochondrial disorders
Mitochondrial cytopathies, either caused by mutations in the maternally inherited 
mitochondrial DNA (mtDNA) or in nuclear DNA, represent a heterogeneous group of 
multisystem disorders [102]. Mitochondria are non-uniformly distributed in tissues and 
mutated and wildtype mtDNA coexist in cells (heteroplasmy). These characteristics 
contribute to the large variety of clinical symptoms seen in mtDNA mutations [102].
Mutations in the tRNA LEU(UUR) gene are mainly associated with the MELAS syndrome 
(mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) [103].
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The most common transition A3243G is also found in patients with FSGS sometimes 
associated with maternally inherited diabetes and/or sensorineural hearing loss [104-111]. In 
most patients proteinuria is below nephrotic range and the FSGS progresses slowly.
The effect of the A3243G mutation to the function of the tRNALEU has been studied 
[112]. A3243G mutant tRNALeu have a shorter life span and the extent of aminoacylation 
(“charging” of a tRNA with an amino acid) was rather low (less than 30%) compared to 
wildtype [112].
Mutations were also found in other mitochondrial tRNA genes. In one patient a 
A5843G transition was found in the tRNATyr gene. The patient presented with mitochondrial 
cytopathy preceded by steroid-resistant FSGS. A skeletal muscle biopsy showed a combined 
respiratory chain deficiency and a partial deficiency of coenzyme Q10 most probably 
secondary to the oxidative damage [113]. Finally, the A4269G substitution in the tRNAIle 
gene is described in a patient with mitochondrial encephalomyopathy and multi-organ 
disorders including deafness, epilepsy, FSGS, and dilated myopathy later in life [114].
Coenzyme Q10 (CoQ10) plays an important role in the electron transport from 
complex I and II to complex III of the mitochondrial respiratory chain. Coenzyme CoQ10 
deficiency is associated with a variety of clinical phenotypes. Recently, a mutation in the 
nuclear DNA was found in a patient with CoQ10 deficiency [115]. This patient presented at 
age 12 months with proteinuria due to FSGS, mild psychomotor delay, and optic atrophy. 
Homozygosity mapping revealed a homozygous mutation in the COQ2 gene, encoding para- 
hydroxybenzoate-polyprenyl transferase, an enzyme involved in the CoQ10 biosynthetic 
pathway [115]. The pathogenity of the mutation was demonstrated by complementation 
experiments in COQ2 deficient yeast and showed full functional complementation after 
transformation with wildtype COQ2 but not mutant COQ2 [116]. This genetic defect of the 
respiratory chain, is related to late-onset nephrotic syndrome with multiple organ 
involvement. However, respiratory chain deficiency has also been reported in one infant with 
congenital nephrotic syndrome characterized by diffuse mesangial hypercellularity and focal 
tubular dilation [117] and in one infant with glomerular lesions characterized by crescentic 
glomerulonephritis [118]. The encephalopathy in patients with primary CoQ10 deficiency may 
be improved by oral CoQ10 suppletion. Recently, it is shown that early administration of 
CoQ10 may also result in progressive recovery of the renal function and reduction of 
proteinuria [119].
Other rare cases of hereditary FSGS and recent findings
The nail-patella syndrome is a rare autosomal dominant disorder characterized by dysplasia 
of the nails, absent or malformed patellas, dysplasia of the elbows and frequently glaucoma 
and progressive nephropathy. Renal biopsies reveal non-specific findings mostly related to 
the degree of renal failure, including FSGS, proliferative glomerulonephritis with crescent 
formation, and hyalinization of the glomeruli [120]. The gene involved is the transcription
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factor LMX1B which, among others, is required for expression of CD2AP protein and podocin 
[121].
Mutations in SMARCAL1 are involved in the development of Schimke immuno- 
osseous dysplasia. This autosomal recessive disorder is characterized by 
spondyloepiphyseal dysplasia causing growth retardation, defective cellular immunity, 
hyperpigmented macules, dysmorphic facial feature and nephrotic syndrome (due to FSGS). 
SMARCAL1 encodes an actin dependent regulator of chromatin which is involved in gene 
regulation, replication, recombination, and DNA repair [122]. More detailed studies of its role 
are provided by Elizondo et al [123]. Recently, mutations in SMARCAL1 were also found in 
two siblings with an incomplete phenotype of Schimke immuno-osseous dysplasia. The 
siblings were initially classified as suffering from familial steroid-resistant nephrotic 
syndrome. In prepuberty they had proportionate short stature which developed into 
disproportions during adolescence. No other syndrome-specific symptoms were found.
Milder phenotypes may be clinically overlooked [124]. It has been demonstrated that 
anthropometric measures are helpful to distinguish Schimke immuno-osseous dysplasia from 
other forms of chronic kidney disease [125].
In three patients (of two families) a nonsense mutation in tetraspanin CD151 causes 
end-stage familial nephropathy with pretibial epidermolysis bullosa and sensorineural 
deafness. The only available renal biopsy of one patient did not show FSGS but splitting of 
the tubular basement membrane and thickening and fragmentation of the GBM [126]. CD151 
null mice, however, develop massive proteinuria while aging caused by FSGS [127].
Mandibuloacral dysplasia (MAD) is a rare autosomal recessive syndrome with 
variable clinical features. These features include mandibular and clavicular hypoplasia, acro- 
osteolysis of terminal phalanges, delayed closure of cranial sutures, joint contractures, 
mottled pigmentation and lipodystrophy. MAD is also genetically heterogeneous: two loci 
have been identified. So far, most mutations were found in LMNA, encoding lamin A, a 
structural protein component of the nuclear lamina determining nuclear shape and size [128]. 
Only three patients have been reported with compound heterozygous mutations in 
ZMPSTE24. This gene encodes a zinc metalloproteinase involved in post-translational 
processing of prelamin A. Two of them presented with renal failure caused by FSGS, 
suggesting FSGS as a phenotypic manifestation in patients with ZMPSTE24 deficiency [129].
The Galloway-Mowat syndrome (GMS) is an autosomal recessive disorder 
characterized by microcephaly, severe mental retardation, hiatal hernia, and steroid- 
resistant nephrotic syndrome. In GMS, the nephrotic syndrome occurs in the first four months 
of life, is steroid-resistant and rapidly progresses to end stage renal disease. Histology 
shows heterogeneous lesions: minimal changes, endocapillary proliferation, FSGS (in most 
cases), and, in end stages, DMS [130]. Recent linkage studies in two Algerian families 
identified a homozygous mutation in the GMS1 gene. The protein encoded by this gene is 
expressed inmany tissues, including brain and glomerular podocytes, and has yet an 
unknown function [Nevo F, Machuca EA, Gribouval O et al (2008) Abstract J Am Soc 
Nephrol].
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Recently, MYH9 and SCARB2 have been identified as being involved in the 
development of FSGS. MYH9 encodes for the heavy chain of nonmuscle myosinIIA 
(NMMHC-IIA). Myosins of class II are widely distributed in most tissues and are essential 
components of the cell motor system involved in several important cell functions. These, 
among others, include phagocytosis, maintenance of cell shape and polarity, and intracellular 
organelle/particle trafficking [131]. Nonmuscle myosinII is composed of two heavy chains and 
two pairs of light chains. The NH2-terminal region contains an actin and ATP binding domain 
required for motor activity. The COOH-terminus allows the molecules to form filaments [132]. 
In the kidney, NMMHC-IIA is localized in the tubular epithelia and in the glomeruli it is 
expressed in podocytes and mesangial cells [133].
Heterozygous mutations of MYH9 are involved in a complex disorder named MYH9- 
related disease characterized by platelet macrocytosis, thrombocytopenia and leukocyte 
inclusions containing NMMHC-IIA. Complications that may arise are deafness, cataracts and 
renal failure. In the past, these patients were classified as being affected by May-Hegglin 
anomaly, Sebastian syndrome, Fechtner syndrome or Epstein syndrome. It is now believed 
that these disorders are not distinct entities, but rather a single illness with a continuous 
clinical spectrum [131]. In a large family with Fechtner syndrome, ten members carried a 
MYH9 missense mutation. Only two members had renal problems. Electron microscopy 
showed FSGS and segmental effacement of podocytes in these patients [133]. Why the 
other family members did not develop renal problems remains unclear. Most probably other 
additional factors play a role [133, 134]. More recently, MYH9 was suggested to be a risk 
gene for the development of idiopathic FSGS by usage of a genome scan on African- 
American individuals with FSGS. However, sequencing of the 40 exons and intron-exon 
junctions of MYH9 did not reveal any causal sequence variation. The authors hypothesize 
that the variation may occur in regulatory elements or splice-site determinants influencing 
RNA expression or protein structure [134]. Future studies are necessary to identify the 
precise role of MYH9 in the development of FSGS.
Action myoclonus-renal failure (AMRF) syndrome is a lethal inherited form of 
progressive myoclonus epilepsy associated with renal failure due to FSGS. It usually starts at 
15-25 years of age with proteinuria or neurological symptoms as tremor, action myoclonus or 
seizures associated with storage material in the brain [135]. Mutations in SCARB2 were 
found in three families with a single AMRF proband [135,136]. However, analysis of patients 
with nonsyndromic FSGS, MCNS, thin-basement membrane nephropathy, or non-Alport with 
haematuria and proteinuria did not reveal any mutations indicating a specific role of SCARB2 
in AMRF [135]. SCARB2 encodes for the ubiquitously expressed lysosomal integral 
membrane protein type 2 (LIMP-2) mainly found in lysosomes and late endosomes [136].
This LIMP-2 protein has been shown to act as a receptor to bind ß-glucocerebrosidase, the 
enzyme defective in Gaucher disease (lysosomal storage disorder) [137]. LIMP-2 deficient 
mice have also a kidney phenotype. The kidneys, which are non-hydronephrotic show pelvi- 
ureteric obstruction and glomerular lesions with mesangial hypercellularity and effacement of 
foot processes [135].
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Outline of the thesis
In the last years, the genetic defects described above, gave insight in the structure and 
function of the podocyte slit membrane and the development of nephrotic syndrome. FSGS 
patients belong to a heterogeneous group with different underlying causes. Although the 
development of FSGS is not completely and solely explained by these genetic defects, the 
knowledge whether a FSGS patient carries a genetic defect turned out to be very important 
for the treatment modality and prognosis of the patient. For example, most of the patients 
with NPHS2 mutations are steroid-resistant and further treatment with steroids may be 
stopped. Also, in most cases, there is no recurrence of nephrotic syndrome after renal 
transplantation in these patients. In patients carrying WT1 mutations further medical 
examination and regular check-ups are important given the higher risk of developing 
malignancies in these patients. Finally, mtDNA mutations may cause multi-systemic 
disorders.
The aim of this thesis was to further elucidate the role of podocyte dysfunction in the 
development of FSGS. In Chapter 2 we describe 2 patients with idiopathic steroid-resistant 
FSGS due to mutations in the WT1 and NPHS2 gene and we discuss the necessity of 
providing a standard mutation analysis protocol for steroid-resistant FSGS patients.
In Chapter 3 a patient is presented with the A3243G transition, particularly associated 
with the MELAS syndrome. This patient, in contrast to other described cases, presented with 
a full-blown nephrotic syndrome caused by FSGS. Physicians should be mindful for 
mitochondrial abnormalities, especially when there is a family history of diabetes mellitus, 
hearing loss, or neuromuscular disorders.
Chapter 4 describes a patient who, at later age than usual, was diagnosed with the 
Denys-Drash syndrome due to a mutation in the WT1 gene. The case is presented to inform 
physicians, other than paediatricians, about the syndrome and its treatment.
The effect of a CD2AP mutation on its interaction with F-actin is described in Chapter 
5. We describe a patient with a homozygous mutation in the CD2AP gene and by in vitro 
studies we showed a decreased interaction between F-actin and the mutated protein. 
Furthermore, isolated lymphocytes of the patient show no CD2AP expression.
An overview of mutations found in patients with idiopathic steroid-resistant FSGS is 
shown in Chapter 6. Moreover the role of combined gene defects is discussed.
Long-term consequences and the role of podocyte gene defects in the development 
of MCNS is evaluated in Chapter 7. Limited genetic abnormalities mutations were found in 
this group of patients suggesting these podocyte genes do not play a major role in the 
pathophysiology of MCNS.
To investigate the role of agrin, a GBM heparan sulfate proteoglycan, in the 
glomerular filtration system, we tried to develop a kidney-specific agrin knockout mouse 
model. These results are described in Chapter 8.
The results of these studies are summarized, discussed and put into perspective in Chapter 
9.
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WT-1 and NPHS2 mutation analysis in patients with 
non-familial steroid-resistant focal segmental 
glomerulosclerosis
Familial forms of steroid-resistant nephrotic syndrome with the histologic 
findings of focal segmental glomerulosclerosis have frequently a genetic 
basis. For the non-familial forms this is still unresolved. Ten children with 
non-familial steroid-resistant nephrotic syndrome along with focal segmental 
glomerulosclerosis were tested for mutations in the WT-1 and NPHS2 genes.
In one patient a mutation in intron 9 of the WT-1 gene and in one patient a 
heterozygous NPHS2 mutation could be detected. Both abnormalities are 
important for the treatment modalities and prognosis. Additional studies will 
have to provide a solid basis for the recommendation of mutation analysis in 
non-familial steroid-resistant focal segmental glomerulosclerosis.
M.M. Löwik, E.N. Levtchenko, L.A.H. Monnens, L.P.W.J. van den Heuvel 
Clin Nephrol. 2003; 59: 143-146
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Introduction
Much progress has been made in the genetic classification of familial steroid-resistant 
nephrotic syndrome with the histologic findings of focal segmental glomerulosclerosis 
(FSGS).
An autosomal recessive form is due to mutations within the NPHS2 gene, encoding 
podocin, a new integral membrane protein localised in the podocyte [1,2]. Autosomal 
dominant FSGS may be due to an abnormality of alpha-actinin 4 or has a gene locus at 
11q21 -q22 [3,4]. In Frasier syndrome, caused by mutations within the intron 9 donor splice 
site of the WT-1 gene, FSGS also occurs [5,6].
The aim of this study was to investigate the possibility that cases of non-familial 
FSGS are associated with WT-1 splice site mutations or NPHS2 gene mutations.
Methods
Patients
Ten patients with a proven histologic diagnosis of FSGS were included in this study. The 
relevant clinical data are summarised in table 1. All patients had normal genitalia and no 
dysmorphic features. In all patients the proteinuria did not disappear after the initial treatment 
by prednisone 60 mg/m2/day for 6 weeks. Subsequent treatment with cyclosporin A and a 
low dose of prednisone, in one patient combined with mycophenolate mofetil, resulted in 
complete remission in two and a partial improvement in 4 patients.
Two patients (numbers 8 and 9) reached end-stage renal failure at the age of 8 and 
14.5 years respectively.
More detailed information on patients 9 and 10 is provided, as DNA abnormalities 
were observed in both.
Table 1 Clinical data of the patients with idiopathic non-familial FSGS
Patient Sex
Age at onset 
months
Data at admission
Responseproteinuria serum albumin serum creatinine Immunosuppressive
g/l g/l ^mol/l treatment to treatment
1 M 12 19.2 20 35 csA, Pred CR
2 M 10 37.9 18 54 csA, Pred CR
3 F 128 11.1 18 51 csA, Pred PR
4 M 138 15.9 15 54 csA, Pred, MMF PR
5 F 22 49.4 19 141 csA, Pred PR
6 M 160 2.2 32 119 Pred PR
7 M 90 7.7 19 67 csA, Pred PR
8 F 49 6.3 30 36 csA, Pred no
9 F 103 14.5 23 51 csA, Pred no
10 M 42 6.0 26 79 csA,Pred no
M = male, F = female, csA = cyclosporin A, Pred = prednisone, MMF = mycophenolate mofetil, CR = complete 
remission and PR = partial remission.
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Case 1
Patient 9, a white female, presented at the age of 8.5 years with general malaise, weight loss 
and abdominal pain. Her parents and two siblings were healthy. Physical examination was 
unremarkable; there was no peripheral oedema. Blood pressure was 120/80 mm Hg. 
Urinalysis revealed 14.5 g/l protein and 25-50 erythrocytes per high-powered field. Serum 
creatinine was 51 ^mol/l, albumin - 23 g/l and cholesterol - 8.6 mmol/l. Complement factors 
C3 and C4 were normal. Hepatitis B, C and HIV serology was negative. Renal ultrasound 
was normal. She did not respond to the initial treatment with prednisone 60 mg/m2/day during
6 weeks. Afterwards renal biopsy was performed. Light microscopic examination of renal 
tissue revealed FSGS in 4 glomeruli. The other 10 glomeruli showed slight mesangial 
hypercellularity. Patient 9 was treated with cyclosporin A and low dose prednisone with an 
initially partial response: decrease of proteinuria to 1 -2 g/l and increase of serum albumin to 
34-37 g/l. The treatment with enalapril had to be discontinued because of the development of 
urticaria. Four years later she developed an overt nephrotic syndrome despite the 
continuation of cyclosporin A treatment and the addition of prednisone and angiotensin II 
receptor antagonist. Renal function deteriorated gradually with the development of end stage 
renal disease at the age of 14.5 years. After the initiation of hemodialysis bilateral 
nephrectomy was performed because of the persistent nephrotic syndrome and severe 
hypertension. Histologic examination of both kidneys revealed no Wilms tumours. She is 
actually on the waiting list for renal transplantation.
Case 2
Patient 10, a white male, the only child of two healthy parents, presented at the age of 3.5 
years with an upper airway infection. Physical examination revealed severe peripheral 
oedema and ascites. Blood pressure was 120/83 mm Hg. Urinalysis showed proteinuria 6 g/l 
and microscopic hematuria. Serum creatinine was 79 ^mol/l, albumin - 26 g/l and cholesterol 
-10.8 mmol/l. Complement factors C3 and C4 were normal. As six weeks of prednisone 
treatment 60 mg/m2/day gave no improvement, renal biopsy was performed. Microscopic 
examination of renal tissue revealed FSGS. Patient 10 was treated with cyclosporin A, low 
dose of prednisone and enalapril. After 18 months of treatment the nephrotic syndrome 
persisted and the renal function deteriorated.
DNA sequencing
Genomic DNA was isolated from whole blood using the salting-out method [7]. Amplification 
of 10 WT-1 exons and 8 NPHS2 exons was performed by PCR. The primers for the WT-1 
gene were developed in intronic sequences flanking the respective exons and are available 
on request (GenBank accession number AH003034). The primers used for the NPHS2 gene 
(GenBank accession number AJ279246-AJ279253) have already been described by Boute 
et al [1]. The PCR products were analysed by DNA sequencing (Dye Terminator Cycle 
Sequencing, PE Applied Biosystems, Foster City, CA). The genomic DNA from 50 healthy 
controls was used to confirm mutations.
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Results
WT-1 mutation analysis
After sequencing the total WT-1 gene, we found one heterozygous de novo mutation in 
patient 9 (case 1). The mutation was not observed in the parents of patient 9. It concerns a 
mutation in intron 9, 1228+ 5 bp G>A substitution (figure 1a). Repeated PCR and DNA 
sequencing analysis affirmed this mutation in patient 9.
NPHS2 mutation analysis
In the NPHS2 gene we found a heterozygous polymorphism in patient 5 and patient 7 in 
exon 5, 686 G>A (Arg229Gln). This polymorphism was found in three out of the hundred 
control alleles.
Beside this polymorphism we also found a heterozygous mutation in patient 10 (case 
2), also in exon 5, 622 G>A (Ala208Thr) (figure 1 b). This mutation was not found in hundred 
control alleles. The mutated allele turned out to be maternal, as we also detected the 
heterozygous mutation in the genomic DNA of the mother.
Repeated PCR and DNA sequencing analyses affirmed the polymorphism and 
mutation in the patients.
A
G/A
T
B
G
T
G/A
!
W ild type Patient W ild type Patient
Figure 1 DNA sequencing results of patients 9 and 10. A. The heterozygous guanine (G) to
adenine (A) substitution at position intron 9 1228 + 5 bp of the WT-1 gene in patient 9.
B. The heterozygous guanine (G) to adenine (A) substitution at position 622 of the NPHS2 gene, 
resulting in a heterozygous substitution of the amino acid Alanine to Threonine in patient 10. The 
patients are shown on the right, wild types on the left.
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Discussion
Although a small group of patients was studied, two mutations were detected. In patient 9 an 
intron 9 splice site mutation within the WT-1 gene was observed. It turned out to be a de 
novo mutation as it was not found in both parents. This mutation has been previously 
described in patients with Frasier syndrome, defined by male pseudohermaphroditisme, 
progressive glomerulopathy and frequent development of gonadoblastoma [8-10]. We found 
this mutation in a patient with normal female phenotype and XX karyotype. The same 
mutation has been found in a female, presenting with proteinuria at the age of 6 and 
developing an overt nephrotic syndrome during the pregnancy at the age of 27. She 
transmitted the mutation to her child, presenting with male pseudohermaphroditism and 
diffuse mesangial sclerosis [11 ]. Further study of 37 children with primary steroid-resistant 
FSGS revealed intron 9 mutations only in a patient with diaphragmatic hernia proximal 
hypospadias and unilateral testicular ectopia [12]. Our finding of a WT-1 gene splice site 
mutation in 1 of 10 examined patients has practical implications for the patient as regular 
control of gonads and kidneys is required because of the risk of gonadoblastoma and rarely 
Wilms tumours.
In patient 10, one heterozygous mutation inherited from the mother was found in exon 
5 of the NPHS2 gene. Beside two families with compound heterozygous mutations, Boute et 
al also found only one heterozygous mutation in four families out of fourteen families [1 ]. 
Concerning the fact that NPHS2 is responsible for the autosomal recessive form of steroid- 
resistant FSGS it is most likely these patients have a second mutation in the DNA sequence 
regulating the RNA splicing process or, alternatively, in the promoter region of the NPHS2 
gene.
During the review process of the present communication, Caridi et al reported in a 
group of 44 patients with steroid-resistant non-familial FSGS mutations in the NPHS2 gene in
9 patients. Six patients had homozygous mutations and three patients had compound 
heterozygous mutations in the NPHS2 gene [13]. This data sustain our results and suggest 
that mutational analysis of the NPHS2 gene is a valuable approach in patients with idiopathic 
FSGS.
The finding of a polymorphism in exon 5 of the NPHS2 gene in 2 of 10 examined 
patients versus 3 of 50 tested controls might rise a question concerning the role of NPHS2 
polymorphisms in the pathogenesis of focal segmental glomerulosclerosis.
Even in this small series the genetic diagnosis was important because the disorder 
will not recur after transplantation (NPHS2 mutations). Our observations support the 
necessity of testing for mutations in the WT-1 and NPHS2 gene in steroid-resistant non- 
familial FSGS, which shall be established in additional studies.
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Mitochondrial tRNALeu(UUR) mutation in a patient with 
steroid-resistant nephrotic syndrome and focal segmental 
glomerulosclerosis
The heterogeneity of mitochondrial cytopathies is characteristic for this group 
of disorders, which preferentially affect the muscle and nerve system. The 
A3243G transition in the tRNA LEU(UUR) gene has been associated with slowly 
progressive forms of focal segmental glomerulosclerosis (FSGS). Here we 
present a patient who developed a severe nephrotic syndrome during her 
first pregnancy, which persisted after delivery, and proved resistant to 
immunosuppressive therapy. A sister of our patient had developed diabetes 
mellitus. We analyzed the DNA for the presence of the mtDNA A3243G 
transition. The DNA was isolated from peripheral blood leukocytes and urine 
sediments. Polymerase chain reaction was performed to amplify the mtDNA. 
Restriction enzyme analysis was used to detect the presence of the A3243G 
transition. Quantitative analysis of the A3243G mutation was done using the 
pyrosequencing technique and revealed a proportion of mutated mtDNA of 
30% in the leukocytes and 68% in the urine sediments of the proband. On 
further analysis we also found the transition in the mother, the diabetic sister 
and the daughter of the proband. MtDNA abnormalities can cause a steroid- 
resistant nephrotic syndrome, histologically characterized by FSGS. 
Physicians should be especially mindful of mitochondrial abnormalities when 
hearing loss, diabetes mellitus, or neuromuscular disorders are present in 
the patient or family members.
M.M. Löwik, F.A. Hol, E.J. Steenbergen, J.F.M. Wetzels, L.P.W.J. van den Heuvel 
Nephrol Dial Transplant. 2005; 20: 336-341
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Introduction
Focal Segmental Glomerulosclerosis (FSGS) is a common cause of the nephrotic syndrome 
in adults. FSGS is a description of a histological lesion and not a disease entity. In recent 
years much progress has been made in unraveling the pathogenesis of (various forms) of 
focal glomerulosclerosis. It has been demonstrated that mutations in podocytic proteins such 
as podocin and a-actinin 4 are responsible for autosomal-recessive and autosomal­
dominant forms of focal glomerulosclerosis [1]. Mutations in mitochondrial DNA (mtDNA) 
have also been associated with focal glomerulosclerosis.
Although mitochondrial cytopathies preferentially affect the muscle and nervous 
system, this group of disorders is characterized by their phenotypic heterogeneity. This large 
variety in clinical symptoms is due mainly to the co-existence of wild type and mutated 
mitochondrial DNA (heteroplasmy), unequally distributed between cells and organs [2].
A typical example of a mitochondrial cytopathy and its variety of symptoms is the 
A3243G transition in the tRNALeu(UUR) gene. In vitro studies have shown that the A3243G 
transition is responsible for a mitochondrial respiratory chain defect and that it disturbs the 
protein synthesis in the mitochondrion [3].
This mtDNA mutation is associated mainly with the MELAS syndrome (mitochondrial 
myopathy, encephalopathy, lactic acidosis and stroke-like episodes) [4]. Occasionally, renal 
tubular dysfunction and FSGS have been associated with MELAS [5]. Several other clinical 
presentations associated with the A3243G mutation include chronic progressive external 
ophthalmoplegia (CPEO), diabetes mellitus, (cardio)myopathy, hearing loss and dystonia 
[6,7].
More recently, this mutation was associated with FSGS in patients who were not 
diagnosed as having a MELAS phenotype [8-15]. In most patients the clinical picture was 
characterized by the absence of a nephrotic syndrome and a slowly progressive renal failure.
We present a patient with a full blown, steroid-resistant nephrotic syndrome, 
histologically characterized by FSGS, with evidence of abnormal mitochondria in the 
podocyte and the detection of mutated mtDNA in urine and blood.
Methods
Molecular Genetic Study
DNA was isolated from peripheral blood leukocytes using the salting-out method. Also, urine 
sediments were used to isolate DNA. After centrifugation of the urine for 10 minutes at 3000 
r.p.m., the pellet was washed with phosphate-buffered saline. DNA was extracted using a 
commercially available DNA isolation kit (Puregene™ DNA isolation kit; Gentra systems,
MN).
Screening for the A3243G mutation was performed by polymerase chain reaction 
(PCR) using the following primers: 5’-CAACTTAGTATTATACCCACAC-3’ and
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5’-ATTAGAATGGGTACAATGAGGA-3’. The PCR conditions were 92°C for 30 s, 55°C for 30 
s and 72°C for 60 s, for a total of 35 cycles leading to a PCR product of 162 bp. PCR 
products subsequently were digested overnight with Apal restriction enzyme. The presence 
of the A3243G mutation results in an additional restriction site on position 104 bp of the PCR 
product. The restriction fragments were analyzed on a 1% agarose gel containing ethidium 
bromide to visualize the DNA.
Figure 1 Light and electron microscopic pictures of the renal biopsy taken from the proband.
A. Light microscopy, silver staining. Shown is a glomerulus with peri-hilar segmental sclerosis, 
hyalinosis and an adhesion, consistent with an FSGS lesion. Arterioles and small arteries show 
moderate hyalinosis, subendothelially and in the media with a spot-like distribution, consistent with 
loss of smooth muscle fibers. B. Electron microscopy, original magnification 3000X. Glomerular 
segment with extensive foot process effacement of the podocytes. Most podocytes showed 
condensation of the actin cytoskeleton and mild vacuolation of the cytoplasm. Multinucleated 
podocytes were not encountered. The endothelium was swollen and vacuolated. The glomerular 
basement membrane has normal structure and width. Electron-dense deposits were observed in the 
paramesangial regions (not shown). C. Electron microscopy, original magnification 10 000x. 
Mitochondria in podocytes show abnormal morphology. Cristae appear irregular and frequently a large 
central vacuole with irregular outline is present. There appears to be transformation of mitochondria 
into lysosome-like vesicles, suggesting degradation of mitochondria.
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Positive DNA samples were analyzed quantitatively using Pyrosequencing™ 
technology (Pyrosequencing, Upsala, Sweden). Pyrosequencing was performed according to 
the protocol of the manufacturer. PCR of a mtDNA fragment containing the 3243 position 
was amplified using the following primers: universal primer (biotinylated), 
5’-GGGACACCGCTGATCGTTTA-3’; forward primer
5’-GACGGGACACCGCT GAT CGTTT ACAACTT AGT ATT AT ACCCACAC-3’ ; and reverse 
primer 5’- ATTAGAATGGGTACAATGAGGA-3’. PCR was carried out in a 50 ^l volume 
containing 0.02 ^M forward primer, 0.2 ^M reverse primer and 0.2 ^M of the biotinylated 
universal primer. PCR conditions were 920C for 30 s, 550C for 30 s, 720C for 30 s, for a total 
of 40 cycles. Single-stranded template DNA, which in the present assay is the forward strand 
of the fragment, was purified using streptavidin-coated Sepharose beads. The actual 
pyrosequencing was performed on the PSQ96 platform using sequence primer 5’- 
TATGCGATTACCGGGC-3’.
In a pyrosequence reaction, the four different deoxynucleotide triphosphates (dNTPs) 
are added separately one after the other. The incorporation of dNTP is accompanied by 
release of pyrophosphate (PPi). This PPi is involved in a light-producing reaction of which the 
amount of light produced is proportional to the number of nucleotides incorporated (figure 
3C). The light is detected by a charge coupled device camera and seen as a peak in a 
pyrogram. Apyrase, a nucleotide-degrading enzyme, continuously degrades ATP involved in 
the light-producing reaction, and unincorporates dNTPs. This switches off light production 
and regenerates the reaction solution. Because the forward strand is used as template in the 
sequencing reaction, the change detected in the present assay concerns a T to C exchange. 
In fact, the amount of dTTP and dCTP incorporated at position 3243 during the sequencing 
reaction was determined in this way and from this the percentage of heteroplasmy was 
calculated.
Results
Clinical history of the proband
Our patient was referred to our out-patient clinic at the age of 31 years because of a 
nephrotic syndrome that persisted after pregnancy. Dipstick-positive proteinuria was noted in 
the first trimester of pregnancy. At the 27th week, she developed pre-eclampsia and a 
Caesarean section was performed because of fetal distress. Six weeks after pregnancy 
termination, she visited the out-patient clinic.
The medication consisted of enalapril 5 mg twice daily, and bumetanide 1 mg twice 
daily. Her medical history was unremarkable. The family history was negative for renal 
diseases, deafness, or diabetes. At physical examination blood pressure was 132/80 mmHg. 
There was moderate oedema. Abdominal ultrasound revealed two normal sized kidneys. 
Laboratory investigation revealed a nephrotic syndrome and normal renal function: serum 
creatinine 73 ^mol/l, serum albumin 26 g/l and serum cholesterol 11.3 mmol/l. Proteinuria 
ranged from 8.2 to 15.8 g/10 mmol creatinine, and urinary ß2-microglobulin was 400 ^g/24h
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(normal value < 240 ^g/24h). The selective index calculated as clearance of IgG/clearance 
according to the Cockcroft and Gault formula was 101 ml/min. The urinary sediment revealed 
only sporadic erythrocytes, and many oval fat bodies.
Because of the persistence of the nephrotic syndrome, a renal biopsy was performed, 
~6 months after pregnancy. On light microscopy, characteristic lesions of focal 
glomerulosclerosis were present in five of eight glomeruli (figure 1a). There was no evidence 
of mesangial cell proliferation. We observed focal tubulo-interstitial infiltrate and tubular 
atrophy. Arterioles and small arteries showed moderate hyalinosis, both subendothelially and 
in the media, in a spot-like distribution, consistent with loss of smooth muscle cells. On 
immunofluorescence, we observed focal segmental coarse granular deposits of IgM and C3 
consistent with FSGS. In addition, there were granular depositions of IgA in the mesangium 
and to a lesser extent in the capillary walls. Electron microscopy showed diffuse podocytic 
foot process effacement (figure 1b). The endothelium was often swollen and vacuolated. 
Paramesangial deposits were noted. In view of the clinical presentation and histological 
picture, we favoured a diagnosis of idiopathic focal glomerulosclerosis occurring in a patient 
with IgA deposits of undetermined significance (see Discussion).
Treatment consisted of enalapril 20 mg, losartan 25 mg, bumetanide 1 -2 mg and 
atorvastatine 20 mg. Blood pressure was relatively well regulated, with values varying 
between 138/78 and 156/84 mmHg. Since proteinuria persisted at levels above 8 g per day, 
and renal function deteriorated with a rise in serum creatinine to levels of 112 ^mol/l, 
immunosuppressive therapy was instituted. However, successive treatment with prednisone, 
cyclophosphamide and finally plasmapheresis were all unsuccessful (figure 2).
Steroid treatment was complicated by the development of diabetes mellitus, which 
required oral antidiabetic therapy. At that time, patient informed us that her sister had in the 
meantime developed insulin-dependent diabetes mellitus. Because of our interest in the 
genetics of steroid-resistant focal glomerulosclerosis, we performed analysis for mtDNA 
mutations in DNA recovered from the blood and the urine.
Because of the abnormality found in the mtDNA, podocytes were visualized at greater 
magnification by electron microscopy. The pictures revealed abnormal mitochondria in the 
visceral epithelial cells (figure 1c). At present, patient is seen regularly at the out-patient 
clinic, with moderate proteinuria and slowly progressive renal failure (figure 2). In view of the 
observed mitochondrial mutation (see below), the patient was referred to the oto-rhino- 
laryngologist who found a hearing loss of 35 dB. Echocardiography disclosed concentric left 
ventricular hypertrophy, with a left ventricular mass index of 140 g/m2 (normal <110 g/m2). 
There was no evidence of asymmetrical hypertrophy of the interventricular septum.
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Figure 2 Time course of serum creatinine (A) and proteinuria (B) in the proband.
Because of a rise in serum creatinine and persistent proteinuria > 8g/day, treatment was instituted. 
Successive treatment with prednisone, cyclophosphamide and plasmapheresis (PF) as indicated was 
unsuccessful.
Molecular genetic study
We isolated DNA from peripheral blood leukocytes and urine sediment and tested the DNA 
for the presence of the A3243G transition in the tRNA LEU(UUR) gene. We found the mutation in 
both DNA samples after digesting the PCR fragment with Apal. Quantitative analysis 
revealed a proportion of mutated mtDNA of 30% in the leukocytes and 68% in the urine 
sediments.
We also tested DNA of the maternal relatives of the patient. The results are shown in 
figure 3. The mother of the proband revealed no mutation in her leukocytes, but a positive 
proportion of 62% in the urine sediments. To our knowledge, the mother has no clinical 
symptoms related to the A3243G mutation. The sister of the proband, who developed insulin 
dependent diabetes mellitus, was also found positive for both DNA samples. A proportion of 
25% was found in the leukocytes and of 28% in her urine sediments. Finally the daughter of 
the proband, who has normal renal function and no proteinuria, revealed the mtDNA 
mutation in a proportion of 51% in her leukocytes and 52% in her urine sediments.
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Figure 3 Family tree and results from the mtDNA A3243G transition analyses.
A. Family tree of the proband. The proband with a nephrotic syndrome is shown in black. The striped 
circle represents her sister who was diagnosed with diabetes mellitus. The percentages indicate the 
proportion of the A3243G transition in the tRNALeu(UUR) gene found in the different DNA samples. B = 
peripheral blood leukocytes; U = urine sediments. B. PCR fragments from the proband (P) and a 
normal control subject (C) after digestion with Apai. The 162-bp PCR fragment is digested to 104 and 
58 bp products when the transition is present. M = marker. C. The principle of pyrosequencing, which 
is described in Methods. D. Pyrogram of the proband obtained from DNA isolated from urine sediment. 
The percentage T indicates the amount of thymine and C the amount of cysteine to which thymine is 
mutated. Before addition of the nucleotides, enzymes (E) and substrate (S) are added.
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Discussion
To our knowledge, our case report is the first to document the development of FSGS and a 
severe steroid-resistant nephrotic syndrome in an adult patient with the mitochondrial 
A3245G transition. Mutated mtDNA amounted 30% in leukocytes and 68% in cells derived 
from urine sediments. Abnormal mitochondria were present in the podocytes. The mutation 
was also found in the family members, notably in a sister with diabetes mellitus.
Admittedly, we must consider whether this patient had IgA nephropathy in view of the 
deposits observed by immunofluorescence and electron microscopy. However, we feel that 
in our patient the clinical presentation and histological data favour a diagnosis of primary 
FSGS co-occurring with the incidental finding of IgA deposits. Specifically, we did not 
observe mesangial proliferative lesions; the patient never had episodes of macroscopic or 
microscopic haematuria. it is well known that IgA deposits in ++ to +++ intensity can be found 
incidentally in biopsies of otherwise healthy cadaveric donors (reported incidence 7-9%), and 
even in living donors without urine abnormalities. Furthermore, many patients have been 
reported who presented with a glomerular disease and displayed mesangial IgA deposits, the 
most characteristic being patients with minimal change disease [16]. In a recent study, 18 
patients with FSGS and IgA deposits were described, clearly demonstrating that these 
patients presented with a clinical picture and a prognosis that closely resembled that of 
patients with typical primary FSGS [17]
The interest of nephrologists for mitochondrial diseases has been fostered by 
publications concerning the involvement of the kidney in mitochondrial cytopathies [5,8]. 
tRNA mutations affects multiple pathways and can be traced to the destabilization of 
structural features that destroy the native tRNA conformation required for protein synthesis 
efficiency, aminoacylation, post-transcriptional modification and processing. The A3243G 
mutation alters the A14 nucleotide that is highly conserved in the tRNALeu. The mtDNA 
A3245G transition has been associated with the MELAS syndrome, and more recently with 
maternally inherited diabetes mellitus, hearing loss, cardiomyopathy and chronic progressive 
external ophtalmoplegia [6,7]. It has become evident that the mutation can also cause 
isolated renal disease in patients without signs of MELAS even after prolonged follow-up [8­
15].
In case reports and small studies, >30 patients have been documented with the 
mtDNA A3245G transition and FSGS [8-15]. Clinically, most patients had non-nephrotic 
proteinuria (<3g/day) and a progressive deterioration of renal function. In only two adult 
patients was proteinuria in the nephrotic range. One male patient was diagnosed at the age 
of 18 years with diabetes mellitus, which was very poorly controlled in the following years
[13]. At the age of 23 years, he had developed a severe renal insufficiency (serum creatinine 
522 ^ o l / l )  and proteinuria of 3.5 g/day. Renal biopsy disclosed numerous globally sclerotic 
glomeruli, an increase of mesangial matrix, thickened glomerular basement membrane on 
electron microscopy, and no foot process fusion. Also, abnormal mitochondria were not 
found in the podocytes. These data strongly suggest that diabetic nephropathy was a major 
cause of the renal disease. The second patient was a 50-year-old female, with a 4 year
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history of diabetes, who was referred with severe renal failure (creatinine clearance 15 
ml/min), polycystic kidneys and a proteinuria of 3g/day, below the nephrotic range [12].
Although our patient was not aware of any hearing loss, an abnormal audiogram was 
noted. Hearing loss was also frequently noted in the described patients, and, in most, 
hearing loss preceded the development or discovery of proteinuria [11,12,14]. Since hearing 
loss was often familial, it is not a surprise that many patients had been diagnosed with 
Alport’s syndrome [8,9]. Diabetes mellitus was also a frequent finding; however, in most 
patients, diabetes mellitus became manifest only during follow-up, after the discovery of 
proteinuria or renal disease [10,12,15].
Information on renal biopsy findings is somewhat limited. In the available biopsies 
there was evidence of FSGS with various percentages of globally sclerotic glomeruli [9-14].
In isolated cases, hyalinosis of the arterioles with evidence of smooth muscle cell necrosis 
and the presence of multinucleated podocytes has been reported [10,15]. Most characteristic 
was the finding of abnormal mitochondria in podocytes and tubular cells, reported in eight out 
of ten patients studied by electron microscopy [9-13].
Our patient disclosed the typical lesions of FSGS, and abnormal mitochondria were 
observed in the podocytes, although we must admit that these abnormalities were identified 
only when we specifically looked at higher magnification after discovery of the mtDNA 
mutation. We did not observe multinucleated podocytes. Notably, as described by others, we 
also observed some abnormalities of the vessel wall, with hyalinosis in a spot-like pattern, 
consistent with loss of smooth muscle cells [10-15]. These findings of vessel wall 
abnormalities have not been not emphasized thus far; however, they might suggest that 
dysfunction of the mitochondria in the vascular endothelial or smooth muscle cells could 
result in early vascular damage.
We analysed the presence of the A3243G transition in blood leukocytes and urine 
sediments. Patients harboring this mutation usually have higher percentages of mutated 
mtDNA in muscle or urine sediments than in cells derived from rapidly dividing tissues such 
as bone marrow. Since urine sediments contain podocytes but also tubular epithelial cells 
and cells of the lower urinary tract, the measured heteroplasmic load does not represent the 
actual load in the podocytes.
Chinnery et al. found no relationship between the level of A3243G in blood and the 
frequencies of any of the clinical features they assessed, such as recurrent stroke-like 
episodes, CPEO, diabetes mellitus, pigmentary retinopathy, deafness, dementia, ataxia and 
myopathy [7]. In contrast, they found a correlation between the levels found in muscle and 
certain clinical features, particularly if the amount of mutated mtDNA exceeded the 15% 
level. For example, the observed frequency of recurrent strokes rose from zero in individuals 
with 21 -60% A3243G in muscle to 94% for individuals with 91 -100% in muscle.
Although the literature data are limited, it is notable that the majority of patients with 
renal diseases and an A3243G mutation are female. Furthermore, in the female patients, the 
disease was often more severe. This suggests that the phenotypic (renal) expression of this 
mitochondrial cytopathy is influenced by hormonal factors. However, the preponderance of 
females is as yet unexplained.
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Should we screen all patients with primary FSGS for mitochondrial mutations? At 
present, the evidence in favour of such a strategy is lacking. In fact, two Japanese studies 
did not find the A3245G transition in 25 and 17 patients with primary non-familial FSGS 
respectively [10,11]. Clinicians should be suspicious of patients with steroid-resistant FSGS 
who present with some particular features such as deafness, diabetes, neuromuscular 
symptoms, cardiomyopathy or a family history positive for any of these. In conclusion, the 
mtDNA A3245G transition can be associated with FSGS and severe nephrotic syndrome. 
Clinicians should be aware of the clinical heterogeneity of mitochondrial cytopathies, which 
will allow earlier detection of these disorders. It is advised that patients with mtDNA 
mutations should be followed closely to detect the development of associated conditions 
such as diabetes mellitus and cardiomyopathy.
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The Denys-Drash syndrome
Chapter 4
A genetic childhood disease with consequences in adult 
life: the Denys-Drash syndrome
In a 17-year-old woman with absent sexual development and a congenital 
nephrotic syndrome leading to renal failure, the Denys-Drash syndrome was 
diagnosed after development of an ovarian dysgerminoma. The Denys- 
Drash syndrome is characterized by the triad: progressive nephropathy due 
to diffuse mesangial sclerosis, male pseudo-hermaphroditism (XY karyotype 
with ambiguous or female genital organs) and an increased risk of 
developing Wilms tumour and gonadoblastoma. The syndrome is generally 
caused by a genetic defect in the Wilms tumour suppressor 1 gene (WT1 
gene). A WT1 mutation and XY karyotype were also found in our patient. The 
WT1 gene encodes a transcription factor playing an important role in renal 
and genital development. The diagnosis of Denys-Drash syndrome had 
important consequences for the treatment and follow-up of the patient. The 
second gonad and the native kidneys were removed due to the increased 
risk of malignancy. Moreover, the finding of a XY karyotype could result in 
serious psychological problems. Physicians responsible for the health of 
adults are confronted more and more often with the consequences of 
childhood diseases. This case illustrates the necessity to inform such 
physicians about previously untreatable genetic diseases of childhood in 
order to provide adequate medical management of these patients.
M.M.Löwik, F.W.P.J.van den Berkmortel, C.Noordam, H.W.van Hamersvelt, L.P.W.J.van den Heuvel en 
E.N.Levtchenko
Ned Tijdschr Geneeskd2005; 149: 1751 -1755
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A growing number of diseased children reach adult life due to progress in medical treatment. 
Physicians responsible for the treatment of adult patients are therefore more often confronted 
with, for them, unknown paediatric disorders and genetic defects of which the symptoms 
manifests itself not sooner than in adult life or are still present at adult age.
Here we describe a case illustrating the complex care arising when a genetic 
paediatric disorder is diagnosed in adult life.
Case Report
Patient A, a 17-year old female, was first seen at the out-patient clinic Medical Oncology 
because of a dysgerminoma in the right abdomen (figure 1). The serum concentration of a- 
foetoprotein was 3.9 |jg/l (normal <10), human choriongonadotrophin (ß-HCG) 540 ng/ml 
(normal <2), and the lactatedehydrogenase (LDH) activity was 1901 U/l (normal <450). The 
tumour capsule was damaged during surgical removal.
Tumour 
renal transplant aorta
bowels
inferior dorsal muscle vertebra 
Figure 1 CT scan from patient A’s abdomen showing a large dysgerminoma of the right ovary.
The medical history of the patient shows a congenital renal insufficiency due to 
diffuse mesangial sclerosis (DMS) with nephrotic syndrome (figure 2). She underwent renal 
transplantation at 4-, 5-, and 16-years of age. The first transplant was removed several 
months after transplantation because of untreatable acute rejection. The second transplant 
was lost as a result of chronic rejection. The function of the third transplanted kidney was 
stable with immunosuppressive treatment: prednisone, tacrolimus and mycophenolate, with 
an endogenous creatinine clearance of 80 ml/min/1.73m2.
The patient was very small (body length of 153 cm) and completely pre-pubic. 
Examination using X-ray revealed a skeletal age of 12 years. Adjuvant chemotherapy with 2 
cycles carboplatin-etoposide-bleomycin was started because of the dysgerminoma and the 
damaged capsule during surgery. Since this treatment is nephrotoxic, the carboplatin was 
replaced by cisplatin and the bleomycin was administered in a lower dose.
V. cava
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Figure 2 Histological image of the kidney with diffuse mesangial sclerosis in the Denys-Drash 
syndrome; in the centre a glomerulus is seen with striking collapses of the capillary tuft, epithelial 
hyperplasia, and expansion of the mesangial matrix which can be recognized by the increase of black 
deposits. (silverstaining, ~ 260x magnified)
The renal insufficiency due to DMS with nephrotic syndrome pointed in the direction 
of the Denys-Drash-syndrome (DDS). This syndrome is characterized by (a) renal 
insufficiency due to DMS; (b) male pseudo-hermaphroditism with gonadal dysgenesis, XY- 
karyotype with ambiguous or female genital organs; and (c) Wilms tumour and a higher risk 
of developing gonadoblastoma which can degenerate in malignant dysgerminoma. When a 
dysgerminoma is diagnosed it is advisable to remove the second gonad as well since there is 
a higher risk of malignant degeneration of the remaining gonad.
In patient A genetic analysis was advisable because of the possible therapeutic 
consequences; the removal of the second gonad and the rudimentary native kidneys due to 
the higher risk of malignancies. Before the analysis was performed, a plan was set up to 
guide the patient through psychological and socio-emotional problems which may arise when 
a XY-karyotype is confirmed. The parents were completely informed and when the patient 
turned out to have a XY-karyotype, they would gradually inform their daughter with the help 
of a professional team.
The genetic analysis indeed revealed a XY-karyotype and also a de novo mutation in 
the Wilms-tumoursuppressor-1 (WT1) gene (1025 T>G, M342R), which confirms the 
diagnosis ‘Denys-Drash syndrome’. This mutation was described before and was found in a 
DDS patient with female genitalia and a 46XY-karyotype [1 ]. Our patient was informed and 
advised to remove the remaining gonad as well, considering the high risk of malignant 
degeneration. To induce puberty, hormonal substitution therapy was started consisting of 
ethinylestradiol, later also with progestatives. Since the risk of developing of a Wilms tumour 
in the patients rudimentary kidneys was substantial, we also advised her to remove them as 
well.
First the remaining gonad was removed by explorative laparoscopy. Pathological 
examination revealed a gonadoblastoma, a benign abnormality and possibly a pre-stage of 
for example a dysgerminoma. Gonadoblastoma were localised all over the peritoneum and 
since a complete removal could not be guaranteed, regular check-ups, especially the
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determination of tumour markers, was advised. Both kidneys showed nephroblastosis, also a 
benign abnormality and possibly a pre-stage of a Wilms tumour.
The secondary gender features developed completely in time and with the cyclic 
administration of progestatives the patient menstruated. At the last follow-up, at the age of 19 
years, she was fully informed about her XY-karyotype. We intentionally choose to inform the 
patient completely at the end of her sexual development and puberty. As yet the patient did 
not have many problems getting over her diagnosis.
Consideration
Nowadays patients survive a genetic and before untreatable condition much longer and this 
makes it necessary for physicians who are responsible for the treatment of adults to get 
notice of these conditions. Congenital (before the age of 1 month) or infantile (before the age 
of 1 year) nephrotic syndrome belongs to this category of conditions which in these days, 
due to helpful supporting treatments and the possibility to receive renal transplantation, have 
a better outcome.
Early nephrotic syndrome usually develops due to mutations in genes expressed in 
the glomerular podocytes. DMS, isolated or seen in DDS, is mostly caused by heterozygous 
mutations in the WT1 gene (chromoxome 11p13). Mutations in this gene are also found in 
patients with the Frasier syndrome (FS). This syndrome strongly resembles DDS and is 
characterized by focal segmental glomerulosclerosis, usually after the age of 5 years, absent 
virilisation with a 46XY karyotype, and a higher risk of developing gonadoblastoma, and 
more rarely Wilms tumours [2].
The WT1 gene consists of 10 exons (figure 3) coding a 52-54 kD transcriptionfactor.
In most cases DDS patients carry missense mutations in exon 8 or 9 resulting in an amino 
acid substitution. Mutations in exon 6 and 7 are found less often. Most mutations are de novo 
mutations although familial cases have been reported [3]. FS patients usually have intron 9 
mutations affecting the alternative splice site of exon 9 [4].
WT1 is essential for a normal development of gonads and kidneys. Postnatal WT1 is 
exclusively expressed in glomerular podocytes, Sertoli-cells of the testis, and granulosa cells 
of the ovaries [5].
Patient A with congenital nephrotic syndrome due to DMS was diagnosed with DDS 
only after developing a dysgerminoma of the ovaries. She was not diagnosed at an earlier 
age because of the complete absence of virilisation despite the 46XY karyotype. This is very 
uncommon in DDS patients and is more characteristic for FS [6]. These common 
characteristics even emphasize more the suggestion that FS and DDS are not single disease 
entities but the boundaries of a broad spectrum [7].
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Consequences of DDS diagnosis
For our patient the DDS diagnosis had important consequences for further treatment and
follow-up:
- Establishing a XY-karyotype in a girl and informing her about this finding may lead to 
psychological problems. It is therefore advisable to consult professionals, physicians and 
psychologists, with experience in these conditions. Often the family of the patient is 
informed first and a confidant is asked to inform the patient. Correct and complete 
information about the condition from the physician, written information and contact with 
other DDS patients are important to get over the emotional impact of this difficult 
diagnosis. An interest group was founded for girls with a XY-karyotype 
(www.aisnederland.nl).
- The removal of the second gonad because of a higher risk of malignant degeneration. 
Patients with a WT1 mutation have a higher risk of developing gonadoblastoma and 
dysgerminoma. The exact percentage of DDS patients who develop these tumours is 
unknown. About 90% of the patients with gonadal dysgenesis develop gonadal neoplasms 
[8]. Gonadoblastoma are stromal neoplasms, non-metastasising in-situ germ-cell 
malignancies. Gonadoblastoma may degenerate to dysgerminoma. These are fast 
growing and metastasising tumours. The are no clear guide lines concerning 
gonadectomy in patients with a WT1 mutation, a XX-karyotype, normal female genitalia 
and echographically normal ovaries. We advise to leave the gonads in situ and to perform 
echographical screenings for gonadoblastoma each year in these patient.
- The rudimentary kidneys were removed because of a higher risk of developing Wilms 
tumour. It is unclear whether or not the presence of undifferentiated kidney tissue found in 
the rudimentary kidneys of patient A meant she still had a risk in developing Wilms 
tumour. According to some, all DDS patients develop a Wilms tumour before the age of 5 
years [9]. This was not the case in patient A, again reflecting the diversity of this 
syndrome. Since the risk of developing a Wilms tumour is high, especially in DDS 
patients, it is advisable to perform bilateral nephrectomy when patients reach terminal 
renal insufficiency. However, this is not advisable before the age of 1 year, since the 
renin-angiotensin system plays an important role in the regulation of the blood pressure in 
infants and renin is produced by the kidney [10].
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Figure 3 Schematic representation of the Wilms tumour suppressor 1 gene (upper part) and the 
WT1 protein: the 10 exons of the gene are depicted as numbered rectangles and the alternative splice 
sites in exon 5 and 9 are colored red and results in 17 or 3 extra amino acids respectively. The 
transcription regulating domain of the WT1 protein is encoded by exon 1 -6; the zinc finger binding 
domain by exon 7-10.
Conclusion
Mutation analysis in the WT1 gene and karyotyping should be performed in all patients with 
DMS, also in patients with focal segmental glomerulosclerosis and ambiguous genitalia.
When at the age of 14 years the patient has not reached puberty yet, also in patients 
with renal insufficiency, we recommend chromosomal analysis.
The physician should be careful in informing the diagnosis to the person involved 
considering the psychological and socio-emotional aspects of this syndrome.
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Focal Segmental Glomerulosclerosis in a patient 
homozygous for a CD2AP mutation
Focal segmental glomerulosclerosis (FSGS) is a histologic diagnosis in 
several kidney diseases characterized by proteinuria and a severe decrease 
in kidney function. Mutations in several genes were found in patients with 
primary FSGS, one of which is a CD2-associated protein, CD2AP (originally 
referred to CMS). This gene encodes an adaptor protein that plays a role in 
endocytosis, cell motility and cell survival. Mice deficient of Cd2ap (the 
mouse homolog) die due to kidney failure, while heterozygous mice develop 
lesions similar to those of FSGS patients. In the kidney, CD2AP regulates 
the actin cytoskeleton. The only previously described patient with CD2AP 
mutation had a severely truncated protein. In this study, we describe a 
patient with a novel mutation resulting in a premature stop codon yielding a 
protein truncated by only 4%. This shortened CD2AP protein displays a 
significantly decreased F-actin binding efficiency in vitro with no expression 
of the mutated allele in the patient’s lymphocytes. Heterozygous expression 
of the CD2AP mutation in both parents did not lead to any kidney pathology, 
as both have normal glomerular filtration rates and no proteinuria.
M.M. Löwik, P.J.T.A. Groenen, I. Pronk, M.R. Lilien, R. Goldschmeding, H.B. Dijkman, E.N. Levtchenko, L.A. 
Monnens, L.P. van den Heuvel 
Kidney Int. 2007; 72: 1198-1203
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Introduction
Increasing numbers of patients, even in non-familial cases, are reported with focal segmental 
glomerulosclerosis (FSGS) owing to mutations in well-characterized genes. One of these 
genes is CD2AP (CD2-associated protein, originally named CMS).
Cd2ap, the mouse homolog of CD2AP, was first found in a yeast two-hybrid screen 
as a protein binding to the mouse T-cell membrane protein CD2, where it plays a role in 
clustering CD2 and polarizing the T-cell [1]. The role of Cd2ap in the kidney became 
apparent when Cd2ap knockout mice developed severe kidney problems and Cd2ap 
haploinsufficiency led to lesions resembling the human condition FSGS [2,3].
The human homolog CD2AP was found to directly bind p130Cas, a docking protein, 
which appears to play a role in the integrin-mediated cell adhesion to the extracellular matrix 
[4]. Over the years, more and more proteins were found to interact directly with 
CD2AP/Cd2ap and its function in several cellular systems became apparent (figure 1 and 
table 1). The direct interaction of the COOH terminus of Cd2ap with F-actin suggests that 
Cd2ap is involved in the regulation of the actin cytoskeleton [15]. Indeed, several studies 
showed interaction of CD2AP/Cd2ap with proteins involved in cytoskeletal remodeling and 
cell motility [7-9,20]. More recently it became apparent that CD2AP/Cd2ap plays a role in 
endocytosis [10-14], in the transforming growth factor-ß-induced apoptosis, and in the 
phosphatidylinositol 3-kinase/AKT survival pathway as well [19,21,22].
The CD2AP protein consists of 639 amino acids (aa) encoded by 18 exons 
(chromosome 6) and has a molecular mass of approximately 75 kDa. The protein structure 
includes several protein-binding domains and is highly homologous to the mouse Cd2ap 
(figure 2). At the NH2 terminus, three SRC homology 3 (SH3) domains are localized followed 
by a proline-rich region containing SH3-binding domains. Kirsch et al found four putative 
actin-binding sites at the COOH terminus (aa 534-538/599-603/610-614 and 631-635) similar 
to the LKKTET motifs found in a number of actin-binding partners [4]. Direct interaction 
between F-actin and Cd2ap was proven by actin filament precipitation assays. The COOH- 
terminal domain (aa 331 -637) of Cd2ap was found to bind to F-actin directly [15]. Finally, 
CD2AP also contains a super-coiled domain (SC, aa 597-639) through which the protein 
forms homodimers [4].
As yet, only one heterozygous CD2AP mutation detected in two patients with primary 
FSGS has been reported. In these patients, the nucleotide changes (GC>CT) affected the 
splice acceptor of exon 7 leading to a reduced expression level of CD2AP in lymphocytes [3]. 
In this report, a novel homozygous mutation is presented. Moreover, we were able to show 
that the CD2AP interaction with filamentous (F-actin) was affected by this homozygous 
mutation and that the mutated allele is not expressed in lymphocytes.
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Table 1 CD2AP/Cd2ap interacting proteins
Protein Function Reference
Anillin Actin-binding protein involved in cytokinesis Monzo et al. [6]
ASAP1 Membrane trafficking and cytoskeletal remodeling Liu et al. [7]
CAPZ/ CP Regulates the growth of the actin filament Hutchings et al. [8] and Bruck 
et al. [9]
c-Cbl Negative regulator of the tyrosine kinase signaling pathway Kirsch et al. [10], Cormont et 
al. [11], and Kobayashi et al. 
[12]
CD2 T-cell polarization Dustin et al. [1]
CFBP Internalization and down-regulation of the EGF receptor Konishi et al. [13]
Cortactin Regulation of receptor-mediated endocytosis Lynch et al. [14]
Endophilin Growth factor receptor endocytosis Lynch et al. [14]
F-actin Major component of the cell cytoskeleton Lehtonen et al. [15]
Flt-1 (VEGFR-1) VEGF receptor 1, involved in angiogenesis Kobayashi et al. [12]
2_QGr Regulates complex formation of proteins involved in growth 
signaling pathways
Kirsch et al. [4]
NPHS1 Key component of the podocyte slit diaphragm Palmen et al. [16] and Shih et 
al. [17]
NPHS2 Establishment of the podocyte slit diaphragm Schwartz et al. [18]
p130Cas Linking the actin cytoskeleton to the extracellular matrix Kirsch et al. [4]
PI3K Lipid kinase that controls complex cellular programs Kirsch et al. [4] and Huber et 
al. [19]
PKD2 Involved in preserving the kidney tubular epithelial cells Lehtonen et al. [5]
Rab4 Involved in early endocytosis Cormont et al. [11]
Synaptopodin Cell shape and motility Huber et al. [20]
Fyn, Scr, Yes Tyrosine kinases Kisch et al. [4]
Interacting domains of CD2AP/Cd2ap with the proteins enlisted above are illustrated in figure 1, with the 
exception of NPHS2, of which the specific domain is not known. The interaction between these proteins and 
CD2AP/Cd2ap are proven by in vitro interaction studies.
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PI3K, c-Cbl, synaptopodin F-actin
*
A - putative actin binding site based on LKKTET motifs 
*  - R612Stop
Figure 1 Schematic representation of the CD2AP/Cd2ap protein and its interacting partners. 
CD2AP/Cd2ap contains three SRC homology 3 (SH3) domains followed by a proline-rich region 
(P). At the COOH terminus, a super coiled domain (SC) is found. CD2AP/Cd2ap uses this domain for 
homodimerization [4]. The putative actin binding sites [4] and the location of the mutation described in 
this chapter are shown. The defined proteins are proven to interact in vitro with CD2AP and/or Cd2ap.
Methods
Study population
The molecular genetic study was performed in a group of 20 non-familial histologically 
proven FSGS patients. The study was performed with informed consent of the patients and 
their family members. The clinical data of the patient with the homozygous CD2AP mutation 
are listed under results.
Molecular genetic study
Genomic DNA was isolated from peripheral blood leukocytes using a salting-out method. 
Amplification of the CD2AP gene (GenBank accession numbers NM_001767 and 
NT_011109) was performed by PCR using primers in the intron regions flanking the exons. 
The PCR products were analyzed by DNA sequencing (Dye Terminator Cycle Sequencing, 
PE Applied Biosystems, Foster City, CA, USA). The genomic DNA from 50 healthy controls 
was used to confirm mutations and to exclude DNA-polymorphisms.
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Human m v d y i v e y d y d av hd d e l t i r v g e i i r n v k k l q e e g w l e g e l n g r r g m f p 50
Mouse MVDYIVEYDY DAVHDDELTI RVGEIIRNVK KLQEEGWLEG ELNGRRGMFP
Human d n f v k e ikre tef kd d s l p i k r e r h g n v a s l v q r i s t y g l p a g g i q p h p q 100
Mouse DNFVKEIKRE TEPKDDNLPI KRERQGNEAS LVQRISTYGL PAGGIQPHPQ
Human t k n i k k k t k k rqc kv l f e y i p q n e d e l e l k v g d i i d i n e e v e e g w w s g t l 150
Mouse TKAIKKKTKK RQCKVLFpYS PQNEDELELI VGD^/IDVIEE VEEGWWSGTL
Human n n k l g l f p s n f v k e l e vt dd g e t h e a q d d s e t v l a g p t s p ips l g n v s e t 200
Mouse NNKLGLFPSN FVKELESTED GETHNAQEES EVPLTGPTSP LPSPGNGSEP-------------  -------- * * * * * * * * * * * *
Human a s g s v t q p k k i r g igfgd if k e g s v k l r t r t s s s e t e e k k p e k p l i l q s l 250
Mouse APGSVAQPKK IRGIGFGDIF KEGSVKLRTR TSSSETEEKK TEKPLILQPL
Human g p k t q s v e i t k t d t e g k i k a k e y c r t l f a y e g t n e d e l t f k e g e i i h l i s 300
Mouse GSRTQNVEVT KPDVDGKIKA KEYCRTLFPY TGTNEDELTF REGEILSLIS* * * * * * * ------------------------- *------*------------------------ *---------- n -------
Human ketgeagwwr gelngkegvf pdnfavqine ldkdfpkpkk p p p p a k a p a p  350 
Mouse KETGEAGWWK GELNGKEGVF PDNFAVQISE LDKDFPKPKK PPPPAKGPAP
Human k p e l i a a e k k  y f s l k p e e k d  e k s t l e q k p s  k p a a p q v p p k  k p t p p t k a s n  400
Mouse K P D L S A A E K K  AFPLKAEEKD  E K S L L E Q K P S  KPAAPQ VP PK  K P T A P T K A S N
Human l l r s s g t v y p  k r p e k p v p p p  ppiakingev ssisskfete pvsklkldse 450
Mouse L L R S P G A V Y P  K RP EK PV PPP PPAAKINGEV SIISSKIDTE PVSKPKLDPE
Human ql p l r p k s v d f d s l t v r t s k etd v v n f d d i a s s e n l l h l t a n r p k m p g r r 500
Mouse QLPVRPKSVD LDAFVARNSK ETDDVNFDDI ASSENLLHLT ANRPKMPGRR
Human l p g r f n g g h s p t h s p e k i l k l p k e e d s a n l k p sElkkd^ c y s p k p s v y l s 550
Mouse LPGRFNGGHS PTQSPEKTLK LPKEDDSGNL KPLEFKKDAS YSSKPS— LS 
* * * * * * ** * * *
Human t p s s a s k a n t t a f l t p l e i k a k v e t d d v k k n s l d e l r a q i i e l lciveAl 600
Mouse TPSSASKVNT AAFLTPLELK AKAEADDGKK NSVDELRAQI IELLCIVDAL
Human k k dHg k e l eK l r k dLe e e k t m r s n l e m e i e KlkkaVl s s 639
Mouse KKDHGKELEK LRKELEEEKA MRSNLEVEIA KLKKAVLLS
Figure 2 Alignment of human CD2AP [4] and mouse Cd2ap [5] showing high homology. The 
asterisks indicate non-matching amino acids. The different domains are shown (SH3 domain 
underlined, praline-rich region in italic, and the SC domain in bold), and the putative actin binding sites 
are in rectangles.
Actin-binding assay
The actin-binding assay was performed as described before by Kaplan et al [23]. In short, we 
developed expression constructs holding the entire coding region of CD2AP for in vitro 
transcription. The wildtype cDNA of CD2AP was cloned into pBluescript II SK (+)
(Stratagene, La Jolla, CA, USA) by PCR and the mutant was created using the QuickChange 
II Site-Directed Mutagenesis kit (Stratagene).
In vitro translation of the wild-type and mutant CD2AP was accomplished according to 
the user’s manual of the TnT-Coupled Reticulocyte Lysate kit (Promega, Madison, WI, USA). 
To study the interaction of the non-labeled in vitro-translated products with F-actin, we first 
polymerized G-actin under the following conditions: incubating G-actin (1.3 pM) in a 40 pl 
reaction buffer containing (in mM): KCl (100), MgCl2 (2), ATP (0.5), DTT (dithiothreitol) (0.5), 
and Tris (10, pH 7.4) for 1 h at room temperature. Later, we added 5 pl (out of 25) of the in 
vitro-translated products and incubated for an additional hour. The samples were 
subsequently centrifuged at 100 000 g for 60 min at 210C. The supernatant was removed 
and used for gel electrophoresis. The pellet was resuspended in the initial volume of 40 pl 
and also used for gel electrophoresis on a 10% acrylamide gel. The samples were
65
Chapter 5
transferred to Immobilon Transfer Membranes (Millipore, Billerica, MA, USA) and probed by 
a rabbit polyclonal anti-CD2AP antibody (diluted 1:200; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) and by a mouse monoclonal anti-actin antibody (diluted 1:10 000; MP 
Biomedicals, Illkirch, France). Secondary antibodies were AP-conjugated goat anti-rabbit IgG 
and goat anti-mouse IgG (diluted 1:10 000, Tropix, Applied Biosystems, Foster City, CA, 
USA) and protein bands were visualized using CDP-Star chemiluminescent substrate 
(Tropix, Applied Biosystems). Finally, bands were quantified by an image analysis system 
(Leika, Cambridge, UK) to determine the percentage of binding protein.
CD2AP expression in lymphocytes
Lymphocytes were isolated from whole blood 4.5x diluted with phosphate-buffered saline 
using Ficoll Paque (1.078 g/ml; Pharmacia, Piscataway, NJ, USA) and centrifugation at 540g 
for 30 min. The interface was removed and washed 4 times with phosphate-buffered saline 
for 15 min at 300g. The cells were lysed on ice for 30 min in RIPA buffer containing protease 
inhibitors PMSG (pregnant mare serum gonadotrophin) (100 pg/ml), aprotinin (5 pg/ml) and 
sodium orthovanadate (1 mM). The cells were subsequently sonificated three times for 10 s 
and centrifuged at 13 000 g and 4 0C for 20 min.
Twelve microgram of total protein was separated on a 12% acrylamide gel and transferred to 
Protran Nitrocellulose Membranes (Schleicher & Schuell, Dassel, Germany). The 
membranes were probed by a rabbit polyclonal anti-CD2AP antibody (diluted 1:200; Santa 
Cruz Biotechnology) followed by a horseradish peroxidase-conjugated secondary antibody 
goat anti-rabbit IgG (diluted 1:2 000; DakoCytomation, Glostrup, Denmark). As a control for 
protein loading a mouse monoclonal anti-GAPDH (diluted 1:10 000; Abcam, Cambridge, UK) 
was used followed by a horseradish peroxidase-conjugated secondary antibody goat anti­
mouse IgG (diluted 1:1 000; DakoCytomation). Protein bands were visualized using the 
ECL+ detection reagents (Amersham Biosciences, Buckinghamshire, UK).
Results
Case report
A male child of consanguineous parents of Mediterranean ancestry with no family history of 
kidney disease was born prematurely at gestational age 35.3 weeks by caesarean section 
because of fetal distress. His birth weight was 2746 g and Apgar score was 9/10.
At the age of 10 months, the patient was evaluated because of a failure to thrive 
(height 68 cm (-2.5 s.d.), weight 6120 g (weight to height < -2.5 s.d.). His clinical examination 
revealed a pale skin color, enlarged liver (2 cm below the right costal margin), and no 
peripheral edema. Blood pressure was elevated (124/57 mm Hg). Laboratory examination 
demonstrated microcytic anemia (hemoglobin 5.8 mmol/l and mean corpuscular volume 78 
fl), normal serum creatinine (30 pmol/l), and low serum albumin 18 g/l. Anemia was 
successfully treated with iron and erythropoietin. Microscopic urine analysis showed 
microscopic hematuria (red blood cells > 30/hpf with > 60% dysmorphic red blood cells) and
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the presence of hyaline cylinders. Urinary protein excretion was severely elevated (total 
protein 10.5 g/l, protein/creatinine 60 g:10 mmol). Laboratory values during follow-ups are 
summarized in figure 3a. Renal biopsy was performed and demonstrated global glomerular 
sclerosis in 4/10 glomeruli ; 1/10 glomerulus showed a palisade conformation of the visceral 
epithelium, suggestive of collapsing type glomerulosclerosis; the other 5/10 glomeruli 
showed mesangial proliferation and matrix expansion and hypertrophic visceral epithelium. 
Electron microscopic examination of two glomeruli showed mesangial matrix expansion and 
mild effacement of the podocyte foot processes (figure 3b and 3c). Immunosuppressive 
therapy was deemed to be unuseful, considering the lesions observed in the renal biopsy.
Antiproteinuric therapy with enalapril and diuretics resulted in an initial reduction of 
proteinuria by >50%. Over the next year, a progressive deterioration of the glomerular 
filteration rate was noted. At 2 years and 10 months, the glomerular filtration rate estimated 
by Schwartz formula was 24 ml/min/1.73 m2, blood pressure was well controlled and the 
clinical condition of the patient was satisfactory. At the age of 3 years, the patient suddenly 
presented with severe hypertension, acute respiratory insufficiency, cardiac decompensation, 
and acute renal failure. This episode was preceded by several days of diarrhea and fever. 
Temporary ventilatory support was instigated, and peritoneal dialysis was commenced.
Blood culture revealed Salmonella Enteritides. Renal failure did not recover. At the age of 5 
years, the patient has undergone a successful post-mortal renal transplantation. No 
recurrence of proteinuria or anemia was observed. Blood analysis showed no lymphopenia. 
Before renal transplantation, the patient was treated with recombinant growth hormone to 
improve his growth velocity; however, after renal transplantation, his growth is still insufficient 
despite normal renal function and low steroid dose.
Urine examination of both parents revealed no proteinuria.
Molecular genetic study
We analyzed a group of 20 histologically proven FSGS patients for the presence of CD2AP 
mutations. In one patient, we found a mutation in exon 18 (figure 4). It concerns a 
homozygous substitution at position 1834 C>T (R612Stop), resulting in a premature stop 
codon situated at the COOH terminus. This premature stop codon leads to a truncation of 
approximately 4% compared to the native CD2AP protein. Both parents were proven to be 
heterozygous for this mutation. The mutation was not found in our control group of 50 healthy 
individuals.
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Figure 3 Clinical data and renal biopsy of the patient with the homozygous CD2AP mutation. A. 
Clinical data during follow-up showing a decline of glomerular filtration rate Schwartz and proteinuria 
and a slight elevation of serum albumin. B. Light microscopy (toluidine blue staining of semi-thin- 
sectioned plastic embedded biopsy). In the centre of the left panel, one glomerulus shows a 
segmental lesion (arrow), while the two other glomeruli show several degrees of mesangial 
proliferation (asterisks). The right panel displays a higher magnification of the glomerulus with 
segmental lesion (original magnification x20 (left) and x40 (right)). C. Electron microscopy. Left picture 
shows a segmental sclerosis lesion. On the right, an example of mesangial proliferation accompanied 
by mild increase of mesangial matrix is shown.
Actin Binding Assay
To investigate whether the detected CD2AP mutation affects the interaction with actin, we 
performed an actin-binding assay. In w'tro-translated CD2AP wild-type and mutant proteins 
were incubated with polymerized F-actin. After incubation, F-actin and the possible bound 
proteins were pelleted by centrifugation.
Western blot analysis shows a successful polymerization of globular-actin (G-actin) to 
F-actin, since a fewer amount of G-actin is present in the supernatant. Non-polymerized G- 
actin (incubated in water) stays in solution after centrifugation (figure 5a). In the absence of 
actin, the in vitro translated CD2AP protein also stays in the supernatant after centrifugation 
(figure 5b).
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Densitometric analysis of the wild-type CD2AP revealed an almost equal distribution 
between the supernatant (not bound) and the pelleted (bound) fraction. More accurately, the 
amount of wild-type CD2AP which was bound to F-actin and formed a pellet, was 
approximately 40% (figure 5c).
The mutant R612Stop protein shows, as predicted, a lower protein band (estimated 
molecular mass of approximately 70 kDa) compared to the wild-type (75 kDa). The amount 
of the R612Stop mutant protein bound to actin was reduced to approximately 6%. 
Consequently, a higher amount of the mutant protein is seen in the supernatant (figure 5c). 
This result provides evidence that the 4% truncation of the CD2AP protein at the COOH 
terminus owing to the mutation results in a disturbed interaction with F-actin. The actin- 
binding assay was performed in duplicate and showed identical results.
Figure 4 Sequence chromatogram of the CD2AP mutant. The arrows show the 1834 C>T 
substitution of the patient (Hom) and in the parents (Het) in comparison with the wild-type (Wt).
CD2AP expression lymphocytes
The patients with FSGS described by Kim et al showed a heterozygous CD2AP mutation 
with a reduced expression level of CD2AP in immortalized B-lymphocytes [3]. To determine 
the in vivo expression of CD2AP in the patient and his heterozygously mutated parents, we 
performed Western blot analysis on lysates from lymphocytes and compared the level of 
CD2AP expression with lymphocyte lysates from a control individual. Membranes were 
incubated with a polyclonal rabbit anti-CD2AP antibody and the results are seen in figure 5d.
The immunoblot shows no CD2AP expression in the patient carrying the R612Stop 
mutation homozygously (Hom). Furthermore, there is no difference in CD2AP expression 
between the parent and the control individual given the equal GAPDH presence. Both the 
control (Wt) and the parent (Het) show a band of the same molecular mass, while the 
truncated CD2AP protein has a predicted molecular mass of approximately 70 kDa. These 
results indicate that the mutated allele is not expressed.
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Figure 5 COOH-terminal truncation of 4% results in a disturbed interaction of CD2AP with F- 
actin and no CD2AP expression in lymphocytes. A. G-actin polymerizes successfully to F-actin under 
physiological conditions (lanes marked buffer) and forms a pellet (P) after centrifugation. In water non­
polymerized G-actin stays in the supernatant (S) fraction, and pellets at a low level (lanes marked 
water). B. In vitro translated CD2AP (5 of 25 pl, incubated in polymerization buffer without actin) is 
found in the supernatant fraction. C. In vitro translated wild-type CD2AP shows an almost equal 
distribution between the fractions, with 40% of the protein co-precipitated with F-actin (upper panel, 
lanes marked wild type). Protein R612Stop exhibits a slightly lower molecular mass because of the 
premature stop codon, and is found in the supernatant with only a negligible amount in the pellet (6%). 
The lower panel shows a successful polymerization of F-actin. D. CD2AP levels in a control sample 
(Wt), the patient (Hom), and one of the parents carrying the mutation R612Stop heterozygously (Het). 
Cell lysates from lymphocytes were immunoblotted with anti-CD2AP (upper panel) and with anti- 
GAPDH as a control for protein loading.
Discussion
In this report we describe a novel homozygous mutation in the adaptor-type protein 
CD2AP in a patient with FSGS. The mutation (R612Stop) results in a premature stop codon 
and a truncation of 4%, such that aa 613-639 of the protein are lacking. An actin binding 
assay, in which the in vitro translated mutated proteins were incubated with filamentous 
actin, showed a dramatic reduction of actin binding due to the R612stop mutation.
The functional consequences of CD2AP dysfunction/absence have been investigated 
by studying a mouse model [2]. The Cd2ap-/" mice (the mouse homolog of CD2AP) die at an 
age of 6-7 weeks because to severe kidney disease involving the glomerulus. Already in 1 - 
week-old knockout mice, glomeruli show an increase in size and cellularity, and electron 
microscopic examination showed foot process effacement. At 2 weeks of age, almost all 
glomeruli were affected and mesangial deposits were detected. By 4 weeks, glomeruli were
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sclerotic, capillary loops were extended, and an increase of mesangial deposits was seen [2]. 
Cd2ap+/" mice did not exhibit proteinuria, but showed glomerular lesions at 9 month of age, 
similar to the ones in 3 to 4-weeks-old Cd2ap-/" mice. Some lesions were similar to FSGS [3]. 
Because of the phenotype of Cd2ap+/" mice, primary FSGS patients have been tested for 
CD2AP mutations. One mutation reported in the literature affects the splice acceptor of exon
7 on one allele that replaces two nucleotides, GC with CT. This change results in aberrant 
splicing between exon 4 and 18, and the predicted protein product would lack more than 
80% of the CD2AP protein. This mutation yields to reduced CD2AP expression, and no 
expression of the truncated allele, as investigated by immunoblotting CD2AP isolated from 
lymphocytes. In these patients CD2AP haploinsufficiency resulted in FSGS [3].
In this study we present a homozygous mutation in CD2AP (R612Stop), not 
described before. The predicted mutated protein would lack only 4% of the COOH-terminal 
end of CD2AP. This effect of the mutation in heterozygous state is subtle, since the 
heterozygous parents are not clinically affected. In the heterozygous state, the CD2AP 
expression level is similar compared to the wild-type expression level as shown by 
immunoblotting (Figure 5d). The presence of the wildtype sized and not the truncated sized 
CD2AP protein in the heterozygous parents strongly suggests that the mutated allele hardly 
influences expression from the wild-type allele. In the homozygous state, the effect of the 
R612Stop mutation is more dramatic. Analysis of the in vivo expression of CD2AP in the 
lymphocytes of the patient showed a complete absence of CD2AP expression (Figure 5d). 
Furthermore, we clearly showed that the COOH-terminal truncation of the CD2AP protein 
has serious consequences on binding F-actin as showed by the in vitro actin-binding system: 
only 6% of the truncated CD2AP protein was bound to F-actin compared to 40% of the wild­
type protein. Direct interaction between F-actin and the COOH terminus of Cd2ap (aa 331­
637) has been proven by precipitation assays before [15], and in CD2AP, four putative actin 
binding sites were found similar to the LKKTET motifs found in a number of actin binding 
partners [4]. The homozygous R612Stop mutation is located in the second putative actin- 
binding site in the super-coiled domain. The disturbance in actin binding, as showed by the 
actin-binding assay, provides evidence that the 27 amino acids COOH-terminal tail that is 
lacking due to the stop mutation is required for actin binding.
The R612Stop mutation may also affect (1) homodimerization that takes places via 
the super-coiled domain of CD2AP or (2) binding to other proteins like NPHS1, Rab4 or 
PKD2 (figure 1 and table 1). These proteins all bind CD2AP at a specific domain in which the 
homozygous mutation is situated. The R612Stop mutation has a subtle effect in 
heterozygous state, in contrast to the exon 7 splice acceptor mutation GC>CT (Kim et al) that 
has severe consequences when found heterozygous [3]. This difference is most probably 
caused by the level of truncation of the CD2AP protein. The 80% truncation owing to the 
splice acceptor mutation will have a more dramatic effect on CD2AP expression and function 
than the 4% truncation resulting from the R612Stop mutation. Apparently, for this reason, the 
effect of the R612Stop mutation is only observed when both alleles are affected.
In this paper, we have described a novel CD2AP mutation (R612Stop Hom) in a 
patient with primary FSGS. Although the first described mutation in CD2AP by Kim et al
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affected only one allele in two FSGS patients, we would like to stress that not all 
heterozygous CD2AP mutations cause kidney diseases as shown in our family. Development 
of FSGS clearly depends on the severity of the mutation.
Chapter 5_____________________________________________________________________
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Chapter 6
Bigenic heterozygosity and the development of 
steroid-resistant focal segmental glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS) is a major cause of steroid 
resistant nephrotic syndrome in childhood with a central role for the 
podocytes in the pathogenesis. Mutated proteins expressed in podocytes 
cause proteinuria. The role of combined gene defects in the development of 
FSGS is less clear. We analysed seven podocyte genes known to cause 
proteinuria and FSGS in a group of twenty non-familial childhood-onset 
steroid-resistant FSGS patients. These genes include NPHS1, NPHS2, 
ACTN4, CD2AP, WT-1,TRPC6, and PLCE1. We also screened for the 
mitochondrial A3243G DNA transition associated with the MELAS syndrome 
(mitochondrial Myopathy, Encephalopathy, Lactic acidosis, and Stroke-like 
episodes), and occasionally FSGS. No mutations were found in the ACTN4 
and TRPC6 genes, and no mitochondrial A3243G DNA transition was found 
in our group of patients. Two patients showed mutations in the CD2AP gene, 
one combined with a NPHS2 mutation. A tri-allelic hit was found in a patient 
carrying compound heterozygous NPHS2 mutations and a heterozygous 
NPHS1 mutation. In another patient a de novo WT-1 mutation was found 
combined with a heterozygous NPHS1 mutation, and finally, one patient 
showed a single heterozygous PLCE1 mutation. In our rather small group of 
20 steroid-resistant FSGS patients, four mutations in podocyte genes were 
found that could explain the pathology. Our data suggests that combined 
gene defects in podocyte genes may play a role in the development of 
FSGS.
M. Löwik, E. Levtchenko, D. Westra, P. Groenen, E. Steenbergen, J. Weening, M. Lilien, L. Monnens, L. van den 
Heuvel
Nephrol Dial Transplant. 2008; 23: 3146-3151
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Introduction
Focal segmental glomerulosclerosis (FSGS) is a major cause of steroid resistant nephrotic 
syndrome in childhood, accounting for about 75% of patients and frequently leading to end 
stage renal disease. The aetiology of primary FSGS remains unknown in most cases. The 
recurrence of the disease after renal transplantation in approximately one third of the 
patients, suggests the presence of a “circulating FSGS factor”, which until now has not been 
identified [1].
Molecular studies in humans and mouse models revealed a central role of glomerular 
podocyte damage in the development of FSGS [2]. A growing number of proteins, expressed 
by podocytes, contributing to the structure of the slit-diaphragm (nephrin, podocin, CD2AP) 
and/or function of the cytoskeleton (alpha-actinin 4) of the podocyte, cause proteinuria when 
mutated [3-6]. Mutations in the WT1 transcription factor [7] and in TRPC6 [8], a calcium­
permeable cation channel, also lead to abnormal podocyte function and proteinuria. More 
recently, mutations in PLCE1, encoding a phospolipase involved in the initiation of a cascade 
of cellular processes resulting in cell growth, cell differentiation, and gene expression, were 
found in familial FSGS patients [9]. The mitochondrial A3243G transition is mainly associated 
with the MELAS syndrome (mitochondrial Myopathy, Encephalopathy, Lactic acidosis, and 
Stroke-like episodes) [10], but is also found in FSGS patients possibly with or without 
maternally inherited diabetes and/or sensorineural hearing loss [11,12].
It might be suggested that the degree of podocyte dysfunction determines whether 
the patient would develop congenital nephrotic syndrome or nephrotic syndrome due to 
FSGS later in life. Studies in mice demonstrated that bigenic heterozygosity in podocyte 
genes (CD2AP¥l~ with Fyn+I~ or Synpo+I~ mice) led to the development of proteinuria and 
FSGS-like renal damage, while isolated haploinsufficiency did not cause renal disease [13]. 
Whether combined defects in podocyte genes play a role in the development of human 
FSGS is less clear. In this study, we have therefore investigated the occurrence of mutations 
of seven podocyte genes in a group of non-familial childhood-onset steroid-resistant FSGS- 
patients.
Subjects and methods
Patients
Twenty patients, aged 10-162 (average 73) months, 14 males, with steroid resistant 
nephrotic syndrome due to biopsy proven FSGS were analysed. Steroid resistance was 
defined as persistent proteinuria after 6 weeks of prednisone treatment (60 mg/m2/day). The 
relevant clinical data of the patients are provided in table 1.
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Molecular Genetic studies
DNA was isolated from peripheral blood leukocytes and urine sediments were collected from 
non-transplanted patients to isolate DNA using a commercially available DNA isolation kit 
(Puregene™ DNA isolation kit, Gentra systems, MN).
Amplification of the NPHS1 (GenBank accession number AF190637-AF035835), 
NPHS2 (AJ279246-AJ279253), CD2AP (AF164377/NT_007592), WT-1 (AH003034), ACTN4 
(NM_004924.2), TRPC6 (NP_004612), and PLCE1 (NM_016341/NT_030059) exons was 
performed by PCR. Primer data are available on request. The 5’-UTR region of NPHS1 was 
also analyzed. The PCR products were analyzed by DNA sequencing (Dye Terminator Cycle 
Sequencing, PE Applied Biosystems, Foster City, CA, USA). The genomic DNA from 150 
healthy ethnically matched control individuals was used to confirm novel mutations.
Screening for the mtDNA A3243G transition (MELAS mutation) was performed by 
PCR using the following primers: 5’-CAACTTAGTATTATACCCACAC-3’ and 
5’-ATTAGAATGGGTACAATGAGGA-3’, leading to a PCR product of 162 bp. PCR products 
were subsequently digested overnight with ApaI restriction enzyme. The presence of the 
A3243G mutation results in an additional restriction site on position 104 bp of the PCR 
product. The restriction fragments were analyzed on a 1% agarose gel containing ethidium 
bromide to visualize the DNA. Due to the heteroplasmic state of the mitochondrial mutation 
and the differences in threshold values of tissues, mutation analysis was performed using 
DNA from peripheral blood leukocytes and from urine sediment.
Results
All patients presented with steroid resistant FSGS. Treatment regiment after renal biopsy and 
response to this treatment are listed in table 1.
Not one patient had a mutation in the ACTN4 or TRPC6 gene and no MELAS 
mutation in the mtDNA was found. Four patients (20%) had mutations in WT1, NPHS1, 
NPHS2 and/or CD2AP genes that could explain the pathology (see table 2 and figures 1 and 
2). In addition, two patients showed three heterozygous PLCE1 mutations (see table 2).
Short clinical summaries and the results of DNA analysis of the four patients in which the 
disease-causing mutations have been established are provided below.
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Table 1 Clinical data of the patients with non-familial steroid-resistant FSGS
Data at admission
Pt Sex Age at onset 
(months)
Proteinuria
(g/l)
Serum
albumin
(g/l)
Serum
creatinine
(ymol/l)
Immuno
suppressive
Response to 
treatment
FSGS
classificationtreatment
1 M 42 6.0 26 79 csA, Pred no NOS, adv. Col.
2 F 36 5 16 21 Cph no mild Col.
3 F 103 14.5 23 51 csA, Pred no early NOS
4 M 10 10.5 18 30 no - Mes. prol.
5 M 38 14 14 45 Cph, Pred no Col.
6 M 138 15.9 15 54 csA, Pred, MMF PR
7 F 22 49.4 19 141 csA, Pred PR
8 M 160 2.2 32 119 Pred PR
9 M 90 7.7 19 67 csA, Pred PR
10 F 49 6.3 30 36 csA, Pred no
11 M 12 19.2 20 35 csA, Pred CR
12 M 10 37.9 18 54 csA, Pred CR
13 F 94 4.6 28 112 csA, Pred CR Col.
14 M 64 3.2 25 43 csA, Pred no adv. NOS
15 F 128 11.1 18 51 csA, Pred PR
16 M 100 55 22 45 csA no na
17 M 72 5.8 11.5 269 no, t - adv. Per.
18 M 40 4.3 16 40 csA, Pred PR Cel.
19 M 162 2.9 38 130 Pred CR* early NOS
20 M 98 21.1 13.9 41 Pred, Renitec CR Mes. prol.
Pt = patient, M = male, F = female, csA = cyclosporin A, Pred = prednisone, MMF = mycophenolate mofetil, Cph = 
cyclophosphamide, CR = complete remission and PR = partial remission. FSGS Classifications: NOS = not 
otherwise specified, Col. = collapsing lesion, Tip = tip lesion, Per. = perihilar lesion, Cel. = cellular lesion, Mes. 
prol. = mesangial proliferation, adv. = advanced, na = not available
In this patient a short-standing decline of proteinuria under prednisone treatment was seen followed by an 
increase of proteinuria and deterioration of renal function.
Patient 1
A white male, the only child of two healthy parents, presented at the age of 3.5 years with an 
upper airway infection and oedema. Physical examination revealed severe peripheral 
oedema and ascites. Blood pressure was 120/83 mm Hg. Urinalysis showed proteinuria 6 g/l 
and microscopic haematuria. Serum creatinine was 79 ^mol/l, albumin - 26 g/l and 
cholesterol 10.8 mmol/l. Complement factor C3 and C4 were normal. As six weeks of 
prednisone treatment 60 mg/m2/day gave no improvement, renal biopsy was performed. 
Microscopic examination of renal tissue revealed FSGS. Patient 1 was treated with 
cyclosporin A, low dose of prednisone and enalapril without clinical response. End stage 
renal disease developed at the age of 8 years, when haemodialysis was initiated. Renal 
transplantation with a post-mortal graft was performed a half year later. Native kidneys 
remained in situ. Because of delayed graft function, renal biopsy was performed two weeks 
after transplantation and demonstrated profound acute tubular necrosis and podocyte foot 
effacement. Recurrence of FSGS in the renal graft was suggested and treated with plasma
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exchange with only slight effect on renal function and proteinuria. At present he is 10 years 
old, has persisting nephrotic syndrome and pre-terminal renal failure.
Together with the earlier reported NPSH2 (A208T) mutation of maternal origin [14], a 
heterozygous mutation of CD2AP (1488 G>A, M496I) (figure 1a), not described before, of 
paternal origin was found. The amino acid substitution in podocin replaces the aliphatic 
amino acid alanine by threonine, an amino acid with a sulphur containing side chain. Using a 
standard phosphorylation prediction site (Netphos 2.0), the presence of threonine in the 
mutated podocin protein may introduce an additional phosphorylation site for the protein 
kinase CKI and may therefore alter the secondary structure and possibly its oligomerization. 
The mutation is situated at the C-terminus responsible for interactions with nephrin and 
CD2AP [15] that may be affected by the mutation as well. The CD2AP (M496I) substitution 
results in the replacement of the sulphur containing amino acid methionine in the aliphatic 
amino acid isoleucine. The mutation is located between the proline rich region and the super­
coiled domain at the C-terminus. Both parents had a normal serum creatinine and no 
proteinuria.
Table 2 Mutations detected in non-familial steroid-resistant FSGS patients
w t-1 n p h s i NPHS2 CD2AP p l c e i
P nt eff. st. 
sut. mut mut
nt eff. st. 
sut. mut mut
nt eff. st. 
sut. mut mut
nt eff. st. 
sut. mut mut
nt eff. st. 
sut. mut mut
1 622 A208T het 
G>A
1488 M496I het 
G>A*
2 791 P264R het 
C>G
413 R138Q het 
G>A
948 frame het
delT 
*  shift
3 1228+5 splice het 
G>A
1126 L376V het 
C>G
4 1834 R612X hom 
C>T
5 1807 E603X het 
G>T 
*
6 3491 T1164M het 
C>T 
*
3518 S1177F het 
C>T 
*
Patient (P) numbers 1-6 correspond with the numbers in table 1. * = Novel mutation, not reported in literature 
before, nt = nucleotide, sub. = substitution, eff. = effect, mut = mutation, st. = status, het = heterozygous, hom = 
homozygous
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Patient 2
A white female presented at the age of 3 years with mild periorbital and pretibial oedema and 
slightly elevated blood pressure (120/70 mm Hg). Urinalysis revealed proteinuria 4-8 g/l and 
microscopic haematuria. Serum creatinine was in the normal range (21 ^ o l/ l) .  During the 6 
week treatment with prednisone (60 mg/m2/day) the oedema became more pronounced. A 
biopsy was performed. Light microscopy showed collapse of some capillary loops with 
moderate sclerosis. Immunofluorescence demonstrated mild staining for IgM, C1q and C3 in 
the mesangium. Electronmicroscopy revealed fusion of the podocyte foot processes. 
Cyclophosphamide treatment gave no improvement. Her renal function gradually decreased. 
She received a post-mortal graft at the age of 5.5 years. The nephrotic syndrome did not yet 
recur.
Patient 2 presented a tri-allelic hit (figure 1 b and c) [16]. The heterozygous NPSH1 
mutation (791 C>G, P264R) has been described before [16]. The amino acid substitution is 
situated in the extracellular domain of nephrin, in the third immunoglobulin motif. The cyclic 
amino acid proline is replaced by the basic amino acid arginine. Two heterozygous NPSH2 
mutations were also found in this patient. The first mutation (413G>A, R138Q), paternally 
inherited, is already known [4]. The amino acid substitution situated at the C-terminus 
involves the replacement of the basic amino acid arginine to the acidic amino acid glutamine. 
The second one (948 del T), has not been described before and results in a truncated protein 
and a premature stop codon 31 amino acids downstream. This mutation is situated in exon 8 
and is responsible for an aberrant C-terminus of podocin. The mother had the NPSH1 
mutation and the NPSH2 deletion. Two brothers of the patient were also screened for the 
presence of the NPHS1/NPHS2 mutations (figure 2b). Both brothers were found to have the 
paternal R138Q NPHS2 mutation and one also showed the maternal P264R NPHS1 
substitution. Both brothers, as well as both parents, had normal serum creatinine and no 
proteinuria.
Patient 3
Patient 3, a white female, presented at the age of 8.5 years with general malaise and 
abdominal pain. Physical examination was unremarkable; there was no peripheral oedema. 
Blood pressure was 120/80 mm Hg. Urinalysis revealed 14.5 g/l protein and 25-50 
erythrocytes per high power field. Serum creatinine was 51 ^mol/l, albumin - 23 g/l and 
cholesterol - 8.6 mmol/l. Complement factor C3 and C4 were normal. Hepatitis B, C and HIV 
serology was negative. Renal ultrasound was normal. She did not respond to the initial 
treatment with prednisone 60 mg/m2/day during 6 weeks. Light microscopic examination of
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A CD2AP 1488 G>A (p)
G A  T N C C T G A T G C C T
(Ûkùûô o
B NPHS1 791 C>G (m)
C NPHS2 948 delT (m)
NPHS2 413 G>A (p)
Figure 1 Sequence chromatograms of patients 1 and 2. The left panel shows the mutations in 
the patients, the right panel the wildtype sequence. A. The heterozygous 1488 G>A (M496I) 
substitution in the CD2AP gene found in patient 1 (paternal, (p)). This patient also carries a 
heterozygous NPHS2 mutation (622 G>A, A208T, maternal) [14]. B. The arrow shows the maternally 
(m) inherited heterozygous 791 C>G (P264R) NPHS1 substitution in patient 2. C. The maternally 
(upper) and paternally (lower) inherited mutations in NPHS2, 948 del T and 413 G>A (R138Q) 
respectively in patient 2.
renal tissue revealed FSGS in 4 glomeruli and slight mesangial hypercellularity in the other
10 glomeruli. Patient 3 was treated with cyclosporin A and low dose prednisone with an 
initially partial response: decrease of proteinuria to 1 -2 g/l and increase of serum albumin to 
34-37 g/l. The treatment with enalapril had to be discontinued because of the development of 
urticaria. Four years later she developed overt nephrotic syndrome despite the continuation 
of cyclosporin treatment and the addition of prednisone and angiotensin II receptor blocker. 
Renal function deteriorated rapidly with the development of end stage renal disease at the 
age of 14.5 years. After the initiation of haemodialysis, bilateral nephrectomy was performed 
because of the persistent nephrotic syndrome and severe hypertension. At the age of 16 
years she received a post-mortal renal graft. Two-and-a-half years later she developed 
proteinuria (0.9 g/l) due to acute rejection without any signs of the recurrence of FSGS on
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renal biopsy. Treatment by methyl-prednisolone was successful. The patient is currently 19 
years old and has a well-functioning renal graft.
In addition to an earlier reported de novo WT-1 mutation [14], she has a 
heterozygous mutation of NPSH1 (1126C>G, L376V), already previously reported [3]. The 
heterozygous NPHS1 mutation was of maternal origin. The mother had no symptoms.
Patient 4
This patient has a homozygous CD2AP mutation (1834 C>A, R612X) and is the subject of a 
separate report [17].
NPHS2
A208T
CD2AP
M496I
1228+5 G>A
CD2AP
R612X
Figure 2 Family trees of the patients with mutations in one or more podocyte genes. A. Patient 
1 with mutations in NPHS2 (A208T) and CD2AP (M496I). B. The tri-allelic hit in patient 2 with 
mutations in the NPHS1 (P264R) and NPHS2 (delT/R138Q) gene. Parents and siblings did not show 
proteinuria. C. Inheritance of the NPHS1 mutation (L376V) in patient 3 also carrying the de novo WT-1 
mutation 1228+5 G>A. D. The CD2AP mutation (R612Stop) in patient 4. (circle = female, box = male, 
dashed circles/boxes represent heterozygous mutations, the filled box a homozygous mutation)
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Discussion
This is the first report on DNA analysis of seven podocyte genes in series of childhood-onset 
non-familial biopsy proven FSGS patients. Although this series of patients is rather small, it 
revealed interesting data suggesting that the combined haploinsufficiency in two podocyte 
genes might be responsible for the development of FSGS in humans.
Patient 1 had a combination of a previously reported maternal NPHS2 mutation [14] 
and a novel paternal CD2AP mutation. Both parents carrying one of these mutations 
exhibited no renal disease. This finding is extremely interesting in light of the recent studies 
in mouse models of FSGS, demonstrating that heterozygous CD2AP mutations might 
sensitise podocytes to mutations of other genes (synaptopodin and Fyn proto-oncogene), 
while isolated heterozygous mutations in these genes did not result in the development of 
FSGS [13]. Our data suggests that in patients with FSGS and heterozygous NPHS2 
mutations, the additional analysis of CD2AP gene is warranted.
A tri-allelic digenic inheritance observed in our patient 2 has been previously reported 
in 5 patients in the series of Koziell et al. [16]. Both NPHS2 mutations are situated in the 
nephrin binding domain (amino acid 125-385) [15]. Most probably the compound 
heterozygous state of the NPHS2 mutations is causative for the development of FSGS. This 
is strengthened by the fact that one of the patients siblings carries the heterozygous R138Q 
NPHS2 and P264R NPHS1 mutations and did not show any proteinuria. Furthermore, the 
NPHS1 mutation is not situated in the podocin interacting region of amino acid 1167-1256 
[18].
In patient 3 the heterozygous de novo intron 9 splice-site mutation of WT1 is probably 
responsible for the renal phenotype. This mutation is previously found in patients with the 
Frasier syndrome (nephrotic syndrome with FSGS, male pseudo-hermaphroditism, and a 
higher risk of developing gonadoblastoma). WT1 intron 9 splice site mutations are 
responsible for a disturbed DNA binding capacity of this transcription factor [19]. The role of 
the additional maternal inherited NHPS1 gene mutation is unclear. The NPHS1 mutation 
(L376V) is first described in a patient with congenital nephrotic syndrome of the Finnish type 
(large placenta, proteinuria at birth with nephrotic syndrome appearing during the first weeks 
of life). The patient was homozygous for one mutation (P368S) and had the L376V mutation 
in only one allele [3].
In one patient (nr 5) a single PLCE1 mutation was found (E603X). In the familial 
cases of nephrotic syndrome, two patients of one family out of six families investigated were 
found to have FSGS [9]. The biopsies of the other families revealed diffuse mesangial 
sclerosis (DMS). The histological differentiation between childhood-onset FSGS and infantile 
DMS is however not a sinecure. The single heterozygous mutation is most probably not 
causative for developing FSGS since both parents, and therefore also one of the carriers of 
this mutation, show no renal abnormalities. In a second patient (number 6) we observed two 
novel missense mutations in the PLCE1 gene (T1164M and S1177F). Both mutations 
originated from the paternal allele and could therefore not explain the clinical pathology. 
Although PLCE1 knockout mice did not show any nephrosis-like phenotype [9, 20], knocking
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down the zebrafish ortholog of PLCE1 showed foot process effacement and disorganization 
of the slit diaphragms. Nothing can be said about any possible effect on the glomerular 
filtration barrier when the zebrafish ortholog of PLCE1 was knocked down only partially. It is 
not unlikely that, as in patient 1, future studies might reveal another gene to be involved in 
the pathogenesis of FSGS in patient 5 and maybe 6.
The meaning of a heterozygous mutation in developing a renal phenotype is not clear 
[21]. A single mutation in a recessive disorder is unable to induce a pathologic effect. The 
second mutation may have gone unnoticed or that another gene(s) may produce an additive 
effect. This additive effect could be the mutation in CD2AP in our first patient. The observed 
mutations in patient 1 is highly interesting in this respect. Podocin is a protein of 383 amino 
acids with a membrane domain and two cytoplasmic ends at the C- and N-terminus [4]. 
Podocin oligomers associate in a lipid raft at the podocyte membrane and clusters nephrin. 
CD2AP is an adaptor protein that functions as an integral member of the slit-diaphragm 
complex by interacting with podocin and nephrin and anchoring them to the actin 
cytoskeleton. Podocin interacts through its C-terminal end (amino acid 125 to 385) with 
CD2AP and nephrin [15]. The heterozygous NPHS2 mutation in our patient was located 
inside the podocin interaction region and may impair the interaction with CD2AP. Two 
patients with FSGS and a mutation affecting the splice acceptor of exon 7 of CD2AP in one 
allele, described by Kim et al [6], resulted in a truncated protein. The paternally inherited 
CD2AP mutation in our patient is located between the proline rich region and the coiled-coil 
domain of the CD2AP protein. It is probable that the mutation in our patient affects the 
function of CD2AP to a lesser degree then in the patients described by Kim et al [6]. The 
CD2AP mutation alone is not responsible for the development of FSGS. The father with the 
heterozygous mutation of CD2AP had a normal serum creatinine and no proteinuria.
New genetic defects explaining FSGS will be revealed in the near future. For 
instance, missense mutations in LAMB2 encoding laminin ß2, may cause FSGS without eye 
abnormalities [22]. Analyses of LAMB2 was not performed in our group since patients with 
this disorder have rarely no eye abnormalities. The knowledge of a genetic defect is 
important as aggressive treatment of the nephrotic syndrome can be avoided and the 
prognosis of the renal transplant can be predicted, although the finding of a genetic defect 
does not exclude the recurrence of nephrotic syndrome in the renal graft [23,24,25].
Our data demonstrate that combined genetic defects in podocyte genes may play a 
role in the development of FSGS in humans. Altered interactions between several podocyte 
proteins can make podocytes vulnerable for the “second hit” factors and result in genetic 
susceptibility of a subset of patients. Further studies of the numerous podocyte genes 
coming from human and animal studies will provide new insights in the pathophysiology of 
FSGS in humans.
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Chapter 7
Long-term outcome of frequently relapsing minimal change 
nephrotic syndrome in children
Frequent relapsing and steroid dependent minimal change nephrotic 
syndrome (MCNS) originating in childhood can persist after puberty in over 
20% of the patients. These patients require immunosuppressive treatment 
during several decades of their life. We examined long-term side effects of 
persistent nephrotic syndrome and immunosuppressive medications 
focussing on renal function, growth, obesity, osteoporosis, hypertension, 
ocular complications and fertility in adult patients with childhood-onset 
MCNS. Molecular analysis was performed to evaluate on a possible 
association of a complicated course of MCNS with podocyte gene mutations.
We performed a prospective clinical examination of 15 adult patients, 
including serum and urine analysis, dual-energy x-ray absorptiometry 
(DEXA), ophthalmologic examination, semen examination and molecular 
analysis of NPHS1, NPHS2, CD2AP and ACTN4 genes. All patients had 
normal glomerular filtration rate. Most frequent long-term complications were 
hypertension (in 8/15 patients), albuminuria (in 7/15 patients) and 
osteoporosis in one third of the patients. Oligospermia was found in 1 
patient, reduced sperm motility in 4/8 patients and teratozoospermia in 6/8 
patients. Ophthalmologic examination revealed myopia in 10/15 patients and 
cataract in 3/15 patients. We found NPHS1 mutations/polymorphisms in 
10/14 patients and a heterozygous NPHS2 polymorphism in 2 patients. 
Children with MCNS persisting into adulthood are at risk for complications as 
osteoporosis, hypertension, cataract, myopia, and sperm abnormalities. Our 
study underscores a need for more effective and less toxic therapies for 
relapsing MCNS.
H.A.C. Kyrieleis, M.M. Löwik, I. Pronk, J.R.M. Cruysberg, J.A.M. Kremer, W.J.G. Oyen, L.P. van den Heuvel,
J.F.M. Wetzels, E.N. Levtchenko
Clin J Am Soc Nephrol. 2009; 4: 1593-1600.
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Introduction
Minimal change nephrotic syndrome (MCNS) accounts for 77 % of all cases of childhood 
nephrotic syndrome in a series of the International Study of Kidney Diseases in children.1 In 
general, long-term outcome of this disease is favourable and treatment with prednisone 
leads to complete remission in one third of the patients [1,2]. However, 30 % of these 
children develop a frequently relapsing course [1]. In this case, patients are treated with 
cyclophosphamide (CP). If relapses persist afterwards, treatment with cyclosporine A (CsA) 
is given, which allows to taper off the steroid dose, but frequently leads to CsA dependency, 
necessitating long-term immunosuppressive treatment. The percentage of childhood MCNS 
relapsing in adulthood varies from 10 to 40 % in the recent studies [2-4]. There are few data 
about the long-term prognosis in this group of patients, especially concerning possible side 
effects of the immunosuppressive medication.
While mutations in proteins expressed by glomerular podocytes were demonstrated in 
up to 30% of children with steroid-resistent focal segmental glomerulosclerosis (FSGS)[5,6], 
it remains undetermined whether underlying genetic alterations determine the susceptibility 
for MCNS, or predispose for a more severe course of the disease.
The aim of this study was to evaluate the long-term-outcome of children with 
frequently relapsing nephrotic syndrome (NS) that persisted into adulthood. We examined 15 
adult patients with biopsy-proven MCNS and focussed on possible side effects of 
corticosteroids and cytotoxic medication such as short statue, obesity, osteoporosis, 
hypertension, decreased renal function and infertility. Additionally, we performed molecular 
analysis of four genes expressed by glomerular podocytes (NPHS1, NPHS2, CD2APand 
ACTN4) to investigate whether the complicated course of MCNS was associated with 
mutations and/or polymorphisms in these genes.
Methods
Out of 103 patients with biopsy-proven MCNS treated in our hospital from 1971 until 2005 we 
identified 78 patients that were aged 16 years and older. Thirteen patients were lost to follow- 
up. Out of 65 patients 19 (29%) had at least one relapse of NS after puberty. Of the latter 
group, 15 patients with still relapsing MCNS agreed to participate in our study. The 
Institutional Review Board of the Radboud University Medical Centre Nijmegen approved the 
study. All subjects provided informed consent after explanation of the aims and methods of 
the study.
The clinical records of the patients were reviewed to determine the course of NS and 
the medications that were used. Complete remission of NS was defined as a reduction in 
urinary protein excretion rate to less than 4 mg/m2/h or proteinuria less than 0.2 g/10 mmol 
creatinine or by 0 to trace albuminuria on dipstick during 3 consecutive days. Partial 
remission was defined as protein excretion between 0.2 and 2 g/10 mmol creatinine without 
hypoalbuminemia. A relapse-free period of minimum 2 years without immunosuppessive
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medication was defined as a permanent remission. Patients were classified as frequent 
relapsers if they experienced 4 or more relapses in a 12 months period.
Baseline clinical and laboratory characteristics of the patients
Baseline clinical data, serum examination (urea, creatinine, glucose, HbA1C, lipids, albumin, 
FSH, LH, testosterone and oestradiol) and urinary analysis (albumin, creatinine, a-1- 
microglobulin) were obtained during complete or partial remission. Microalbuminuria was 
defined as urine albumin excretion between 20-300 mg/10 mmol creatinine in males and 
between 30-300 mg/10 mmol creatinine in females.
Short stature was defined as a height less than -2.5 SD compared to normal stature 
for age and sex in the Dutch population [7]. Body mass index (BMI) was calculated as 
weight/(height)2 (kg/m2). Weight excess was defined as a BMI greater than 25 in men and 
greater than 24 in women. Obesity was defined as a BMI greater than 30 [8]. Hypertension in 
adults was defined as a blood pressure of > 140/90 mm Hg or taking medication for high 
blood pressure [9]. Glomerular filtration rate (GFR) was calculated as creatinine clearance by 
the Cockroft -  Gault formula and corrected for body surface area (BSA) [10,11].
Treatment
At onset of NS all patients were treated with prednisone 60 mg/m2/day for 6-8 weeks and 
with prednisone 40 mg/m2/per 2 days during subsequent 4-6 weeks. Relapses of NS were 
treated by prednisone 60 mg/m2/day until the disappearance of proteinuria followed by 
prednisone 40 mg/ m2/2 days for 4 weeks. Because of the frequent relapsing course of NS, 
CP (2-3 mg/kg/day during 8-12 weeks) was administrated in all patients after performing the 
renal biopsy confirming minimal change disease. All patients continued to relapse after CP 
course and were treated with CsA combined with steroids. The dose of CsA was regularly 
adapted to maintain CsA trough levels between 100-150 ng/ml and was decreased in case of 
suspected toxicity, which was determined as 10% rise of serum creatinine between two 
outpatient visits. It was attempted to decrease the dose of prednisone to the lowest possible 
levels for preventing relapses and long-term side effects.
Because of the relapsing disease despite of CsA treatment, further immunosuppressive 
therapy was determined individually as mentioned in table 1.
Ophthalmologic examination
All patients underwent a standardized ophthalmologic examination, including assessment of 
best-corrected visual acuity, measurement of refraction, external inspection, measurement of 
intraocular pressures with applanation tonometry, anterior segment slit-lamp microscopy 
after mydriasis of the pupils, and direct and indirect ophthalmoscopy.
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Table 1 Clinical characteristics of the patients
Patiënt Sex Age at Age at Number of Cum. Height BMI Blood Current Duration
N onset time relapses CP dose pressure medications cyclosporine
of NS of study after last therapy
years years CP mg/kg cm kg/m2 mm Hg months
1 m 3 42 20 248 156.5 24.5 126/80 pred, CsA, 
ena, Ca
72
2 m 1.2 32 29 412 173.5 20.2 112/70 pred 115
3 m 6.4 17 7 154 183.5 19.8 125/80 CsA 109
4 m 2.7 28 12 176 174 22.0 130/70 pred, FK560, 
ena
72
5 m 2.5 36 41 414 159.5 17.6 120/75 tri, peri 66
6 m 2.2 32 9 182 183.5 31.0 120/80 pred, CP 58
7 m 3 32 10 129 184 31.4 115/70 - 7
8 m 3.6 20 34 165 175 22.2 140/70 pred, CsA, 
MMF
135
9 m 7.7 23 14 158 200 22.2 155/88 - 0
10 m 4.8 16 18 168 159.8 17.7 115/70 MMF 28
11 m 3 42 Unkn. 334 177 23.5 118/80 atenolol 124
12 m 5 19 26 168 169 18.8 136/64 CsA, Ca 144
13 v 2.6 18 16 150 172 19.2 110/70 pred, tacro, 
MMF, ena, vit 
D, Ca
81
14 v 7.3 23 30 Unkn. 162.5 20.5 120/80 pred, lor 148
15 v 2.6 26 >50 387 175 25.9 138/86 pred, CsA 174
Abbreviations: N, number; NS, nephrotic syndrome; CP, cyclophosphamide; Cum, cumulative; pred, prednisone; 
CsA, ciclosporin A; ena, enalapril; Ca, calcium; tri, triamcinolone; peri, peridopril; MMF, mycophenolate mofetil; 
vitD, vitamin D; lor, lorsatan; tacro, tacrolimus ; Unkn., unknown.
Dual-energy x-ray absorptiometry (DEXA-scan)
All patients underwent bone densitometry measurement by DEXA using a QDR 4500 
densitometer (Hologic, Inc., Waltham, MA). Standard procedures supplied by the 
manufacturer for scanning and analyses were followed. Bone mineral content (BMC, g) and 
areal bone mineral density (aBMD, g/cm2) were measured at the lumbar spine (L2-L4) and at 
the right femoral neck. Volumetric BMD was estimated using the formula for bone mineral 
apparent density (BMAD, g/cm3): BMAD-LS (lumbar spine) = BMC/A3/2; and BMAD-FN 
(femoral neck) = BMC/A2, where A is the projected bone area. The T-score is the BMD 
compared to young adults expressed in standard deviation difference. T-score between -1 
and -2.5 was defined as osteopenia and a T-score of less than -2.5 was defined as 
osteoporosis [12].
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Semen analysis
Fresh semen was obtained by masturbation from 8 patients and was analysed within 2 
hours. Concentration, motility and morphology were noted and WHO criteria were used for 
the cut-off levels [13]. The semen analysis was done once during the current study and had 
no defined temporal relationship to the last cyclophosphamide medication.
Molecular analysis
Genomic DNA was isolated from peripheral blood leukocytes and coding sequences of 
individual genes were amplified by polymerase chain reaction using intronic primers flanking 
the exons. Fragments included both DNA sequences of the individual exons, the splice donor 
and splice acceptor sites. Primer data are available on request. The following genes were 
screened: NPHS1 (accession number AF190637-AF035835), NPHS2 (AJ279246- 
AJ279253), CD2AP (AF164377-NT 007592), and ACTN4 (NM. 004924.2). The obtained 
products were analyzed by double stranded DNA sequencing on a 3130 XL Genetic 
Analyzer (PE Applied Biosystems, Foster City, CA, USA). The genomic DNA from 50 healthy 
controls and database search were used to confirm new mutations and exclude 
polymorphisms.
Results
Out of 65 adult patients with childhood-onset frequently relapsing MCNS we identified 19 
patients (29%) with at least one relapse in adulthood. Clinical and laboratory data of 15 
patients who agreed to participate in the study, the results of DEXA-scan and molecular 
analysis are presented in tables 1 and 2.
Clinical characteristics of the patients
The median follow-up period after the onset of NS was 24 years (10-39 years). The group 
consisted of 12 males and 3 females. The median age was 27.5 years (range 17.2-43.9 
years). Median number of relapses after CP course was 18 (7 -  50). Median cumulative dose 
of CP was 172 mg/kg (158 -  414). Five patients had one CP course, 6 patients had a 
second and 3 patients also a third course of CP. The cumulative dose of steroids could not 
be calculated because doses given for relapse treatment could not precisely be retrieved 
from the patient’s records. Twelve of 15 patients (80%) were still treated with 
immunosuppressive medication for preventing relapses of NS. The current 
immunosuppressive medication included prednisone (n=8), triamcinolone (n=1), CsA (n=5), 
tacrolimus (n=2), mycophenolate mophetil (MMF) (n=3), CP (n=1) (table 1).
Blood pressure was elevated in 2/15 patients and 6/15 patients used antihypertensive 
medication: ACE inhibitors (n=4), AT II antagonists (n=1) and beta blocker (n=1).
Short stature was observed in 3/12 men. The height of the female patients coped with the 
Dutch growth diagrams. In the male patients we observed obesity in 2 patients and a
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decreased BMI (18.8 kg/m2) in one patient (table 1). No correlation was found between 
height, BMI and the number of relapses.
Laboratory examinations, bone densitometry and ophthalmologic examination (table2)
The GFR calculated by the Cockroft-Gault formula and corrected for BSA was normal in all 
patients. There were no cases of diabetes mellitus or hyperlipidaemia. No patients received 
cholesterol-lowering drugs.
Urinary examination showed microalbuminuria in 3/15 patients and albuminuria in 
4/15 patients, while serum albumin was normal in all patients. Two patients had increased 
excretion of alfa-1- microglobuline (alpha-1 MG).
Osteoporosis was observed in 3/9 males and in 1/3 females. There was no 
correlation between BMC and BMI or height of the patients.
Ophthalmologic examination revealed myopia in 10/15 patients, bilateral 
posterior subcapsular cataract (PSC) in 3/15 patients, and amblyopia and convergent 
strabismus (esotropia) in 1/15 patients.
Fertility examination (table 3)
All patients completed normal pubertal development and achieved Tanner stages G5P5 in 
males and M5P5 in females. Sperm analysis was performed 0-32 years after the last CP 
treatment in 8 males. Hormonal status was normal in all examined men and women.
The semen analysis showed oligozoospermia in 1/8 males. Sperm motility was 
decreased in 4/8 subjects and 6/8 patients had teratozoospermia. Patient 6 still using CP at 
the time of analysis had normal sperm count and motility. Thus far one male patient fathered 
a child and one of the 3 females is actually pregnant.
Molecular analysis of NPHS1, NPHS2, CD2AP and ACTN4 
Molecular analysis of podocyte genes demonstrated a heterozygous NPHS1 mutation 
(Pro264Arg) in 3 patients, described before in patients with congenital nephrotic syndrome
[14]. The known NPHS1 Glu117Lys polymorphism was detected in a heterozygous state in 8 
patients and in a homozygous state in 1 patients [15]. The NPHS2 Arg229Gln polymorphism 
was found heterozygously in two patients. There was no correlation between number of 
relapses and the presence of genetic abnormalities. No mutations or polymorphisms leading 
to an amino acid substitution were detected in CD2AP and ACTN4 genes.
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Table 2 Results of laboratory examinations, dexa scan and molecular analysis
GFR Serum examination Urine examination Dexa scan Mutation analysis
N Sex Cockroft Album in Cholesterol Albumin Alpha 1 MG T-score T-score
ml/min/
1,73m2 g/l mmol/l mg/10 mmol mg/10 mmol right hip L2-L4
creatinine creatinine
1 m 131 40 4.9 861.1 7.4 -1.8 -2.3 NPHS1 349 G>A (E117K)
2 m 112 34 6.7 81 6.7 -1.2 -1.8 NPHS1 791 C>G (P264R)
NPHS2 686 G>A (R229Q)
3 m 101 47 3.6 12.4 2.2 nd nd NPHS1 349 G>A (E117K)
NPHS1 791 C>G (P264R)
4 m 109 44 4.8 187.6 26.2 -0.8 -2.5 NPHS1 349 G>A (E117K)
NPHS2 686 G>A (R 229Q)
5 m 101 47 5.9 7 7.8 -2 -2.8 NPHS1 349 G>A (E117K)
NPHS1 791 C>G (P264R)
6 m 144 39 5.7 347.6 17.7 0 -0.5 NPHS1ho349 G>A (E117K)
7 m 122 49 3.7 3.7 nd nd nd -
8 m 131 42 5 360.3 14.3 nd nd NPHS1 349 G>A (E117K)
9 m 196 43 4.1 13.9 2.5 0 -0.8 NPHS1 349 G>A (E117K)
10 m 123 39 4 5.4 4.4 -2.2 -3.6 -
11 m 105 42 4 nd 10.4 -1.8 -0.9 nd
12 m 185 46 3.5 21.8 2.3 nd nd NPHS1 349 G>A (E117K)
13 v 145 29 5.2 nd nd -1.9 -3 NPHS1 349 G>A (E117K)
14 v 108 40 4.2 344.3 4.4 -0.1 -0.5 -
15 v 126 39 4 7.9 3 0.4 -0.5 -
Ref.
values > 90 35-52 4,7-6,5 males <20 < 15
females <30
Abbreviations: N, patient number; GFR, glomerular filtration rate; Alpha1 MG, alpha-1 microglobulin; 
nd, not done; ho, homozygous; Ref., reference
D is c u s s io n
There are scarce data concerning the long-term outcome of children with MCNS. Two 
studies in the eighties conducted in the pre-cyclosporin era revealed a percentage of 5.5 % 
and 26 % of persistent relapses of biopsy proven MCNS in adulthood [3,4].
There are two more recent studies also including patients using calcineurin inhibitors. 
The first one by Fakhouri demonstrated that 42 % (43 of 102 patients ) of all childhood 
MCNS had at least one relapse after puberty [2]. Another recent study by Ruth found that 33 
% (14 of 42 patients) relapsed in adulthood [16]. Our own recent survey showed that more 
than 25 % of CP treated patients with childhood onset of MCNS needed medical therapy in 
adulthood [17]. In the latter study we found that the early age at presentation of NS
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influenced the risk of frequent relapses after puberty: an age at onset under 3 years 
significantly correlated with a higher risk of relapses after puberty [17].
Out of 78 patients described by Kyrieleis et al. [17], who achieved the adult age (>16 
years old), we examined 15 patients (19%) with relapsing course of NS after puberty and 
focused on long-term complications and possible underlying molecular defects.
Table 3 Results of fertility examination in male patients
Patient N* Concentration
10*6/ml
Motility
%
Dysmorphic head LH
E/l
FSH
E/l
Testosterone
nmol/l%
2 30 50 93 8.9 10.2 24
3 5 10 94 3.3 2 16
4 20 50 96 6.7 4 28
5 125 50 80 6.1 7.1 26
6 29 85 91 10.4 5.4 15
7 65 30 79 4.2 4.6 17
8 40 20 97 6 2.8 19
12 20 15 97 8.7 5.7 18
Reference values >20 >40 <90 1.4-8.5 1.5-11 11.0-45.0
N*: patient numbers in table 3 correspond to the numbers in tables 1 and 2.
Growth
It is generally accepted that prolonged use of corticosteroids results in impaired growth 
[18,19]. All our patients developed nephrotic syndrome at young age and were treated with 
corticosteroids for years. Three of 12 male patients had impaired growth, which supports the 
concept that the susceptibility for corticosteroids varies highly among different patients [18]. 
Growth impairment was not observed in 3 female patients, however, the low number of 
patients precludes any conclusion. Two men also had an increased BMI > 30, indicating 
obesity. No correlation between the number of NS relapses and the height or BMI of the 
patients could be observed, admittedly the cumulative dose of the steroids could not be 
calculated.
Treatment
At the time of the study only 2 of 15 patients did not receive any medications and were in a 
permanent remission of NS. Twelve patients were still using immunosuppressive 
medication. Two patients had elevated blood pressure and six patients were also on 
antihypertensive treatment indicating that hypertension is a frequent complication in this 
group of patients. This is in contrast with the data of Fakouri who did not report hypertension 
in his patient population [2].
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Renal function outcome and co-morbidity
As found in the other studies, renal function outcome was good in all patients, all of them had 
a normal creatinine clearance [2,16]. Our strategy of decreasing calcineurin inhibitors dose in 
case of serum creatinine elevation probably prevented overt renal toxicity. There were no 
patients with hyperlipidemia, diabetes or malignancies. Early reviews reported few cases of 
malignancies after protracted courses of CP, but these patients were treated continuously 
with CP up to 2 years [3]. It seems that the currently used dose of CP is rather safe 
concerning malignancies [20].
Ocular complications
Cataract and increased ocular pressure are recognized complications of prolonged steroid 
therapy [21]. Typically, cataracts caused by steroids are posterior subcapsular cataracts 
(PSC) which occur within the visual axis and therefore substantially impair visual acuity [22]. 
Despite its common occurrence, the mechanisms behind this complication has not been 
elucidated. Possibly steroids dysregulate proliferation and apoptosis of the lens epithelial 
cells [23,24], or can even directly bind to the lens proteins, resulting in changes of normal 
protein structure and lens opacities [25].
Hayasaka found in a group of 45 Japanese children with NS of various origin 33% 
with PSC [26]. The maximum total duration of prednisone treatment in these patients was 11 
years. Nine of 45 children had a transient increase in ocular pressure during the steroid 
treatment, which normalized after cessation of the medication in all but one patient.
Another study by Ng examined 29 children with NS (73 % with MCNS) [27]. In this study 10 
% of the patients had bilateral PSC and 6.5 % - marginally elevated intraocular pressure.
In our study population 20 % of the patients had PSC and no one had glaucomatous damage 
of the optic nerve head, possibly due to a transient character of ocular pressure elevation.
Interestingly, we observed a high prevalence of myopia, which was found in 66% of 
the patients. Although myopia nowadays affects over 30% of adults world-wide [28], its 
frequency in our patient group was twice as high. As far as we know, there are no reports on 
a deteriorative effect of immunosuppressive medications on ocular refraction. However, it 
would be important to study visual acuity and refraction in more detail in larger population of 
patients treated for a long time with steroids, CsA and CP. One might speculate that a 
transient elevation of intra-ocular pressure or changes of ion composition in the vitreous fluid 
due to the administration of loop diuretics could influence eye axial dimensions and refractory 
capacity.
Bone mineral density
Data concerning bone mineral density in patients with steroid sensitive NS are conflicting. 
Gulati demonstrated a decreased bone mineral content of the spine in a group of 100 
children with NS in 61 % of these patients [29]. In contrast, Leonard could not show 
significant deficits in bone mineral content in sixty children ages 9 +3.4 years with 
glucocorticoid sensitive nephrotic syndrome, when correction was made for bone area, age, 
gender, race and Tanner stage [30,31]. Only one study dealt with adults who were treated for
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childhood NS: Hegarty found in 34 adults a significantly decreased distal radial trabecular 
volumetric BMD (mean T-score -1.04) [32]. The authors suggest that their method is the only 
correct way to measure bone mineral content in patients with abnormal body size, which is 
often the case in subjects who have used corticosteroids [32]. Interestingly, 33/34 of the 
patients in this study had no relapses of NS during adult life. In contrast, all our 15 patients 
suffered from relapsing disease in adulthood. Therefore, the cumulative steroid dose should 
be higher in our group compared to the group of Hegarty. This might also explain that they 
found normal T-scores for BMD of the lumbar spine, whereas one third of our patients had T- 
scores of the lumbar spine lower than -  2.5, indicating osteoporosis.
Fertility
In the study by Hsu sperm analysis in 16 patients with idiopathic NS, 3-8 years after cytotoxic 
treatment, revealed azoospermia in 3/16 and oligozoospermia in 7/16 patients [33]. Six 
patients had normal sperm counts. The serum levels of LH and FSH were normal in most of 
these patients [33]. In this study there was no correlation between the cumulative dose of CP 
and the degree of abnormal sperm counts. However, a meta-analysis of the risk of infertility 
after CP treatment defined a threshold dose of 168 mg/kg [34].
We diagnosed one patient with oligozoospermia, the sperm motitlity was decreased 
in 4/8 subjects and the majority of patients had increased proportions of abnormal forms. The 
latter has been described in several studies as concurring with reduced sperm counts [17]. 
We did not find a correlation between the cumulative dose of CP and the risk of sperm 
abnormalities. The results of sperm analysis were better than expected: 7/8 patients should 
be able to father children according to semen quality. Female patients seem to have less risk 
of developing ovarial dysfunction after CP. In 12 women with NS treated by a shortcourse of 
CP no gonadal dysfunction was observed [35].
Molecular genetics
Alterations in podocyte genes, involved in the pathogenesis of congenital or steroid resistant 
nephrotic syndrome, might predispose the development of MCNS. The most frequent genetic 
defects found in our patient’s group were heterozygous mutations or polymorphisms in the 
NPHS1 gene encoding nephrin. Interestingly, these genetic defects were different from those 
described by Lahdenkari et al in a Finnish group of MCNS patients [36]. The NPHS1 
polymorphism Glu117Lys was previously described in association with decreased creatinine 
clearance in patients with IgA nephropathy [37]. According to the literature the allele 
frequency of this polymorphism is 36.7% in an ethnically matched control population.15 A 
similar allele frequency of 33.3% was found in our group of patients. The previously 
described polymorphism in NPHS2 (Arg229Gln), associated with increased risk of 
microalbuminuria [38], was detected on one allele of two MCNS patients. Tsukaguchi 
described an allele frequency of 3.6% for this polymorphism [39]. Since in vitro translated 
Arg229Gln podocin showed a decreased binding efficiency to nephrin, the possibility that 
NPHS2 Arg229Gln enhances susceptibility to focal segmental glomerulosclerosis in 
association with a second mutant NPHS2 allele is suggested [39]. In our study population the
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allele frequency for NPHS2 Arg229Gln was only slightly higher (6.7%). Because of 
comparable frequency of genetic alterations in NPHS1 and NPHS2 genes between our 
patient’s group and healthy population, it seems unlikely that these defects make podocytes 
more susceptible for nephrotic insults.
In conclusion, at least one quarter of patients with childhood-onset frequently relapsing 
MCNS will continue to relapse in adult life and require prolonged medical therapy. Although 
these patients maintain normal GFR, they frequently develop extra-renal complications such 
as osteoporosis, hypertension and decreased visual acuity due do cataracts and myopia.
One third of male patients treated with CP demonstrate decreased sperm count and motility. 
These findings indicated that new more effective and less toxic therapies should be searched 
for relapsing MCNS.
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A glomerulus-specific agrin knockout mouse -  
Practical Information
It is a general consideration that the permeability of the glomerular capillary 
wall is based on both size and charge of the proteins. In the glomerular 
basement membrane (GBM) the heparan sulphate proteoglycans (HSPG’s) 
are responsible for the anionic charge of this structure. Agrin is the major 
HSPG of the GBM and believed to play a considerable role in the charge- 
dependent permeability of the glomerular capillary wall. Agrin knockout mice 
die at birth with severe neuromuscular defects. To investigate the precise 
role of agrin in charge-dependent permeability, the aim was to develop a 
glomerulus-specific agrin knockout mouse model. The strategy was to 
generate a mutant mouse with floxed agrin genes. By subsequent 
crossbreeding with mice expressing cre-recombinase under the control of a 
nephrin-promoter, a mutant mouse deficient of agrin in the glomerulus only 
would be generated. Embryonic stem cells with a f-lox P flanked agrin gene 
were created by homologous recombination and were used to develop the 
mouse with floxed agrin genes. Unfortunately, germline transmission was not 
successful, thereby preventing the generation of the conditional mouse 
model. Recent studies in this field and new insights in the role of agrin in the 
charge-dependent permeability are discussed.
M.M. Löwik, L.A. Monnens, L.P. van den Heuvel, P.J.T.A. Groenen
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In tro d u c tio n
The filtration of the glomerular capillary wall is based on size- and charge-dependent 
permeability. The glomerular filtration barrier consists of a fenestrated endothelium covered 
by an anionic glycocalyx, the glomerular basement membrane (GBM) existing of extracellular 
matrix proteins and acting like a sieve, and finally the visceral epithelial cells or podocytes 
with cytoplasmic extensions called foot processes also covered by a glycocalyx. The 
structure of the glomerular filtration barrier determines the size-dependent permeability, while 
certain specific components are important for the permeability based on charge. Both 
endothelial cells and podocytes have an anionic glycocalyx, largely formed by 
glycosaminoglycan (GAG) sidechain containing proteoglycans and podocalyxin respectively 
[1,2]. Morphological alterations in the endothelial glycocalyx have functional consequences 
for glomerular permeability [2,3]. Injection of GAG-degrading enzyme chondroitinase in an 
experimental mouse model resulted in a decreased thickness of the endothelial cell 
glycocalyx and in an increase of albumin clearance [3]. A decreased thickness of the 
glycocalyx resulting in an increased flux of albumin is also seen when conditionally 
immortalized human glomerular endothelial cells are treated with neuraminidase, heparinise 
III, and human heparinitase II [2]. Podocalyxin is important in maintaining podocyte foot 
process structure. Podocalyxin deficient (-/-) mice exhibit profound defects in kidney 
development because podocytes fail to form foot processes and slit diaphragms [4]. These 
mice die within 24 hours after birth with anuric renal failure [4].
It is generally believed that the GBM is of primary importance in charge-dependent 
permeability. The anionic charge of the GBM is caused by proteoglycans. Proteoglycans 
consist of a core protein with Glycosaminoglycan (GAG) sidechains, mainly heparan 
sulphate GAG (HSPG’s) [5,6]. Three different HSPG’s have been identified in basement 
membranes so far: perlecan and collagen XVIII are mainly present in the mesangial matrix 
and Bowman’s capsule [7,8], whereas agrin is predominantly found in the GBM [9,10]. The 
agrin core protein carries at least two GAG chains (figure 1a) [10], mostly HS but also 
chondroitin sulphate (CS) [11].
Several studies have shown the importance of heparan sulphate (HS) for the charge- 
dependent permeability. In animal models, enzymatic removal or neutralization of GBM-HS 
results in proteinuria [6,12,13]. Human and experimental glomerulopathies show a reduced 
amount of GBM-HS [14,15] and a reduced staining for GBM-HS is correlated with an 
increase of albuminuria in both human glomerulopathies and animal models [16-18].
HSPG mutant mouse models show different effects on the function and structure of 
the glomerulus, dependent on the core proteins that are affected by homologous 
recombination. Mice lacking the perlecan HS binding sites show no kidney malfunctions or 
proteinuria but have small eyes with degenerating lenses and show a greater susceptibility of 
protein-overload proteinuria [19,20]. In these mice the mutant perlecan compensates the HS 
loss with attachment of other GAG chains like CS [20]. Ocular abnormalities are also seen in 
mice lacking collagen XVIII (Col18a1 -/-) [21]. The collagen XVIII deficiency also leads to 
structurally altered basement membranes and hydrocephalus in some cases [22]. In the
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glomerulus mild mesangial expansion is seen and also elevated serum creatinine levels were 
measured [22]. The authors did not look if proteinuria was present in these mice. The effect 
of agrin deficiency in mice is more dramatic. These mice have a normal development, but die 
at birth with sever neuromuscular defects [23]. For this reason, we tried to develop a 
glomerulus-specific agrin knockout mouse to analyse the role of this major HSPG in the 
function of the glomerular ultrafiltration. This chapter describes the strategy used to achieve 
this goal. Unfortunately, due to lack of germ line transmission, it was not possible to generate 
glomerulus-specific agrin knockout mice. Finally, we will discuss literature about this subject 
published after our attempt to develop a glomerulus-specific agrin knockout mouse.
M a te ria ls  and  M e th o d s
Construction of the floxed agrin targeting vector and introduction in Embryonic Stem cells. 
The targeting vector was constructed using genomic DNA from an Ola129 mouse strain. The 
arms of homology were amplified by PCR and inserted into a pBluescript SKII (Stratagene) 
already containing a phosphoglycerine kinase (PGK)-Hygromycin selection cassette flanked 
by Lox P sites (pBS-Hygro). Three arms of homology are inserted (figure 1 b) using unique 
restriction sites. The left arm (L) constitutes exon 2 through a part of intron 5 and is 
approximately 1950 bp. This arm is inserted in pBs-Hygro at the 5’ site of the selection 
cassette. The middle arm (M) of ~1200 bp continues through intron 9 and is placed at the 3’ 
site of the floxed (Lox P flanked) Hygromicin selection cassette. At the 3’ end of the middle 
arm, an additional Lox P site was added. To assure a proper insertion of this Lox P site into 
the mouse genome through homologous recombination, a right arm (R ~4710 bp) was 
inserted directly after the Lox P site and this arm starts in intron 9 and exceeds until exon 22. 
The vector was linearized with NotI and 15-20 ^g was electroporated in embryonic stem (ES) 
cells (~50*106) derived from an Ola129 mouse strain. Electroporation conditions: 250 Volt 
and 500 ^F. Putative homologous recombinants were isolated after ten days selection with 
hygromycin (300 ^g/ml) and DNA was isolated for Southern Blot analysis.
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Figure 1 Gene strategy glomerulus-specific agrin knockout mouse. A. The endogenous agrin 
gene with intron/exon boundaries. The filled boxes represent the exons and are numbered starting 
from the first shared exon after the distinct N-termini. Underneath, the structure of endogenous agrin 
with distinct N-terminal domains (N), alternative splice sites x, y and z, and two putative GAG 
attachment sites. F = follistatin-like repeats, L= laminin EGF like, S/T = serine/threonine rich, SEA = 
sperm protein/enterokinase/agrin, E = EGF like, LG = laminin globular domain. B. The targeting vector 
for the floxed agrin mouse model. Three arms of homology (L = exon 2/intron 5, M = intron 5/intron 9, 
and R = intron 9/exon 22) are inserted in pBSKII-Hygro. An additional Lox P site (triangle) was 
inserted between arm M and R in intron 9. Homologous recombination between the homology arms L, 
M, R and the endogenous agrin gene leads to the insertion of the Lox P flanked hygromycin cassette 
in intron 5 and the insertion of the third Lox P site in intron 9 (Lox P integrated agrin gene). 
Glomerulus-specific agrin knockout mice are generated by crossbreeding the floxed agrin mice with 
mice expressing cre-recombinase under the control of a nephrin-promoter. Cre-recombinase disrupts 
the agrin gene by removing exon 6 to 9 (disrupted agrin gene after Cre recombinase), resulting in a
F F F F F F F F F
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frame shift directly after exon 5 and a premature stop-codon 33 bp after the shift. The disrupted agrin 
protein only contains the first four follistatin-like repeats (disrupted agrin protein after Cre 
recombinase).
Molecular Analysis
DNA was digested with HindIII and separated on a 0.8% agarose gel. For Southern Blotting, 
the gel was denaturated for 1 hour in 1.5M NaCl / 0.5M NaOH and neutralized for 1 hour in 
1M TrisHCl / 1.5M NaCl at room temperature. The DNA was transferred O/N on 
nitrocellulose paper (Millipore) by capillary action in 2xSSC and then baked for 2 hours at 
80°C. Blots were prehybridised in 6xSSC, 0.5% SDS, 5x Denhardt’s solution and 100 |jg/ml 
denaturated Salmon testis DNA for 2-4 hours at 68°^. For the hybridization additional 0.01 M 
EDTA and 33P-labeled probe were added. Probes were made by PCR using complement 
primers and 33P-labeled dCTP. Blots were hybridized O/N at 680C. After washing the blot in 
2xSSC / 0.5% SDS the bands were visualized using X-ray film.
Positive clones are karyotyped to establish the number of chromosomes in the 
clones. ES cells were cultured in 6-wells plates and at 80% confluency, Colcemid (200 ng) 
was added to the media and cells were incubated for 1 hour at 370C. After trypsinizing and 
pelleting, three ml KCl (75mM, 370C) was added to resuspend the cells (10 min at 370C). 
Cells were washed three times with fixative (Methanol:Glacial Acetic acid = 3:1 ) and after the 
final wash resuspended in ~10 drops of fixative. The cell-suspension was dropped on a 
microsope slide and stained with Giemsa (10%). Further analysis of Southern-blot-positive 
clones was done by PCR.
ES Injection and Breeding
The ES cells were injected into blastocysts isolated from C57Bl6J mice according to 
standard protocol at MURINUS GmbH, Hamburg, Germany.
R e s u lts
Targeting Vector
In order to achieve a kidney specific agrin knock-out mouse, a targeting vector (figure 1b) is 
used to produce mice with floxed agrin genes. Crossbreeding these mice with mice 
expressing cre-recombinase under the control of a nephrin promoter [24], will result in 
glomerulus-specific agrin deficient mice. Three arms of homology were successfully inserted 
into pBs-Hygro. The strategy using three arms of homology instead of the normal two, was 
performed in order to achieve a frameshift resulting in a premature stop codon after cre- 
recombinase treatment. Detailed study of the structure of the agrin gene showed us this is 
only possible if the Lox P sites are placed in intron 5 and 9. The third most right arm was 
placed in the targeting vector to ensure proper insertion of the Lox P site in intron 9 by 
homologous recombination. After homologous recombination, the targeting vector will insert 
a floxed hygromycin cassette in intron 5 of the agrin gene and, as stated before, an
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additional Lox P site in intron 9. Thus, the mutated gene would lack exon 6 through exon 9 
after cre-recombinase. This results in a premature stop-codon 11 amino acids directly after 
exon 5. The linearized vector was electroporated in embryonic stem (ES) cells derived from 
Ola129 mice. Hygromycin selection resulted in the formation of clones. These clones were 
isolated and grown further for DNA isolation.
Molecular Analysis
To assure proper homologous recombination, Southern Blot analysis was performed. For 
Southern Blot analysis, genomic DNA from hygromycin selected clones and wildtype DNA 
were digested with HindIII and probed with 33P-labeled probes. Two probes (figure 2a) were 
used which both give a band of 10.1 kb in wildtype DNA. Positive clones also give a band of 
4 and 4.8 kb for probe 1 and 2 respectively. Of the clones isolated only two were found 
positive for both probes (figure 2b).
Positive clones were further analysed by PCR. To further exclude random integration 
of the targeting vector into the genome of the ES cell, we performed a PCR using a forward 
primer situated in exon 21 and a reverse primer in the pBlue vector. Visualisation of a band 
of 1197 bp indicates random integration, while no band implies a successful homologous 
recombination. Figure 2b (left panel) shows a band for randomly integrated vector DNA (-) 
while one of the positive clones (+) revealed no band.
A second PCR was performed to test the presence of the third Lox P site in intron 9. 
The forward primer in exon 9 and reverse primer in exon 10 give rise to a band of 280 bp in 
wildtype DNA and a band of 370 bp when Lox P is inserted. Figure 2b (right panel) clearly 
shows two bands of both the wildtype allele and the mutated allele with the additional Lox P 
site for the positive clone (+). Both PCR’s clearly confirm the results found with the Southern 
Blot. Both clones were found positive for homologous recombination.
To exclude any chromosomal degeneration, a karyotype was performed for both 
clones. The result of one clone is shown in figure 2c. The karyogram shows a normal number 
of 40 chromosomes.
ES Injection and Breeding
Positive ES cells were injected into E3.5 blastocysts isolated from C57Bl6J mice and 
replaced in C57Bl6J foster mothers. Six litters were born. Many pups were small and died 
shortly after birth. One litter was destroyed by the mother. Six chimeric mice, recognizable by 
their striped fur colour, survived. Three of them were male and first used to crossbreed with 
wildtype mice in order to get mice heterozygous for the floxed agrin gene. Since several 
attempts were unsuccessful, also the female chimeric mice were crossbred with wildtype 
mice. Also these did not lead to heterozygous mice with floxed agrin gene. Therefore, it was 
not possible to undertake the additional steps to generate glomerulus-specific agrin knockout 
mice. The designed glomerulus-specific agrin knockout mice would express an aberrant 
agrin protein, as Cre-recombinase excision would result in a disrupted agrin gene with 
removal of exon 6 to 9 which consequently results in an agrin protein that only contains the 
first four follistatin-like repeats.
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Figure 2 Molecular analysis of hygromycin selected ES clones. A. Floxed agrin gene after 
homologous recombination. Restriction enzyme HindIII is used for Southern Blotting. The HindIII 
restriction sites labelled with an asterisks are native sites and result in a band of 10.1 kb using probe 1 
or 2 (filled boxes numbered 1 or 2) when no Lox P sites are integrated (the so-called WT allele). The 
additional HindIII sites give a band of 4 and 4.8 kb for probes 1 and 2 respectively in case of 
homologous recombination. B. Northern Blot analysis of HindIII digested DNA. Wildtype DNA (lane 
marked WT) shows one band of 10.1 kb. Probe 1 and 2 (lanes marked 1 and 2) show an additional 
band of 4 and 4.8 kb respectively in positive clones. C. PCR analysis of positive clones. Random 
integration of the targeting vector is seen in a negative clone (left panel, lane marked -) since the PCR 
with a forward primer situated in exon 21 and a reverse primer situated in pBlueScript shows a band of 
approximately 1.2 kb. No band is seen in the positive clone after homologous recombination (lane 
marked +). The right panel shows a positive clone with two bands representing wildtype intron 9 (~280 
bp) and the mutated Lox P containing intron 9 (~370 bp), while the negative clone only shows the 
wildtype band. D. Karyogram of a positive clone with 40 chromosomes.
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D is c u s s io n
Agrin is the major heparan sulphate proteoglycan in the glomerular basement membrane and 
a decrease in heparan sulphate is generally associated with proteinuria. To investigate the 
precise role of agrin in the glomerular filtration, we tried to develop a glomerulus-specific 
agrin knockout mouse. This chapter describes the steps taken to achieve this goal. 
Unfortunately, we were not able to develop this mouse model because of the lack of germline 
transmission of the f-lox P mutated agrin allele.
The results described in this chapter shows a successful set up of the gene strategy 
necessary to develop the glomerulus-specific agrin knockout mouse. To ensure the targeting 
vector would result in a frameshift and a premature stop of the agrin protein, Lox P sites were 
placed in intron 5 and 9. For this reason, the targeting vector had to have three arms of 
homology. This gives rise to several ways of homologous recombination when transformed in 
ES cells. Homologous recombination could take place between the left and middle arm, the 
left and right arm, and the middle and right arm, with the latter not being viable because of 
the hygromycin selection. Because of the two possibilities left, more clones had to be 
checked for proper homologous recombination. Furthermore, since no negative selection 
cassette (like thymidine kinase (TK)) was used for random integration of the targeting vector, 
the number of false positive clones was even higher. Nevertheless we succeeded to find two 
positive clones as proven by Southern Blot and PCR analysis.
Very important in the development of transgenic animals when using ES cells, is the 
condition of these cells. They need to be of low passage number to lower the change of 
differentiation of the cells. Pluripotency is also more guaranteed when a differentiation­
inhibition factor like LlF (Leukemia lnhibitory Factor) is added to the medium during culturing. 
ln addition, culturing the cells on a layer of “feeder” cells (irradiated or mytomycin treated 
mouse embryonic fibroblasts) ensures pluripotency since feeder cells also produce LlF but 
are not able to divide any more. Non-pluripotent ES cells are not suitable for the generation 
of transgenic mice because this lowers the change of germline transmission dramatically.
The quality of our clones used to develop glomerulus-specific agrin knockout mice was 
apparently not sufficient for germline transmission. Most likely this can be attributed to the 
pluripotency of the used ES cells, since another attempt to generate mutant mice using the 
same batch of ES cells, failed as well.
Recently, glomerulus-specific agrin deficient mice were developed [25]. The gene 
targeting resulted in a frameshift (deletion exon 7 until 34) and truncated agrin proteins that 
lack most of the C terminus. Mice homozygous for the deficiency had no phenotypic effect. 
N-terminal fragments of agrin (deletion from the first follistatin-like domain on) were 
synthesized and properly localized to the GBM. The truncated N-terminal fragments were not 
glycanated, neither did any other GBM-HSPG compensate for the loss of HS. The anionic 
charge of the GBM was dramatically reduced but glomerular ultrastructure was 
indistinguishable and no pathological abnormalities were observed. These mice show that 
agrin is not essential for the initial assembly of the glomerular capillary wall or for its 
maintenance. ln all fairness, it is possible that the still synthesized N-terminal fragments of
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agrin in the mutant mice have retained unknown functions to ensure proper incorporation and 
assembly of the GBM [25].
Another in vivo study also shows no major role for HS in the permselectivity of the 
glomerulus [26]. lnjection of heparinase lll into rats resulted in removal of HS without 
alterations in expression levels of the agrin core-protein. This cleavage of HS did not result in 
proteinuria in these rats [26].
Why is it that former studies in animal models and human glomerulopathies show an 
important role for HS in glomerular permeability [25-27]?. In vivo perfusion of heparinase in 
rats resulted in an increase of native ferritin permeability [6], but other GAG-degrading 
enzymes did not [27]. Moreover, in this study no thorough check was performed whether HS 
was removed completely [26]. Loss of HS in human glomerulopathies like membranous 
nephritis, lupus nephritis, and diabetic nephropathy has been observed [11,12] as well as in 
animal models [13]. However, a recent study has shown no change in heparan sulphate 
structure in early human and experimental diabetic nephropathy indicating that the loss of HS 
might be a secondary event in a more advanced stage of the disease [28].
The studies discussed in the previous paragraph will become a subject of debate 
whether or not the GBM and/or agrin is involved in the charge-dependent permeability of the 
glomerular capillary wall or if this role is more attributed to the glycocalyx of the endothelium 
and/or visceral epithelial cells. Future studies will give more clearance in this.
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Chapter 9
Summary, general discussion, and future perspectives
Podocytes are highly specialized, terminally differentiated epithelial cells with 
cytoplasmic extensions, called foot processes, involved in the glomerular 
ultrafiltration. Adjacent foot processes form slit pores with a width of 
approximately 25-40 nm. These slit pores are covered with a membrane and 
many researchers have investigated the structure of this slit membrane as 
being the leading part of the glomerular filtration barrier. Although the 
structure is not completely elucidated yet, several data from animal models 
and/or genetic analyses suggest a substantial role of slit membrane proteins, 
and proteins involved in maintaining the slit membrane structure, in the 
development of nephrotic syndrome. Other aspects of the glomerular 
filtration barrier are not discussed here [1].
The objective of the studies described in this thesis was to determine to what 
extent podocyte genes are involved in the development of congenital 
nephrotic syndrome, and to provide insight in the role of these genes in the 
development of focal segmental glomerulosclerosis (FSGS), diffuse 
mesangial sclerosis (DMS) and minimal change nephrotic syndrome 
(MCNS).
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T he  in v o lv e m e n t o f p o d o c y te  g e n e s  in  th e  d e v e lo p m e n t o f n e p h ro t ic  s y n d ro m e
- a nd  fo c a l s e g m e n ta l g lo m e ru lo s c le ro s is
To investigate the involvement of podocyte genes in the development of childhood onset 
steroid-resistant non-familial FSGS, we tested 20 patients for mutations in seven podocyte 
genes (NPHS1, NPHS2, CD2AP, WT1, ACTN4, TRPC6 and PLCE1) and for the mtDNA 
A3243G transition generally involved in the MELAS syndrome (chapter 2, 5, and 6). No 
mutations were found in the ACTN4 and TRPC6 genes and no patient was found to have the 
A3243G transition. ln four patients, mutations were found which could explain the 
development of the nephropathy. They are discussed in the next four paragraphs. Of these 
four patients, two had an additional heterozygous NPHS1 mutation. The role of these 
additional heterozygous NPHS1 mutations is unknown.
Bigenic heterozygosity: NPHS2 and CD2AP
Single heterozygous mutations in genes normally involved in a recessive mode of inherited 
FSGS (like NPHS2), are frequently reported. The significance of these heterozygous 
mutations is not clear so far, but may be explained in several ways. Other yet unidentified 
mutations in the regulatory or intronic sequence may be present. The heterozygous 
mutations may also lead to an enhanced susceptibility to develop proteinuria triggered by 
environmental factors as seen in mouse models. Depending on the genetic background, 
heterozygous NPHS2 knockout mice develop proteinuria when aging [2], and heterozygous 
CD2AP knockout mice are more susceptible to glomerular injury by nephrotoxic antibodies 
and immunocomplexes [3]. Finally, multigenic inheritance may cause the development of 
nephrotic syndrome. This statement was investigated in mouse models. CD2AP+/- mice were 
crossbred with either Synaptopodin+/- or Fyn proto-oncogene+/- mice. Synaptopodin and Fyn 
proto-oncogene have an interaction with CD2AP. All three heterozygous mice had a 
relatively unremarkable clinical phenotype. Bigenic heterozygosity, however, resulted in an 
increased incidence of proteinuria and pathological changes resembling FSGS [4].
A role of bigenic heterozygosity in the development of FSGS is also seen in our 
patient group (chapter 2 and 6). One patient presented with a maternally inherited 
heterozygous NPHS2 mutation and a heterozygous paternally inherited CD2AP mutation. 
Both parents had normal creatinine levels and no proteinuria. Podocin (NPHS2) 
oligomerization clusters nephrin at the slit diaphragm and CD2AP serves as an adapter 
protein to the overall structure. Bigenic heterozygosity in genes closely involved in the slit 
membrane assembly may result in an aberrant assembly and ultimately proteinuria and 
nephrotic syndrome. The precise role of bigenic heterozygosity in the pathophysiology of 
FSGS needs to be elucidated in further studies.
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Homozygous CD2AP mutation
Recently, a heterozygous CD2AP splice site mutation, affecting 2 nucleotides, was found by 
Kim et al [3] in two patients with primary FSGS. The mutation results in aberrant splicing 
leading to truncation of 80% of the protein. lmmunoblot analysis of CD2AP expression from 
lysates of immortalized B lymphocytes from the patients showed a lower CD2AP expression 
[3].
ln our rather small group of twenty patients, two were found to have CD2AP 
mutations, suggesting an important role of this protein in the development of FSGS. Besides 
the bigenic heterozygous case mentioned in the previous paragraph, we also found a 
homozygous CD2AP mutation in a patient from consanguineous parents (chapter 5). The 
R612Stop mutation affects the COOH-terminus of CD2AP and the premature stopcodon 
would result in a 4% truncated protein. The mutation is situated in the F-actin interacting 
domain and in vitro studies showed a reduced binding efficiency of the mutated CD2AP with 
F-actin. lmmunostaining lymphocytes of the patient with CD2AP antibody, demonstrated a 
lack of CD2AP expression in the patient, while both parents, who are heterozygous for the 
mutation, had a (close to) normal CD2AP value. ln mouse models, homozygous CD2AP 
knockout mice show proteinuria, already in week 2, and die around 6-7 weeks [5]. The 
phenotype of heterozygous CD2AP knockout mice is less severe [3]. These mice show no 
proteinuria, but develop glomerular lesions consisting of mild to extensive mesangial 
expansion and occasionally immunoglobulin deposits at age 9 months [3]. The CD2AP splice 
site mutation found in the two primary FSGS patients was also of heterozygous state. ln case 
of our patient, the parents, who are heterozygous for a CD2AP nonsense mutation, show no 
proteinuria. The difference between the outcome of both heterozygous CD2AP mutations 
may be explained by the severity of the truncation, but it is possible that in the patients with 
the splice site mutation, a second hit in another gene is present (bigenic heterozygosity). ln 
these patients, no other podocyte genes were analyzed. Recently three heterozygous 
mutations were reported by Gigante et al [6] in a study of 80 ltalian patients with idiopathic 
steroid resistant nephrotic syndrome
Compound heterozygous NPHS2 mutations
Hereditary steroid resistant nephrotic syndrome is frequently associated with mutations in the 
podocyte gene podocin, NPHS2. ln our group, renal disease in one patient could be 
explained by a compound heterozygous podocin mutation (chapter 6).
The knowledge of having podocin mutations is important for determining treatment 
modalities. Aggressive treatment with immunosuppressive drugs can be avoided and the 
favorite prognosis of the renal transplant can be more or less predicted. Early studies 
showed no recurrence of proteinuria after renal transplantation in patients having a NPHS2 
mutation. However, later on, several patients did show recurrence of proteinuria, and it is 
now believed that the finding of a NPHS2 mutation does not definitely exclude the recurrence 
of nephrotic syndrome in the renal graft. Collective data from patients with NPHS2 mutations 
who received a renal transplant showed an unexplained higher risk for recurrence in patients 
having a heterozygous mutation, compared to patients with homozygous or compound
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heterozygous mutations [2]. This group of patients should be closely monitored in the post­
graft phase.
De novo WT1 mutation
ln the group of twenty patients with non-familial steroid-resistant FSGS, we found one 
mutation in the WT1 gene (chapter 2), frequently found in patients with the Frasier syndrome 
(FS).
Denys-Drash syndrome (DDS) and FS are closely related syndromes characterized 
by nephrotic syndrome (due to DMS (DDS) or FSGS (FS)), male pseudohermaphroditism 
and a higher risk of developing Wilm’s tumor (DDS) or gonadoblastoma/dysgerminoma (FS). 
Both DDS and FS are caused by de novo mutations in the transcription factor WT1. 
Proteomic investigation of glomerular podocytes from a DDS patient indicated a role of WT1 
in the regulation of expression of key components and regulators of the cytoskeleton [7].
The patient with the WT1 mutation has a normal female phenotype and a XX 
karyotype. Our finding of a WT1 gene mutation has practical implications for the patient as 
regular control of gonads and kidneys is required because of the risk of gonadoblastoma 
and, more rarely in FS, Wilms tumours.
The mtDNA A3243G transition in adult FSGS patients
No A3243G transition in the mtDNA, associated with the MELAS syndrome, was found in the 
group of childhood-onset FSGS patients. mtDNA is present in heteroplasmic state with 
mutated and wildtype DNA coexisting in cells. Since the amount of mutated mtDNA has to 
exceed a certain threshold value to cause a phenotype, and this is more likely to happen 
while aging, we also analyzed a group of adult-aged steroid-resistant FSGS patients (chapter 
3).
ln one patient the A3243G transition was found (30% in blood sample and 68% in 
urine sample). This patient developed full-blown nephrotic syndrome during pregnancy, 
which persisted after delivery. Steroid treatment was complicated by the development of 
diabetes mellitus, and also her sister had in the meantime developed insulin-dependent 
diabetes mellitus. The sister has the A3243G transition in a lower percentage; 25% in blood 
sample and 28% in urine sample. At the time of DNA analyses, the sister had no signs of 
renal disease. Electron microscopy of the patient showed podocyte foot process effacement 
and abnormal mitochondria.
The mtDNA A3245G transition can be associated with FSGS and severe nephrotic 
syndrome. Clinicians should be aware of the clinical heterogeneity of mitochondrial 
cytopathies, and should be suspicious of patients with steroid-resistant FSGS who present 
with some particular features such as deafness, diabetes, neuromuscular symptoms, 
cardiomyopathy or a family history positive for any of these.
Conclusion
FSGS may be subdivided into three categories: idiopathic, genetic, and secondary due to 
injury, medication, or drug abuse. We investigated to what extent the genetic factor plays a
116
Summary and discussion
role in the development of FSGS in patients with childhood onset steroid-resistant FSGS. 
With the number of mutations found, we would like to conclude that podocyte genes play a 
substantial role in the development of FSGS, and moreover, the role of multigenic inherited 
podocyte gene mutations may be substantial in this as well. For this reason, and because the 
knowledge of having a genetic defect is important for future treatment modalities, it is 
important to provide a standard molecular analysis assay for these patients.
T he  in v o lv e m e n t o f p o d o c y te  g e n e s  in  th e  d e v e lo p m e n t o f n e p h ro t ic  s y n d ro m e  
- a nd  d if fu s e  m e sa n g ia l s c le ro s is
De novo mutations in the transcription factor WT1 are frequently found in patients with DDS 
and DMS. We screened patients with DMS for the presence of a WT1 mutation and found in 
one patient with inherited nephrotic syndrome and a dysgerminoma in the right abdomen at 
age 17 years, a mutation confirming the diagnosis DDS (chapter 4).
The WT1 mutation had far-reaching consequences for the further treatment and 
follow-up of the patient. A XY-karyotype was established in this patient with female genitalia, 
and the second gonad was removed because of the higher risk of malignant degeneration. 
The rudimentary kidneys were removed since the risk of developing Wilms’ tumour. Both 
kidneys showed nephroblastosis, also a benign abnormality and possibly a pre-stage of 
Wilms tumour.
This case shows the importance of WT1 mutation analysis in patients with DMS and 
informs physicians responsible for the health of adults about previously untreatable genetic 
diseases of childhood in order to provide adequate medical management of these patients.
Not much is known about the genetic role in the development of DMS. Mutations in 
the WT1 gene are frequently found in complete or in incomplete forms of DDS, but do not 
explain cases of DMS without genital abnormalities or malignancies. Recently, mutations in 
the PLCE1 gene (phospholipase C epsilon) and LAMB2 gene (laminin ß2) were found in 
patients with familial form of DMS. PLCE1 mutations were found in patients with early onset 
nephrotic syndrome and rapid progression to end stage renal disease (ESRD) [8]. Notably, 
two individuals responded to therapy. LAMB2 mutations are associated with the Pierson 
syndrome (microcoria-congenital nephrotic syndrome with early progression to ESRD), but 
are also found in patients with congenital nephrotic syndrome without eye anomalies or with 
minor ocular changes [9]. The exact role of these genes in the development of DMS needs to 
be elucidated in future studies.
T he  in v o lv e m e n t o f p o d o c y te  g e n e s  in  th e  d e v e lo p m e n t o f m in im a l c h a n g e  n e p h ro t ic  
s y n d ro m e
To investigate the role of podocyte genes in the development of MCNS, we screened 15 
MCNS patients with frequently relapsing course of the disease, persisting after puberty, for
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mutations in the genes NPHS1, NPHS2, CD2AP, WT1, and ACTN4 (chapter 7). We did not 
find homozygous or compound heterozygous mutations in these genes which could explain 
the pathology. However, two heterozygous NPHS1 mutations (P264R in 3 patients, and 
T1152M in 1 patient), and one known NPHS1 polymorphism (E117K, heterozygous in 1 
patient and homozygous in 2) were found. This polymorphism is associated with decreased 
creatinine clearance in patients with lgA nephropathy [10]. Also one heterozygous NPHS2 
polymorphism (R229Q) associated with microalbuminuria in the general population was 
found in one patient. These results support the statement that genetic changes in nephrin 
may have a pathogenic role in some MCNS patients [11]. The genetic changes might make 
the glomerular slit membrane more vulnerable for a ‘second hit’ causing proteinuria and 
MCNS.
No mutations were found in NPHS2, CD2AP, WT1, and ACTN4 suggesting no role 
for these genes in the pathogenity of MCNS. However, a WT1 splice site mutation in a 46XX 
female patient with MCNS and Wilms’ tumor has been reported [12]. One report also 
describes NPHS2 mutations in MCNS patients; R138Q (heterozygous in one family and 
homozygous in one family and two sporadic cases) and 855-856delAA (homozygous in one 
sporadic case). ln the family with heterozygous R138Q mutation, two members had steroid- 
resistant nephrotic syndrome. Remarkably, in one patient the renal biopsy revealed MCNS, 
while the other family member was diagnosed with FSGS [13]. Recently a lowered 
expression of galectin-1, normally binding to nephrin, is reported in MCNS [14].
F u tu re  p e rs p e c tiv e s
The common denominator of all FSGS variants is a podocyte disease. lncreased knowledge, 
originating from inherited podocyte disease, will direct the future treatment. New hereditary 
disorders will be discovered and elucidate new functions of the podocyte. Careful clinical 
studies are needed to establish genotype/phenotype correlations. When possible, podocytes 
should be obtained of these patients. The development of conditionally immortalized human, 
and mouse, podocyte cell lines, have considerably advanced the field. All aspects of 
podocyte biology can be approached [15]. lt makes micro-array and proteomics technology 
possible [7] and RNA interference can be applied [16]. The technique for obtaining human 
podocytes in culture from urine should be vigorously continued [17].
Experimental work in animals also contributes to the progress in this field, especially 
since it is possible to restrict or delete expression to the podocyte. Specific podocyte 
depletion causing glomerulosclerosis was reached by diphtheria-toxin injections in rats 
expressing the human diphtheria-toxin receptor under the control of a podocin promoter [18]. 
Ablation of developing podocytes disrupts cellular interactions and nephrogenesis both inside 
and outside the glomerulus [19]. Animal models, however, do not always reflect the human 
disease. PLCE-1 knockout mice do not have a nephrosis-like phenotype [8]. ln the zebrafish, 
using antisense morpholino oligonucleotides to knockdown the PLCE-1 ortholog, the 
glomerular barrier function was disturbed [8]. lt may be interesting to use the zebrafish more
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frequently in the future. Another useful model may be the in Drosophila described podocyte- 
like cell type the nephrocyte. lt closely resembles the mammalian podocyte, including the 
nephrin-based slit diaphragm. Endothelial cells, however, are lacking in the filtration barrier 
[20].
When exposed to nephrotic plasma samples, nephrin, podocin and CD2AP assumed 
a cytoplasmic distribution in cultured human podocytes, and nephrin and synaptopodin were 
selectively downregulated. Nephrin could be relocated to the plasma membrane by co­
incubation with non-nephrotic plasma samples, indicating that nephrotic plasma seems to be 
deficient in factors that act via the podocyte slit membrane complex [21]. This factor, or these 
factors, may be lost in urine [22]. The glomerular albumin permeability significantly reduces 
when isolated rat glomeruli are incubated with serum and an equal volume of urine of 
patients with a nephrotic syndrome. This is not seen when the nephrotic serum is mixed with 
normal control urine [22].
Podocytes are not isolated cells. VEGF produced by the podocytes binds to VEGF 
receptors on endothelial cells, inducing endothelial fenestration and maintaining glomerular 
permeability. Anti-VEGF therapy may induce glomerular endothelial swelling with loss of 
endothelial fenestrae and effacement of foot processes. Thrombotic microangiopathy has 
been reported [23]. Angiopoetin l originating from the podocyte may stabilize the endothelium 
and resist angiogenesis [24].
ln the concept of Meyrier [25], FSGS starts with podocyte injury which drives the 
glomerular lesions to build up of fibrosis and scarring. Besides being an inherited podocyte 
disease, FSGS may also be due to an immunological disorder, a viral cause or to a toxic 
compound [26]. Corticoids and Cyclosporin remain the mainstay of therapy based on the 
concept that the lesions and proteinuria are due to an immunological assault [27,28]. 
However, the beneficial effect of Cyclosporin on proteinuria turns out not to be caused by 
inhibition of signaling of activated T cells, but rather results from the stabilization of the actin 
cytoskeleton in kidney podocytes by prevention of synaptopodin degradation [29]. Also, in 
the in vitro model of puromycin-aminonucleoside induced podocyte injury, glucocorticoids 
protect and enhance recovery via actin filament stabilization [30]. Angiotensin ll has not only 
a dynamic effect on the renal circulation, but also induces a reorganization of F-actin fibers 
and a redistribution of ZO-1 in murine podocytes accompanied by increased albumin 
permeability [31].
Mature podocytes are postmitotic cells that do not proliferate. The podocytes, 
however, can be regenerated from a resident population of renal progenitors localized within 
the parietal epithelium of Bowman’s capsule mainly at the urinary pole. lnjection of these 
cells into mice with adriamycin-induced nephropathy reduces proteinuria and improved 
glomerular damage [32]. These data illustrate that by studying the biology of the podocyte, a 
new therapy can emerge or at least better understood.
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Achtergrond en doelstelling van het onderzoek
Het glomerulaire filtratie systeem bestaat uit tenminste drie lagen. De filtratie laag bestaande 
uit podocyt cellen speelt een belangrijke rol bij de ontwikkeling van het nefrotisch syndroom. 
Patiënten met een nefrotisch syndroom verliezen belangrijke en nuttige bestanddelen, zoals 
eiwitten, via de urine (proteïnurie).
Podocyt cellen zijn enorm gespecialiseerde cellen met uitlopers die “ foot processes” 
worden genoemd. Deze “foot processes” zijn onderling met elkaar verbonden door een dun 
membraan, het ” slit membraan”. De laatste jaren is veel duidelijk geworden over de 
samenstelling en opbouw van dit “slit membraan”. Wanneer de samenstelling van het ‘slit 
membraan” om welke reden dan ook afwijkend is, kan dit tot het nefrotisch syndroom leiden.
Het hier beschreven onderzoek houdt zich bezig met podocyt eiwitten die betrokken 
zijn bij het ontstaan van een nefrotisch syndroom, dat morfologisch gekenmerkt wordt door 
focale segmentale glomerulosclerose (FSGS). Bij FSGS ontstaat de proteinurie doordat in 
een aantal, maar niet alle (focaal) glomeruli bindweefsel is gevormd en bovendien is slechts 
een deel van de glomerulus aangedaan (segmentaal). FSGS is een histopathologische 
bevinding en geen ziektebeeld op zich. Het heeft daarom verschillende achterliggende 
oorzaken, die onder andere genetisch kunnen zijn. Om deze reden hebben we in een groep 
patiënten met FSGS de genen coderend voor podocytaire eiwitten, betrokken bij de opbouw 
van het slit membraan, in detail onderzocht. Deze genen zijn ook geanalyseerd bij patiënten 
met diffuus mesangiale sclerose (DMS) en patiënten met minimale laesies (MCNS) om de rol 
hiervan bij de ontwikkeling van deze ziektes te bepalen.
Podocyt genen spelen een belangrijke rol in de ontwikkeling van FSGS 
Een groep van 20 FSGS patiënten (FSGS ontstaan in de kinderleeftijd) is geselecteerd op 
basis van het niet reageren op de standaard behandeling met steroïden en bij deze patiënten 
is er niet sprake van een familiale vorm van FSGS. Bij deze groep is een mutatie analyse 
uitgevoerd in een aantal podocyt genen, te weten NPHS1, coderend voor nefrine, NPHS2, 
coderend voor podocine, CD2AP, WT1, ACTN4, TRPC6 en PLCE1. Daarnaast is gekeken 
naar de mitochondriële DNA (mtDNA) afwijking A3243G welke over het algemeen 
geassocieerd wordt met het MELAS syndroom (myopathie, encefalopathie, lactaatacidose, 
'stroke- like' episoden), maar ook gevonden wordt bij patiënten met een minder progressieve 
vorm van FSGS. Geen mutaties werden gevonden in de ACTN4, TRPC6 en PLCE1 genen, 
evenmin de A3243G mutatie in mtDNA. ln 4 patiënten werden mutaties gevonden in NPHS2, 
CD2AP en WT1 die het ontstaan van FSGS zouden kunnen verklaren omdat mag worden 
verondersteld/is aangetoond dat door de mutaties in deze genen de vorm en/of de functie 
van het gecodeerde eiwit in de slit-membraan veranderd is.
Hoofdstuk 2 beschrijft een patiënt met FSGS waarin een WT1 mutatie is gevonden. 
De transcriptie factor WT1 is betrokken bij het ontstaan van het Denys-Drash (DDS) en 
Frasier (FS) syndroom, twee sterk op elkaar lijkende syndromen gekenmerkt door een
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nefrotisch syndroom, mannelijke pseudohermafroditisme en het ontwikkelen van 
maligniteiten. Het kennisnemen van deze mutatie is belangrijk voor de verdere behandeling 
van de patiënt, aangezien WT1 mutanten een verhoogd risico hebben op het ontwikkelen 
van maligniteiten.
Erfelijke steroïd-resistente nefrotisch syndroom wordt over het algemeen 
geassocieerd met mutaties in het podocine (NPHS2) gen. Bij één patiënt kon de FSGS 
pathologie verklaard worden door een compound heterozygote mutatie in dit gen (hoofdstuk 
6). Ook voor mutaties in het NPHS2 gen, evenals WT1, geldt dat het kennisnemen van een 
mutatie in dit gen belangrijke gevolgen heeft voor de verdere behandeling van de patiënt. 
Onderzoek heeft laten zien dat bij aanwezigheid van een mutatie in NPHS2 verdere 
agressieve behandeling met steroïden, cyclophosphamide en cyclosporine vermeden kan 
worden en de prognose na niertransplantatie min of meer voorspeld kan worden. 
Aanvankelijk werd verondersteld dat bij een patiënt met een podocine mutatie op een van de 
allelen (heterozygoot), de kans op proteinurie na transplantatie van de patiënt sterk werd 
gereduceerd. lnmiddels is door het nauwkeurig vastleggen van gegevens het inzicht 
gewijzigd en wordt verondersteld dat patiënten met een enkele heterozygote mutatie juist 
meer risico lopen op terugkeer van proteïnurie dan patiënten met een homozygote of 
compound heterozygote mutatie.
Regelmatig worden enkele heterozygote mutaties gevonden in genen die normaal 
gesproken betrokken zijn bij een autosomale recessieve vorm van FSGS (zoals bv NPHS2). 
Onlangs is in muismodellen aangetoond dat heterozygotie in twee genen kan leiden tot een 
nefrotisch syndroom. Muizen heterozygoot knockout voor CD2AP zijn gekruist met muizen 
heterozygoot knockout voor synaptopodine (eiwit betrokken bij de opbouw van het cytoskelet 
van de podocyt) of Fyn (enzym dat andere podocyt-eiwitten fosforyleert). Deze muizen 
hebben geen afwijkende fenotype, maar de nakomelingen laten proteïnurie en FSGS zien. 
Ook in onze groep patiënten is bij één patiënt twee heterozygote mutaties gevonden 
(hoofdstuk 2 en 6) in twee verschillende genen: NPHS2 (afkomstig van de moeder) en 
CD2AP (afkomstig van de vader). Beide ouders hebben geen proteïnurie en normale serum 
creatinine waarden. Heterozygotie in meerdere genen coderend voor eiwitten betrokken bij 
de opbouw van het slit membraan, kan dus ook in de mens leiden tot een afwijking in de 
opbouw en uiteindelijk proteïnurie en nefrotisch syndroom.
Een mutatie in het CD2AP gen is slechts één keer beschreven in de literatuur. Onze 
groep patiënten laat twee mutaties zien in dit gen en dit suggereert een grotere rol van dit 
gen bij de ontwikkeling van FSGS. Hoofdstuk 5 beschrijft een nieuwe CD2AP mutatie in een 
patiënt met steroïd-resistente FSGS. De mutatie (1834 C>T, R612Stop) resulteert in een 
vroegtijdige stopcodon en wordt in de patiënt homozygoot gevonden. Beide (gerelateerde) 
ouders hebben de mutatie op een van de allelelen (zijn heterozygoot), maar hebben geen 
afwijkende nierfunctie. Onze biochemische studie laat zien dat het gemuteerde eiwit in 
mindere mate aan actine bindt. Bovendien is er geen CD2AP expressie waargenomen in 
geïsoleerde lymfocyten van de patiënt, terwijl de ouders een normale hoeveelheid laten zien 
ten opzichte van controle lymfocyten. We concluderen dat heterozygote CD2AP mutaties 
niet perse tot nierfalen leiden.
124
Samenvatting
Mitochondriële aandoeningen zijn erg heterogeen van aard vanwege de 
eigenschappen van het mtDNA. mtDNA wordt maternaal overgeërfd en is, in tegenstelling tot 
kern-DNA, ongelijk verdeeld over de cellen. Bovendien komen in de cellen wildtype kopieën 
van het mtDNA voor naast gemuteerd mtDNA (heteroplasmie). Om tot een bepaald 
ziektebeeld te leiden, moet de hoeveelheid gemuteerd mtDNA een bepaalde drempelwaarde 
overstijgen. De kans dat dit gebeurt neemt toe in leeftijd van de patiënt. Om die reden 
hebben we naast de groep patiënten waarbij de FSGS op kinderleeftijd ontstond, ook 
gekeken naar volwassen patiënten met steroïd-resistente FSGS en het voorkomen van de 
A3243G mutatie in het mtDNA. ln hoofdstuk 3 wordt een patiënt beschreven met de A3243G 
mutatie. ln tegenstelling tot voorheen beschreven gevallen, waarbij minder progressieve 
vormen van FSGS beschreven werden, ontwikkelde deze patiënt een uitgesproken 
nefrotisch syndroom gedurende haar zwangerschap met resistentie voor steroïden wat voort 
duurde na de bevalling. Een zus van de patiënt had diabetes mellitus ontwikkeld. Ons advies 
is dat artsen mitochondriële aandoeningen in overweging zouden moeten nemen wanneer 
doofheid, diabetes mellitus of neuromusculaire aandoeningen aanwezig zijn bij de patiënt of 
familieleden.
De rol van podocyt genen bij de ontwikkeling van DMS
Niet veel is bekend over de rol van podocyt genen bij de ontwikkeling van DMS. Mutaties in 
het WT1 gen, wordt vaak gevonden bij patiënten met DMS in relatie tot de complete of in­
complete vorm van DDS, maar verklaart niet de geïsoleerde gevallen van DMS. Zeer 
recentelijk zijn er mutaties beschreven in de PLCE1 en LAMB2 genen bij patiënten met 
DMS. De precieze rol van deze en eventueel andere genen bij de ontwikkeling van DMS zal 
in de toekomst onderzocht worden.
Zoals eerder aangeduid heeft het vinden van een WT1 mutatie gevolgen voor de 
verdere behandeling van de patiënt, waarbij tevens psychische problemen kunnen ontstaan. 
Hoofdstuk 4 beschrijft de casus van een 17-jarige vrouw met een afwezige seksuele 
ontwikkeling en een nefrotisch syndroom vanaf de geboorte dat heeft geleid tot nierfalen. Bij 
haar werd de diagnose ‘Denys-Drash-syndroom’ (DDS) gesteld nadat zich bij haar een 
dysgerminoom van een ovarium had ontwikkeld en een WT1 mutatie was vastgesteld. De 
tweede gonade evenals de rudimentaire natieve nieren werden verwijderd in verband met 
het verhoogde risico op het ontwikkelen van maligniteiten. Tevens werd een XY-karyotype bij 
haar vastgesteld. Artsen verantwoordelijk voor de behandeling van volwassenen worden 
steeds vaker geconfronteerd met de gevolgen van ziekten ontstaan op kinderleeftijd. Deze 
casus geeft de noodzaak weer deze artsen kennis te laten nemen van voorheen 
onbehandelbare erfelijke kinderziekten om zo een adequate behandeling van deze patiënten 
te kunnen garanderen.
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Een bescheiden rol van podocyte genen in de ontwikkeling van MCNS 
Om de rol van podocyte genen in de ontwikkeling van MCNS te onderzoeken hebben we in 
een groep van 15 patiënten gekeken naar mutaties in de genen NPHS1, NPHS2, CD2AP, 
WT1 en ACTN4 (hoofdstuk 7). Geen mutaties werden gevonden die direct de pathologie 
zouden kunnen verklaren. Wel werd een heterozygote NPHS2 polymorfisme (R229Q) 
gevonden die in een normale populatie tot microalbuminurie kan leiden. Ook twee 
heterozygote NPHS1 mutaties en een bekende NPHS1 polymorfisme (E117K) werden 
gevonden. Deze laatste polymorfisme wordt geassocieerd met een verlaagd creatinine 
klaring bij patiënten met lgA nefropathie. Deze resultaten ondersteunen de gedachte dat 
genetische veranderingen in het nefrine gen een rol speelt in MCNS. Deze verandering 
maakt het glomerulaire slit membraan waarschijnlijk kwetsbaar voor een ‘second hit’.
Toekomstperspectieven
Nieuwe erfelijke aandoeningen zullen in de toekomst ontdekt worden. Zorgvuldig uitgevoerde 
klinische studies zullen de relatie tussen genotype en fenotype vaststellen. lndien mogelijk, 
zouden specifiek de podocyten geïsoleerd kunnen worden uit bijvoorbeeld urine-monsters 
van de patiënten. De ontwikkeling van geïmmortaliseerde humane, en muis, podocyt 
cellijnen heeft namelijk het onderzoeksveld een grote impuls gegeven. Deze ontwikkeling 
maakt technieken als micro-array en proteomics mogelijk als mede RNA interferentie. 
Optimalisatie van de procedure voor isolatie van de podocyten uit urinemonsters is nog 
noodzakelijk.
Een belangrijke rol in het onderzoek spelen ook de diermodellen, met name sinds het 
mogelijk is bepaalde genen weefselspecifiek te beïnvloeden. Echter, diermodellen geven niet 
altijd de humane pathologie weer, zoals te zien is bij PLCE1 knockout muizen. Deze muizen 
laten geen nefrotisch ziektebeeld zien. ln de zebravis wordt deze pathologie wel gevonden 
als de PLCE1 homoloog uitgeschakeld wordt. Om de rol van agrine in het glomerulair 
filtratiesysteem te onderzoeken, hebben wij geprobeerd een glomerulus-specifieke agrine 
knockout muis te ontwikkelen. Hoofdstuk 8 beschrijft de wijze waarop wij geprobeerd hebben 
dit doel te bereiken. Helaas zijn we er niet in geslaagd het diermodel te ontwikkelen, omdat 
er geen kiembaan transmissie heeft plaatsgevonden.
Toekomstig onderzoek zal ook proberen een antwoord te vinden op de vraag welke 
factor of welke factoren missen in het serum van patiënten met een nefrotisch syndroom. 
Wanneer podocyt cellen blootgesteld worden aan serum van deze patiënten, vindt er 
relocatie plaats van nefrine, podocine en CD2AP van het celmembraan naar het cytoplasma. 
Deze relocatie kan opgeheven worden door serum van gezonde mensen. Het vinden van 
deze factor in het serum blijft een grote uitdaging voor vervolgstudies.
Behalve een erfelijke oorzaak, kan FSGS ook veroorzaakt worden door een 
immunologische afwijking, een virus of een toxine. Steroïden en cyclosporine zullen een 
steunpilaar blijven in de behandeling van FSGS. Deze behandeling is gebaseerd op het 
concept dat de laesies en proteinurie afkomstig zijn van een immunologische reactie. Bij 
PAN(puromycin aminonucleoside )-geïnduceerde podocyt schade zorgen steroïden voor 
bescherming en herstel door actine-filamenten te stabiliseren. Angiotensin ll heeft een
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dynamisch effect in de renale circulatie en veroorzaakt een verhoogde permeabiliteit van de 
nier voor albumine. Tevens veroorzaakt het een reorganisatie van het cytoskelet van muis- 
podocyten door relocatie van F-actine en ZO-1.
Zowel deze studies, als ook naar genetische afwijkingen zoals in dit proefschrift beschreven, 
laten zien dat onderzoek naar de biologie van de podocyt meer inzicht geeft in de 
pathogenese van het nefrotisch syndroom, en door beter inzicht wellicht kan leiden tot een 
meer gericht therapeutisch beleid.
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De duur van mijn promotieonderzoek is alles behalve gemiddeld te noemen. Elk jaar weer 
dacht ik “dit wordt mijn jaar”, maar de jaren tikten voorbij. Met recht is het een tien-jaren-plan 
te noemen, maar uiteindelijk heb ik toch mijn resultaten kunnen bundelen en ziehier het 
resultaat.
Dat ik toch na al die jaren mijn onderzoek succesvol heb kunnen afsluiten heb ik aan vele 
mensen te danken. Omdat er in de loop der jaren veel mensen zijn geweest die mij gesteund 
hebben, is het moeilijk iedereen bij naam te noemen. lk wil daarom beginnen met iedereen in 
zijn algemeenheid te bedanken die, op welke wijze dan ook, betrokken zijn geweest bij het 
tot stand komen van dit proefschrift.
Een aantal namen wil ik hier toch zeker noemen. Zij hebben lange tijd een belangrijke rol 
gespeeld in mijn leven of doen dat nog steeds. Zij hebben een substantiële bijdrage geleverd 
aan het onderzoek, hebben mijn tijd op het lab enorm veraangenaamd of hebben altijd met 
interesse mijn onderzoek gevolgd.
Ten eerste ‘mijn promotor’ Leo Monnens. ln het begin van mijn promotieonderzoek heb ik 
altijd vol verwondering naar uw verhalen geluisterd en naar uw spreuken op de wand 
gekeken. Nog steeds kan ik genieten van de verhalen die u soms op ludieke wijze verteld. 
Niet alleen wetenschappelijk stak en steekt u er bovenuit, ook sociaal bent u erg betrokken 
bij uw medemens en hebt u hier duidelijk een mening over. Het is jammer dat u bij de 
afsluiting van mijn promotieonderzoek niet als promotor kan optreden. Ondanks dat heeft u 
zich altijd ingezet voor mijn promotie, zowel wetenschappelijk als politiek gezien. Het waren 
bewogen jaren, maar uw inzet waardeer ik het meest. Voor mij blijft u ‘mijn promotor’.
Ook promotor Bert van den Heuvel wil ik bedanken.
Bert, bedankt voor je vertrouwen in mij. lk ben als stagiaire op het lab gekomen en na het 
behalen van mijn diploma kon ik als analist blijven. Je bood me de kans om als HBO-er 
promotieonderzoek te gaan doen en die kans heb ik genomen. lk kon altijd bij je terecht voor 
vragen, ondanks je drukke schema. Ook nadat ik weg ben gegaan uit Nijmegen hebben we 
goede overleggen kunnen houden. Naast de te bespreken punten toonde je ook altijd 
interesse in mij als persoon (‘hoe gaat het met moeders’) en mijn familie. Nu ben ik de eerste 
promovendus die onder jouw begeleiding gaat promoveren.
Copromotores Patricia Groenen en Elena Levtchenko mogen ook zeker niet ontbreken. 
Patricia, je bent in eerste instantie bij het onderzoek betrokken geraakt vanwege je kennis 
van diermodellen en deze kennis heb ik mogen ervaren. Voor vragen over de knockout muis 
kon ik altijd bij je terecht. Helaas is onze inzet niet beloond met een levend diermodel, de 
natuur had anders besloten. Toch bleef je betrokken bij mijn onderzoek, kwam je met ideeën 
en heb je vele artikelen gecorrigeerd. Ontzettend bedankt voor je steun en gezelligheid!
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Elena, je was altijd enthousiast en geïnteresseerd in mijn onderzoek en je hebt mij van 
voldoende patiëntenmateriaal voorzien om het onderzoek uit te kunnen voeren. lnmiddels 
ben je al enige tijd geleden gepromoveerd en ben je werkzaam in Leuven. Toch ben je 
betrokken gebleven bij mijn onderzoek en ben je bij onze besprekingen aanwezig geweest. 
Bedankt voor je inzet, ideeën en je hulp bij het schrijven van artikelen!
Paranimfen Nicole en Martijn.
Nicole, vaak word ik geprezen om mijn doorzettingsvermogen, maar nog meer bewonder ik 
die van jouw en Barry. lk ben er van overtuigd dat dit jaar ook jullie jaar wordt. Bedankt voor 
je steun tijdens mijn promotie, je enthousiasme en adviezen. Je bent een lieve zorgzame 
tante voor mijn kinderen en ik wens je simpelweg jouw wens.
Martijn, je stond altijd voor me klaar, was altijd geïnteresseerd in mijn onderzoek en je kletste 
er altijd gezellig op los. lk vond het fijn om met je samen te werken en ben je ook erg 
dankbaar voor alles wat je gedaan hebt ook toen ik uit Nijmegen weg was en ik je weer een 
keertje mailde met een bepaalde vraag. Je bent nu zelf met promotieonderzoek bezig en ik 
wens je daar veel succes mee. lk hoop dat het met wat minder obstakels zal verlopen dan bij 
mij, maar daar heb ik de volste vertrouwen in. Met jouw positieve houding en inzet kom je er 
wel. Beiden bedankt!
Karin, je was geweldig (gezellig) om mee samen te werken. Zonder jouw was mijn tijd in 
Nijmegen niet hetzelfde geweest. Zowel op het lab als daarbuiten heb ik van jouw 
vriendschap genoten en hoewel we elkaar nu minder vaak zien, ben ik nog steeds blij met 
onze vriendschap. lk zal onze kweek-avonturen nooit vergeten, evenmin de gezellige tijd die 
we op het lab hebben gehad, de etentjes bij ons thuis en de vakantie in Oostenrijk en Disney 
land. lk wens je heel veel succes met je nieuwe carrière en heel veel geluk met je (nog 
groeiende) gezin.
Een ontzettend gezellige en plezierige tijd heb ik beleefd op Lab Kindergeneeskunde en 
Neurologie. Mensen van de niergroep: Maroeska, Rikke, Joyce, onze enige echte Thea 
(altijd met een lach), maar ook de studenten Emir, Ellen, Anouk, llse en Dineke het was een 
kleine maar fijne groep om mee te werken. lk zal vooral de gezellige lunches bij de Blonde 
Pater niet vergeten.
Ook de andere onderzoeksgroepen, de DNA-groep, mitochondriële groep en homocysteïne 
groep, hebben zeker een steentje bijgedragen aan de gezelligheid die onder andere ten top 
was tijdens de ‘sintekersten’. Overige medewerkers van lab Kindergeneeskunde en 
Neurologie, waarvan ik de spiergroep als ‘directe buren’ graag nog even wil noemen, bedank 
ik ook voor de fijne periode en de getoonde interesse.
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